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Abstract
Non-small cell lung cancer represents 85% of all lung cancers with an average 5 year life
expectancy of 15-20%. A wealth of data suggests that altered glycosylation contributes to the
progression of these tumors and efforts to improve the specificity of biomarkers have logically
shifted towards glycoproteomic investigations. For this purpose, recent innovations in
experimental strategies and analytical techniques could be combined to provide a more detailed
characterization of glycans than previously achievable. These new methods have not yet been
assessed for feasibility in experimental procedures useful for discovery phase efforts. Therefore,
we aimed to investigate the utility of novel glycoproteomic and glycomic approaches for
defining alterations in glycosylation which may accompany disease progression. To this end, we
implemented an azido-sugar metabolic labeling, alkyne-agarose bead enrichment, and liquid
chromatography-tandem mass spectrometry for profiling glycoproteins in a cell model of lung
cancer induced to express transforming growth factor beta ligand-1. This approach identified
putative changes in the sialylation of glycoproteins related to metabolic, cell adhesion, glycan
biosynthesis, and extracellular matrix-related proteins. The application of a secondary digest to
glycopeptide-bound beads, using peptide-N-glycosidase-F, was useful for verifying N-glycan
sites as well as exposing previously undetected glycoproteins. A stable isotope labeling of amino
acids in cell culture approach was used to gauge if altered protein expression was contributing to
differential capture, however this method provided limited information due to a low overlap of
proteins identified from enriched vs. unenriched fractions. In another set of experiments, we
applied a novel derivatization strategy combined with high resolution/high mass accuracy mass
spectrometry for discerning glycan structures in human lung cancer proximal fluids. This
procedure effectively defined the sialic acid anomeric configuration of several prevalent species
iii

and identified preliminary trends in the expression of oligomannose and complex glycans in
clinically-relevant materials. Finally, matrix-assisted laser desorption ionization imaging mass
spectrometry was used to spatially resolve the distribution of N-glycans in lung tissues matched
to the proximal fluids. Histological assessment of these tissues facilitated cross-reference of
acquired glycan species to regions of interest and provided a direct means for assessing how
these trends correlated in the proximal fluids.
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Chapter 1
Literature Review
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Overview
Lung cancer accounted for the most cancer-related deaths in 2014, with 85% of
these being classified as NSCLC. The late detection and heterogeneous progression of
this disease plays a significant role in the mortality rate, therefore efforts to intervene are
focused on the identification of biomarkers for early diagnosis and prognostic
stratification. Here we present a review of the etiology, characteristics, and detection of
NSCLC as a basic primer of disease pathology and why there is a need for additional
metrics to predict outcomes. Next, TGFβ1 signaling is outlined to highlight a pathway
hypothesized to promote the acquisition of invasive tumor phenotypes. This information
establishes the relevance of our experimental model of NSCLC, H358 cells induced to
express TGFβ1, as a system for screening for changes in the glycosylation of cell
adhesion, extracellular matrix, and cytoskeletal proteins. We next provide an overview of
glycoprotein biosynthesis, functional roles, and observed changes in glycans which often
accompany transformation and metastasis. In addition, some of the mechanisms by which
neoplastic cells produce specific glycan structures and the clinical utility for their
identification are exemplified. These sections provide a base set of knowledge for
understanding why cancer-associated glycosylation changes may occur and which
structures are often modified. Furthermore, this information demonstrates the value of
glycoproteomic endeavors by providing examples of how previous research has
translated to clinical use. Finally, we present the methods utilized for mass spectrometrybased glycoproteomic investigations. Strategies and experimental approaches for the
selective study of these molecules are compared and common acquisition techniques are

2

reviewed. Recent innovations in glycoproteomic mass spectrometry and data analysis,
and the benefits they provide relative to previous methods, are featured.

1.1 Non-Small Cell Lung Cancer
1.1.1 Introduction
Lung cancer, including both non-small cell and small cell carcinoma, is
responsible for the most cancer-related deaths in the United States. For 2014, the
American Cancer Society estimates approximately 224,000 new cases of lung cancer and
a mortality rate of about 159,000 for both sexes(1,2). Efforts introduced to reduce the risk
for lung cancer development, such as smoking cessation therapy and early screening,
have resulted in a decreasing mortality rate over the last 30 years for males and the last
10 years for females. While these trends are encouraging, the need for further
intervention is evidenced by the outstanding difference in mortality between lung cancer
and other prominent neoplasms like breast, prostate, and colon. In addition, the 5-year
survival rate of lung cancer is among the lowest (17% for all stages) and the probability
of identifying a tumor while it is still localized is dismal (15%)(2,3).

1.1.2 Etiology and Detection
Cigarette smoking is by far the leading cause of lung cancer. Numerous
epidemiological studies implicate cigarette smoking in the development of lung disease
and current estimates suggest it is responsible for about 80% of respiratory
malignancies(1,2,4). Smokers are estimated to have a 20x increased probability of
acquiring lung cancer of in their lifetime relative to never-smokers. Former smokers
decrease their risk by about half of current smokers and the probability of developing a
3

tumor continues to decrease over time, albeit never returning to non-smoker levels.
Further evidence of a causal link between smoking and lung cancer development is
provided by the changes in the prevalence of histological subtypes over time
accompanying public attitudes toward smoking; that is, as more people have quit
smoking, there has been a shift in the occurrence of specific subtypes of lung cancer most
associated with smoking(4). While smoking is clearly the most relevant environmental
exposure in the etiology of lung cancer, it alone does not account for all cases. Other
carcinogenic agents include asbestos, radiation, arsenic, chromium, uranium, nickel,
polycyclic aromatic hydrocarbons, diesel exhaust, and radon ("extrinsic components")(4).
From a pathological perspective, extrinsic factors insight an initial injury within the lung.
As a normal biological response, inflammatory cells are recruited to these sites where
they produce cytokines/chemokines, growth factors, and pro-angiogenic molecules to
protect and induce healing of the affected tissue. Typically these responses are selflimiting and wane following repair of the underlying insult. However in the context of
repeated injury, such as in a smoker, inflammatory and wound-healing programs persist,
inducing increased cell proliferation(5–7). This increased cellular replication, in
combination with exposure to carcinogenic agents, reactive oxygen species from immune
infiltrate, and an altered microenvironment signaling milieu, promotes the accumulation
of genetic mutations and may induce the initial transformation. Intrinsic components,
such as inherent genetic variation and epigenetic modifications, may also play a role in
the transition to cancer. For example, alterations in genes that control the metabolic
conversion of pro-carcinogens to carcinogens, chromosomal instability, and promoter
hypermethylation at certain loci, are all thought to contribute to pathogenesis(1,4,8).
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The late detection of lung cancer plays a significant role in the high mortality rate.
Signs and symptoms, including cough, hoarseness, bloody sputum, and weight loss, are
often absent until the tumor has grown beyond a curable time-point. This is partially due
to the formidable volume of the respiratory tract, allowing tumors to grow for some time
before affecting other physiological processes. In addition, smokers may overlook
signs/symptoms; attributing them as a consequence of the cigarettes themselves and not
the underlying pathology. Efforts to reduce the mortality rate have therefore been focused
on identifying tumors at earlier stages, when surgical intervention/chemotherapy may be
curable(3,4,9). Imaging-based methods remain the gold-standard for the discovery of
lung tumors, with low-dose spiral computed tomography (LDCT) being of particular
utility(4). LDCT allows physicians to survey respiratory tissues for suspicious lesions in
a manner more sensitive, faster, and with reasonable increases in radiation exposure
relative to standard chest x-ray(9,10). Studies evaluating the use of LDCT as an early
screening method, such as the National Lung Screening Trial (NLST), demonstrated its
ability to detect cancer sooner than other methods and thereby decrease the mortality rate
in a specific patient population(11). These results were promising enough to prompt the
American Cancer Society to publish screening guidelines based on its use; however the
study also unveiled a high rate of false-positive diagnoses associated with LDCT
assessment alone. Subsequent research approaches aimed at increasing the specificity of
screening are now focused on identifying molecular/proteomic biomarkers of early
tumors in serum, proximal fluids and tissue, which could be used in combination with
imaging for early diagnosis(9,12–15).
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The histological and molecular attributes of lung cancer play an important role in
prognostic and therapeutic considerations. Classifying lung cancer generally begins by
grouping tumors into either non-small lung cancer (NSCLC) or small cell lung cancer
(SCLC) subsets based on cytological characteristics of the primary tumor(s). NSCLC
represents about 85% of all lung tumors, SCLC around 10%, and other rare forms
(carcinoid) less than 5%(1). Within NSCLC, histologic sub-classifications of
adenocarcinoma (ADC), squamous cell carcinoma (SCC), and large cell carcinoma
(LCC) are made based on examinations of biopsies or cytological specimens; with
immunohistochemistry being the most reliable means to differentiate subtypes(3,4,12,16). These sub-classifications were originally used to stratify patients into
prognostic and therapeutic groups; however advances in molecular biology now permit
for the identification of specific genetic mutations driving individual tumors.
Consequently, therapeutic strategies have evolved for personalized medicine based on
this information and a restructuring of the lung cancer classification system has been
implemented to incorporate radiological, histological, and molecular typing(4,16,17).

1.1.3 Sub-types and Features
Adenocarcinomas represent the most prevalent subtype of NSCLC, accounting for
about 50% of all new diagnoses. This classification encompasses cancers arising in
secretory epithelial cells associated with glandular structures; which tend to form
peripherally and grow slowly(4). ADCs develop in smokers more commonly than nonsmokers; however, within the non-smoking population ADC is the predominant form.
Within this classification (but not limited to), point mutations/overexpression in the
epidermal growth factor receptor (EGFR) and rearrangement of the EML4-ALK gene
6

serve as predictive biomarkers for therapeutic efficacy of specific tyrosine kinase
inhibitors (TKI)(4,8,18). In addition, acquired mutation in EGFR following TKI therapy
indicates resistance to these drugs. Alterations in the K-Ras gene occur at a high
frequency in lung adenocarcinomas and result in the constitutive activation of signaling
pathways for proliferation and survival programs. Targeting this mechanism is an area of
intensive research for clinical management purposes; unfortunately with minimal gains as
of yet(8). Several other genetic aberrations have been documented, mediating effects in
epigenetics, transcription, proteolysis, tumor suppressor and cell cycle control
proteins(19). An important observation regarding these genetic anomalies is that they
tend to occur in a mutually exclusive manner and often drive ADC development in nonor light smokers (4,8,18). Continued research efforts to uncover the molecular pathology
of ADC will likely provide novel therapeutic targets as well as diagnostic/prognostic
biomarkers for stratification of patients presenting with this subtype.
Squamous cell carcinomas frequently originate in the central portions of the
respiratory tract; particularly in epithelial cells lining the bronchi. SCC tumorigenesis is
highly associated with smoking and its incidence (40% of all NSCLC) has declined
following public disclosure of the dangers of cigarettes(1). The pathology of SCC has
been well-defined and follows a predictable progression in tissue dysplasia and genetic
modification. Molecular changes accompanying this subtype include loss of
heterozygosity in CDKNA, TP53, and RB1, as well as overexpression of genes SOX2
and TP63(19,20). Documentation of SCC driver mutations lags behind ADC,
particularly because of sub-type prominence issues and tissue availability. More recently,
SCC-associated alterations with potential therapeutic/prognostic value have been
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identified in FGFR1, PI3KCA, and DDR2 genes. Conflicting information exists
regarding the status of mutations associated with adenocarcinoma occurring in SCC;
specifically EGFR, EML4-ALK, and K-Ras mutations. Some reports suggest that these
particular events may be associated with SCC initiation /progression, while other research
asserts that these findings were the result of mixed histologies in study specimens (i.e.
adenosquamous carcinoma)(19,20). In fact, further definition of the molecular diversity
in SCCs is currently an area of great interest. Importantly, this work will likely contribute
to targeted therapies and prognostic indicators similar to the significance of findings in
ADCs.
Large cell carcinoma is the least prevalent sub-type, representing about 10% of
NSCLC cases. LCC usually begins in the periphery of the lung, grows rapidly and may
secrete hormones (1,4). LCC is difficult to diagnose using traditional methodologies (i.e.
immunohistochemistry) because of the inability to distinguish it from non-differentiated
forms of ADC and SCC; therefore the LCC diagnosis commonly used when there is no
clear ADC or SCC differentiation(17).

1.2 Inflammation and TGFβ1 in NSCLC
1.2.1 Inflammation and the Pathogenesis of NSCLC
Persistent inflammation and chronic tissue remodeling, from environmental
factors such as smoking, as well as contributions from intrinsic components, characterize
the initiation of tumorigenesis in NSCLC. Inflammatory pathways are activated in
response to the initial insult, leading to recruitment of immune cells and restructuring of
the tissue by various cell populations. While this response is typically of a self-limiting
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nature, chronic activation of these pathways not only propagates tumor formation, it is
also hypothesized to advance existing cancer cells towards the acquisition of invasive
phenotypes. Numerous cytokines, growth factors, and inflammatory mediators regulate
these processes under tight temporal and spatial control. However, the dysregulated
growth and signaling networks of tumor cells, in the presence of the inflammatory tumor
microenvironment, may take advantage of these signals to propagate survival and
metastasis. Amongst the altered signaling milieu present in inflammatory
microenvironment, the pleiotropic cytokine transforming growth factor beta ligand 1
(TGFβ1) is of particular interest for the promotion of invasive phenotypes.

1.2.2 Introduction to TGFβ1
TGFβ1 is a multi-functional cytokine contributing to physiological processes
including tissue development, regulation of immunological responses, epithelial/stromal
cell proliferation and differentiation, induction and down-regulation of inflammation, and
the initiation and resolution of wound-healing(21,22). Three family members of TGFβ
ligands exist (i.e. TGFβ1, TGFβ2, TGFβ3). TGFβ1 is the major form produced relevant
to immune functions/wound-healing regulation, however all 3 ligands have potential to
mediate similar signal transduction pathways because they may share common
downstream 2nd messengers (21,23). The initial synthesis of TGFβ1, in stromal or
immune cell populations, results in the production of a pre-pro-protein form of the
molecule, which requires proteolytic cleavage for activation. The latent precursor
molecule is often secreted into the extracellular matrix, where it remains dormant until
acted upon by molecules such as integrin αvβ6, matrix metalloproteases (MMPs),
thrombospondin-1, and various other enzymes/proteases as biological context
9

dictates(21,24). Liberation of active TGFβ1 from its regulatory molecules, latent TGF
binding protein (LTBP) and latency associated peptide (LAP), results in binding of
dimeric-ligand complexes to type II TGFβ receptor (TGFβRII). This binding induces
conformational changes on the homodimeric TGFβRII, moving it into proximity to TGFβ
receptor type I (TGFβRI or ALK5) homodimers. Ligand-bound TGFβRII forms a
heterotetrameric unit with TGFβRI, allowing cross phosphorylation of its (TFGβRI)
cytoplasmic tail via TGFβRII’s Ser/Thr kinase domain(25). At this point, the activated
ligand/receptor complex is primed for the activation of downstream effectors capable of
inducing canonical and non-canonical effects of TGFβ1. An important consideration to
note is that different TGFβRI isoform subtypes (ALK1-7) may be preferential activated
depending on cell lineage, resulting in activation of diverging downstream signaling
effectors(22,23,25). Although the predominant TGFβRI isoform activated in immune,
epithelial, and fibroblast populations by TGFβ1 is ALK5, recent research suggests some
outcomes may also be mediated through ALK1 in endothelial and epithelial
cells(23,25,26).

1.2.3 Canonical TGFβ1 Signaling
The canonical pathway initiated by ligand-bound TGFβRII-ALK5 complexes
begins with the phosphorylation of receptor-Smad proteins (R-Smads: Smad-2 and -3) by
type I TGFβRI, a Ser/Thr kinase. R-Smads are brought into proximity to activated
receptor complexes by Smad-anchor for receptor activation (SARA), allowing each to be
phosphorylated. Following this activation, Smad-2 and Smad-3 individually form
heterodimers with the common Smad (Smad-4) and translocate to the nucleus where they
function as transcription factors(22,25,27). Smad-binding elements (SBE) on pertinent
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genes are targeted for modulation by a combination of R-Smad/Smad-4 and various coactivators or co-repressor molecules. Importantly, these co-regulatory molecules, such as
AP-1, Ets, basic helix loop helix, Forkhead and Homeobox-containing transcription
factor families, confer tight binding and specificity to genes regulated by TGFβ1(22,28).
R-Smads also recruit histone acetyltransferases (CBP/p300) and de-acetylases (Sno/Ski)
in their complex orchestration of transcription control. Depending on the biological
context/cell type, different co-regulatory molecules may preferentially interact with the
R-Smads to influence gene expression. Some of transcription targets of TGFβ1 relevant
to inflammation/wound-healing include genes affecting morphology (α-actinin,
tropomyosin), extracellular matrix-modifying enzymes (collagens, MMPs, plasminogen
activator inhibitor), and cell adhesion properties (cadherins, integrins,
fibronectin)(29,30). In addition, canonical TGFb1 signaling results in the transcription of
Smad-7 (inhibitory-Smad). Through this mechanism TGFβ1 is able to regulate its own
signaling via negative feedback; by direct competition of Smad-7 with Smad-2/3 for
binding at TGFβRI as well as the recruitment of an ubiquitin ligase for degradation of
ALK5.

1.2.4 Non-Canonical TGFβ1 Signaling
Several studies have also uncovered the ability of TGFβ1-bound
TGFβRII/TGFβRI to affect cell-signaling pathways that are Smad-independent or that
interact with Smads outside of the mechanism described above ("noncanonical")(22,27,31). Models of TGFβ1 signaling using mutated TGFβR1 or Smad-4
deficiency demonstrate activation of pathways such as p38 MAPK, JNK, and Erk MAPK
following stimulation(31). Other effectors such as PI3K-Akt and NF-κB are reportedly
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stimulated by kinase cascades following TGFβ1 ligand-binding; however the distinct
means by which this is achieved has yet to be elucidated. One hypothesis is that TGFβinduced kinase (TAK1) and Ras propagate transduction through these pathways via direct
TGFβ1 activation(27). An important outcome of non-canonical activation of these
pathways is convergence with Smad-dependent signaling. TGFβ1 activation of MAPK
signaling has been shown to regulate Smad-dependent transcription targets through
effects on co-regulatory transcription factors(22). The potential results mediated by the
interaction of these pathways are diverse and confer a further level of regulation for
generating context-dependent outcomes in TGFβ1 signaling. Other effectors in noncanonical TGFβ1 signaling include the Rho-like GTPases (RhoA, Rac, Cdc42) and
PP2A(27,31). These molecules impart effects ranging from the modification of
cytoskeletal organization, to serving as intermediates for the regulation of other noncanonical pathway molecules, as well as affecting cell cycle progression. Detailed
characterization of Smad-independent signaling, and its significance to physiological
responses of TGFβ1 is still underway.

1.2.5 Paradoxical Effects of TGFβ1 in Cancer
TGFβ1 is well-known to promote growth-inhibition on non-transformed epithelial
cells via canonical signaling; through modification of specific transcriptional targets
controlling cell cycle and apoptosis(28). In the context of carcinogenesis, these actions
suggest that the molecule promotes the suppression of tumor growth. In support of this
role, retrospective analyses have identified mutated forms of TGFβ1 receptors/effectors
present in tumors of various origins; inferring that altered signaling may contribute to
initial tumor formation(23,32). These functions of TGFβ1 became particularly perplexing
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following the observation that many advanced tumors over-express the ligand, and, that
loss of growth-inhibitory response increased metastases and resulted in poor
prognoses(25,33–36). Subsequent investigations, aimed at clarifying these apparently
paradoxical roles for TGFβ as a tumor suppressor and promoter, were carried out using
transgenic murine models of cancer with various modified components of the TGFβ1
pathway. The studies confirmed the dual functionality of the cytokine and provided
insight into some of the mechanisms established tumors use to overcome growthinhibitory effects of TGFβ1 and utilize them for the propagation of survival/invasion.

1.2.6 TGFβ1 and Invasive Tumor Phenotypes
TGFβ1 is initially secreted into inflammatory tumor microenvironments by
immune infiltrate and stromal cells recruited to protect/repair underlying tissue damage.
However, over time, transformed epithelial cells acquire the ability to produce and
secrete the cytokine (37). In addition, latent TGFβ1 present in the extracellular matrix
may be activated by the enzymes/proteases secreted by these cells during the process of
tissue restructuring. The effects of active TGFβ1 within this physiological context
influence the genetic programs of tumor and stromal cells, as well as regulating hosttumor immune interactions and promoting angiogenesis. One such effect, hypothesized to
play a central role in the acquisition of invasive phenotypes, involves modification of a
set of genes controlling epithelial cell differentiation, morphology, and function. The
phenotypic changes incurred as a result of targeting these genes are collectively referred
to as the epithelial to mesenchymal transition (EMT). EMT is a normal biological
occurrence during embryogenesis, tissue development, and wound-healing. It provides a
reversible mechanism for differentiated epithelial cells to undergo phenotypic transition
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into de-differentiated, migratory states (mesenchymal) for the colonization of tissues in
processes like organ development or wound repair(38). This program is typically under
tight regulatory control; requiring specific extracellular cues and the cooperation of
several molecular effectors for coordination. However, in a state of altered signaling,
such as chronic inflammation and/or carcinogenesis, the inappropriate activation of EMT
may occur and propagate pathological progression(28). An example of this is evidenced
in states of organ fibrosis. In such cases, habitual EMT, stemming from un-resolved
inflammation, TGFβ1 production, and other molecular contributors, results in increased
epithelial cell de-differentiation to fibroblast precursors(39). These fibroblast-like cells
produce collagen in an attempt restructure the supporting tissue. Without resolution of the
EMT-promoting events, hardening and dysfunction of the affected organ may result(40).
More recently, EMT has been hypothesized to be a mechanism for initiating
metastasis in epithelial based tumors. Murine models and In vitro experiments
demonstrate the ability of tumorigenic epithelial cells to respond to EMT-inducing
molecules and acquire phenotypic changes consistent with mesenchymal cells. These
phenotypic changes include loss of epithelial cell markers E-cadherin, Zona Occludens-1,
and MUC1. In addition, these cells gain markers such as α-smooth muscle actin,
fibroblast-specific protein, N-cadherin, and vimentin; all highly suggestive of a
mesenchymal-like state(28,38). TGFβ1, along with other growth factors from within the
tumor microenvironment, has been shown to induce the genetic changes consistent with
acquisition of these phenotypic alterations; for example, through the modification of
genes such as Snail, Slug, Zeb-1/2, Goosecoid, and Twist. TGFβ1 imparts its pro-EMT
effect through both canonical and non-canonical pathways, with cooperative interaction

14

of certain pathway effectors resulting in a synergistic effect. Canonical signaling
influences the expression of target genes mentioned above, through direct
activation/repression of transcription factors or epigenetic modifications. Smadindependent signaling, such as through Ras activation, promotes EMT by modifying
adherens junctions as well as working together with canonical signals for the induction of
genes like Snail. In addition, non-canonical signaling contributes the cytoskeletal
organization changes and the dissolution of tight junctions, through interactions with
molecules like Erk, JNK/p38, Rho-like GTPases, and CDC42. Each pathway is also
hypothesized to contribute to the autocrine production of TGFβ1 by transformed cells,
feeding back to strengthen these signaling outcomes(28,38,41). Furthermore, oncogenic
changes within the cells may assist in TGFβ1-induced EMT. For example, loss of the p53
tumor suppressor, in combination with TGFβ1 signaling, promotes the de-regulation of
key mediators of cell cycle progression(42). Outside of the direct tumor cell effects of
TGFβ1, the cytokine also primes the tumor microenvironment for invasion. Immune
cells, such as neutrophils and monocytes, are recruited to the tumor by TGFβ1 and other
inflammatory mediators. Upon arrival, these cells secrete matrix-modifying enzymes,
growth factors and cytokines as a normal physiological response(21,43). The dissolution
of the extracellular matrix by matrix-metalloproteases, collagenases, and other proteases
by these cells may help facilitate intravasation of tumor cells as an initial step in
metastasis. Finally, TGFβ1 skews the phenotype of immune cells away from anti-tumor
responses, further supporting aggressive tumor growth(24).
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1.2.7 TGFβ1 and Glycosylation
Several of the proteins targeted for modification by TGFβ1 in the acquisition of
invasive tumor phenotypes share functional characteristics: being related to cell adhesion,
cytoskeletal organization, and extracellular matrix (ECM) remodeling. The change in
differentiation state of tumor cells stimulated with TGFβ1 requires a comprehensive reorganization of these types of molecules and their biological properties. Beyond effects
on protein expression levels, other characteristics likely regulated by TGFβ1 influence
protein-protein interaction, localization and stability. Based on this rationale,
investigations are now exploring additional mechanisms by which TGFβ1 influences
tumor cell phenotypes. For example, several studies are investigating alterations in
protein glycosylation as a potential means to propagate TGFβ1-induced invasive
characteristics(44–47). The principle behind this is seeded in the abundance of relevant
biological functions that glycans carry out and the high frequency with which these
PTM's are attached to proteins modified during invasion. Glycans influence cell-cell and
cell matrix-adhesion, protein-trafficking, ligand-receptor interaction, and immune
recognition(48). Furthermore, a wealth of literature demonstrates alterations in
glycosylation profiles accompanying embryonic tissue development and cell
differentiation, neoplastic transformation, and metastatic dissemination(48–53).
Examinations of microarray data from cell models of cancer stimulated with
TGFβ1 have uncovered significant differences in the mRNA levels of potentially relevant
enzymes responsible for glycan synthesis, extension, and degradation. For example,
Maupin et al. detected alterations in the levels sialyl-transferases and polypeptide Nacetylgalactosaminyltransferases transcripts following TGFβ1 stimulation(45). This
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group further demonstrated that various pancreatic cancer cell lines, designated as either
epithelial or mesenchymal, present with vast differences in expression profiles of genes
vital to branching/lengthening of existing glycans and O-type glycosylation. Another
complementary analysis revealed contrasts in glycan-related gene expression between
actively migrating and stationary cancer cells. Conclusions drawn from their efforts
indicate that glycosylation-related genes, as a group, are significantly enriched for
modification following TGFβ1 stimulation. However, clear relationships regarding how
TGFβ1 influences these genes have yet to be elucidated. Zhang et al. provide evidence of
a pSmad-2 dependent effect for the induction of the glycosyl transferase GCNT2 and
demonstrate the requirement of its enzymatic activity in the induction of certain
migratory characteristics(46). Other suspected pathways may be influenced by TGFβ1's
ability to affect epigenetic modifications. The MGAT3 gene codes for the glycosyl
transferase GnT-III, which catalyzes the addition of bisecting N-acetylglucosamine
(GlcNAc) to core N-glycan structures. The presence of these bisecting structures
precludes further branching of glycan chains catalyzed by the glycosyl transferase (GnTV). An important observation has been that increased levels of GnT-V, and decreased
levels of GnT-III, are associated with increased metastases in some cancer models(54–
56). Pinho et al. used this information to research mechanisms by which aggressive
cancers may modify the expression of these enzymes(47). Their work established that
promoter hypermethylation of MGAT3 occurs following TGFβ1 exposure and they
conclude that the subsequent loss of bisecting GlcNAc on E-cadherin may allow for an
increased turnover rate of the cell adhesion molecule. Beyond cell-specific effects, other
studies have put forth hypotheses proposing that TGFβ1 can modify the glycosylation
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status of vital ECM components in contributing to invasion. Freire-de-Lima et al.
revealed increased enzymatic activity of specific N-acetylgalactosaminyl transferases
(GalNAc-T) following TGFβ1 stimulation of prostate cancer cell lines(57). These
GalNAc-Ts were shown to be responsible for the addition of a specific O-linked glycan
on fibronectin, which defines a variant form of the protein associated with metastatic
cancer (oncofetal fibronectin). The authors conclude their study by demonstrating that
blocking oncofetal fibronectin expression, through upstream inhibition of the GalNAcTs, attenuates TGFβ1-mediated acquisition of invasive phenotypes in these cells.

1.3 Glycosylation and Biomarker Discovery
1.3.1 Introduction to Glycoproteins
Glycosylation is the most common post translational modification, estimated to
occur on around 50% of all mammalian proteins. These sugar molecules ("glycans")
carry out various biological functions, which can be broadly defined into
structural/modulatory roles and the regulation of cell-cell and cell-environment
recognition events. Glycosylation may occur on proteins, lipids, DNA, and other organic
molecules; with the collective group of substrates being referred to as glycoconjugates.
For proteins in particular, the attachment of carbohydrate molecules influences
conformation, localization, retention, and protein-protein interaction. At the cellular level,
this translates into effects on processes such as cell-cell and cell-matrix adhesion,
receptor-ligand binding, ECM structure and integrity, and cytoskeletal dynamics (58,59).
Consequently, glycans are often found attached to secreted or cell-membrane associated
proteins, although cytosolic and nuclear glycoproteins also exist. From an evolutionary
18

standpoint, glycosylation is thought to increase the diversity of functions that a limited set
of molecules (proteins, lipids) may carry out for normal biological function and in
responding to environmental stimuli. Supporting this idea is the array of mono- and
polysaccharide molecules used to synthesize these structures. Carbohydrates may be
attached in alternative orders, differing anomeric configurations, and in branched or
linear configurations for a given glycosite on a single protein under different
physiological conditions (48). In addition, glycans may be further modified by sulfation,
methylation, or acetylation following attachment. The relevance of glycosylation in
influencing biological processes is evident in the multitude of disorders identified from
its dysregulation. For example, glycans play a role in pathogenic, congenital, and
acquired disease states. The congenital disorders of glycosylation (CGD) are a collection
of inherited maladies caused by ineffective glycan anabolism commonly presenting at
early stages of life. In addition, several of the lysosomal storage syndromes, including
Tay-Sachs disease, are related to the inability to properly degrade glycans(48,60,61). A
common theme in these glycosylation disorders is that pathology is often evident at early
stages of life, reflecting the nature of these molecules to carry out functions in
developmental/differentiation cell programs(62). In line with this were observations that
cancer cells present with an altered repertoire of glycans relative to non-transformed cells
of the same origin. Studies using lectins (molecules which recognize glycan epitopes),
glycan-specific antibodies, and protein separation techniques initially uncovered the
changing "glycome" tumors often exhibit(63). Subsequent efforts confirmed that the
repertoire was again changing as tumor cells undergo metastatic dissemination and
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hypotheses began being formed regarding how tumor cells may utilize these changes to
propagate the neoplastic phenotype.

1.3.2 Biosynthesis and Roles of Glycoproteins
The potential for great diversity in glycan structures attached to proteins in
mammalian cells exist. At present, 10 different precursor sugar molecules are known,
which are derived from metabolic and/or glycan salvage pathways(64). These
monosaccharide molecules are "activated" in the cytoplasm by attachment to high-energy
nucleotide-phosphates and then transported to the endoplasmic reticulum and Golgi
apparatus. Within these compartments, the molecules now serve as donor-substrates for
the enzymes that initiate and elongate these structures. The glycosyltransferases (GTs),
which catalyze the formation of substrate-glycan bonds, typically act in a manner
consistent with one enzyme being responsible for the attachment of one donor sugar to an
acceptor substrate in a specified linkage conformation(65). However, within this large
group of highly conserved enzymes (over 96 GT families exist), exceptions to the "one
enzyme-one linkage" observation exist. For example, cases where more than one GT
catalyzes the addition of the same donor-substrate and linkage conformation have been
demonstrated (i.e. shared specificity). Other exceptions include single GTs being capable
of adding a donor substrate in different linkages or being promiscuous in acceptor
specificity(65). GTs may also compete amongst themselves for donor glycan substrates,
and as well, cell/tissue specific expression of different GT families has been observed(64)
. In addition, the enzymes which hydrolyze glycan-substrate linkages, the glycosidases,
function along the anabolic pathway creating intermediate glycan structures. These
exceptions to the one enzyme-one linkage observation have confounded efforts to predict
20

glycan structures based on the presence/absence of specific GTs in different cell types.
However, other useful information regarding these enzymes has been deduced with
potential applications for uncovering specific glycan roles(66). For instance, the
initiating-GTs tend to have higher levels of specificity for acceptor substrates
(polypeptides, lipids, nucleic acids) relative to later-acting GTs which extend
oligosaccharides (where acceptor substrates are previously attached glycans). Consensus
sequence/motifs have been identified for some of the initiating enzymes, aiding in the
calculation of where these structures may be attached. Furthermore, this information was
useful for elucidating the molecular mechanisms by which carbohydrates are bound to
other molecules. As an example, protein N-linked glycosylation only occurs in the amino
acid consensus sequence Asn-X-Ser/Thr, where X is any amino acid other than Proline.
The biological rationale for this consensus sequence is evidenced by amide bond
formation between the initial GlcNAc molecule of the glycan and the nitrogen on the side
chain of Asn. It should be noted for this particular example, however, that just because a
consensus sequence is present does not necessarily mean glycosylation will be initiated;
the same being true for glycan acceptor substrates of the extending GTs. Further
complexity in carbohydrate structures are mediated through monosaccharide substrate
availability, the potential for multiple anomeric configurations, and chemical
modification of glycans(64,67). These examples provide only a partial insight into some
of the mechanisms responsible for the exuberant amount of oligosaccharide diversity in
mammalian cells. Importantly, cells utilize these assortments of glycan
structures/attachments to influence the functionality of glycoconjugates and may alter the
structures in response to different biological contexts(67).
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Three major types of mammalian glycoproteins exist: N-linked, O-linked, and
proteoglycans. As mentioned above, N-linked glycosylation is defined by bond formation
between Asn residues in the consensus sequence Asn-X-Ser/Thr and a GlcNAc substrate.
O-linked glycans are attached ambiguously at Ser/Thr, through a reaction with the side
chain hydroxyl group of these amino acids. The third class of glycoproteins,
proteoglcyans, is composed of a protein backbone with one or more glycosaminoglycan
(GAG) branches occurring along the length of the core. These linear, highly-sulfated
molecules are abundant in the ECM where they influence biological processes through
charge state effects from the GAG molecules they carry(68). N- and O- glycans share
some characteristics in their biosynthesis and function. Each of these molecules exerts
distinct influences on the underlying protein to which they are attached based on the
unique repertoire of sugars they carry.
The synthesis of N-linked glycans begins in the ER and is completed in the Golgi,
where structural complexity may be added by concerted efforts of glycosyltransferases
and glycosidases. The glycoprotein products are typically destined for secretion or
insertion into the cell membrane; a fate that is inherently tied to the localization of
enzymes required for their production (66). The N-linked glycan pathway is unique in
that these molecules are first constructed by the transfer of a "core" set of glycans from a
dolichol-phosphate donor. This highly conserved, constitutive pathway is orchestrated
co-translationally, as a growing polypeptide chain enters the ER. First, a 14-sugar core
(Glc3Man9GlcNAc2) is covalently linked to the substrate by the oligosaccharide complex
(OST), yielding an immature N-glycan. Glycosidases present in the ER and Golgi cleave
glucose and mannose residues from the core, typically resulting in N-glycan structures of
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Man5GlcNAc2(69). These "fully trimmed" glycans may now be elongated with various
monosaccharides through the action of medial and trans- Golgi-based GTs. However, not
all N-linked glycans undergo full trimming, and as well, not all trimmed N-glycans will
be elongated. The carbohydrate moieties present on N-linked glycoproteins which retain
>5 core mannose sugars cannot be further processed by Golgi GTs. This type of N-glycan
is referred to as "oligomannose" and variations in their presentation on final protein
products range from fully trimmed (Man5GlcNAc2) to untrimmed (Man9GlcNAc2) and
anywhere in-between(69). Another important biological consequence of the trimming
reactions is the facilitation of protein quality control, through interactions with ER-based
chaperones. Unfolded or mis-folded proteins may not be appropriately processed by the
glycosidases responsible for removing core glucose molecules, resulting in retention and
possible proteosomal degradation of the polypeptide(70). Those glycans which
successfully undergo complete trimming have the additional potential to become either
"complex" or "hybrid" type N-glycans(69). Complex N-glycans are generated from the
Man5GlcNAc2 core structures through reactions mediated by GlcNAc-transferase I & II
as well as the glycosidase α-mannosidase II. The action of these enzymes further reduces
the mannose content ( to Man3GlcNAc2) and adds GlcNAc residues to both of the core
"branches", providing an acceptor substrate for further GT action. In addition each branch
may form a bond with up to two GlcNAc linkages, resulting in bi-, tri-, and tetraantennary and bisecting complex glycans. Hybrid N-glycans, as the name implies, are a
combination of oligomannose and complex structures. This type of N-glycan is produced
when α-mannosidase II cleaves only 1 mannose from the fully trimmed core, resulting in
GlcNAc1Man4GlcNAc2. The terminal GlcNAc residue present on one of the branches
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may be extended with other sugars (like complex) while the other branch is terminated
with core-derived mannose (like oligomannose). As complex and hybrid N-glycans
progress through the Golgi, various modifications may occur to the core and GlcNAc
branches. For example, the addition of a fucose molecule to the GlcNAc bound to Asn
("core fucosylation") or glycosidic linkages between GlcNAc antennae and galactose
("LacNAc"). Capping sugars, or the terminal carbohydrates added to elongated branches
of complex/hybrid glycans, include GalNAc, sialic acid, fucose, and galactose. These
monosaccharides may protrude from the secondary structure of repeated sugar units
(poly-LacNAc) commonly present in complex/hybrid antennae. In this manner of
presentation, these carbohydrates play a central role in determining the interaction of Nlinked proteins with their environment(69).
O-linked glycosylation on protein substrates is a broad term for the attachment of
various carbohydrate molecules to the hydroxyl group of Ser/Thr residues(50,71). For
this type of glycosylation, several subdivisions can be made by categorizing the initiating
sugar attached to the polypeptide. For example, the O-GalNAc type O-glycosylation,
which are commonly synthesized on cell-membrane and secreted proteins, mediate
effects similar to N-glycans in cell-cell and cell-ECM interaction. Another type, OGlcNAc, may be synthesized on cytosolic and nuclear proteins and are hypothesized to
regulate signaling cascades(64). Other forms of O-glycosylation include linkages
beginning with as xylose, mannose and fucose. For simplicity, relevance, and functional
similarities to N-glycans, all further information presented here will based on O-GalNAc
type O-glycosylation.
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The synthesis of O-GalNAc glycans on proteins (also termed "mucins") begins
with transfer of the sugar molecule to Ser/Thr residues on proteins transiting through the
Golgi. The reaction is carried out by the polypeptide-GalNAc-transferase family of
enzymes (ppGalNAcT), who require the GalNAc molecule to be attached to the highenergy donor UDP. There is no consensus sequence required for the initiation of the
reaction; however steric effects from proximal amino acids may influence the access of
ppGalNAcTs to specific residues(71). Once the first GalNAc is attached to the
polypeptide, additional linkages may be made using GlcNAc or galactose. This results in
the production of various O-GalNAc core structures, to which other sugars may be
further added ("extended core"). 8 distinct core structures exist, some of which present
with differential tissue distributions. The most common arrangements, cores 1-4, are
defined by secondary monosaccharide linkages to the initial GalNAc molecule.
Glycoproteins carrying these types of sugars tend to be widely distributed in glandular
tissues(50). Other configurations are seemingly more limited in their expression and may
be associated with pathological states. For example, the minimum requirement for an OGalNAc glycans is simply the linkage of the first GalNAc to Ser/Thr (termed "Tn
Antigen"). The Tn Antigen, and its sialic-acid linked form ("Sialyl-Tn Antigen"), are
rarely expressed as final glycan architectures in normal tissues, yet they have been
identified in several tumor types(63,72). In a manner similar to N-glycans, the O-GalNAc
glycans may be extended (core structures 1-4 and 6 only) with repeating units of GlcNAc
and galactose, producing poly-LacNAc. This again allows terminal sugars such as fucose,
sialic acid, galatcose, and GlcNAc to protrude for roles in cell-environment interaction.
Limitations in the final O- glycan structures at a given tissue are ultimately determined by
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the expression/activity, distribution/order, and acceptor specificities of GTs and substrate
availability(71). Importantly, these factors may be modified in different biological
contexts, such as pathological conditions, and in response to external stimuli such as
growth factors/cytokines.
The biological roles for the O-GalNAc glycosylation often overlap with those of
N-glycans. For example, these molecules may impact cell-cell and cell-matrix interaction
through protein conformation effects or by acting as ligands themselves. The importance
of O-glycosylation in cell adhesion is exemplified by the Lewis blood group
determinants(73). These molecules are fucosylated extended core O-glycans presented on
cell membrane-based proteins which may undergo further modification by the addition of
sialic acid. A vital role for the sialylated epitopes has been demonstrated in selectinmediated adhesion, where they serve as ligands for leukocyte homing and extravasation
during inflammation/tissue injury(51). Since the elucidation of this function, subsequent
roles for the altered expression of sialylated Lewis antigens have been identified in
invasive forms of cancer. In addition to adhesion effects, these carbohydrate moieties
may protect protein substrates from protease digestion, mask antigens, and affect cell
receptor turnover rates. Outside of the cell, secreted O-glycoproteins induce the
formation of a protective barrier from pathogenic organisms for epithelial cell
populations. This layer of mucinous glycans is composed of negatively charged sugars
(sialic acid) which induce the formation of a hydration layer along luminal surfaces(74).
A critical role for O-glycosylation in differentiation and development has also been
observed through studies using Drosophila melanogaster. These investigations exposed
the importance of O-glycans in integrin-mediated cell adhesion, cell polarity, and tight

26

junction formation during organogenesis(50). As well, this work showed that efficient Oglycosylation is required for the secretion of vital ECM and basement membrane
components during development. Furthermore, transgenic murine models deficient in
specific core-extending GTs present with embryonic-lethal phenotypes due to ineffective
cell adhesion in vasculature development(50).

1.3.3 Sialic Acid
N-acetylneuraminic acid (Neu5Ac or sialic acid) is a monosaccharide frequently
found at the non-reducing terminus of N-glycans and may occur as an intermediate or
terminal sugar in O-glycans. The molecule is a nine carbon, acidic α-keto sugar which is
produced by metabolic conversion of N-acetylmannosamine (ManNAc) or from glycan
salvage pathways(75). Neu5Ac is activated as a substrate for glycan linkage by reaction
with the nucleotide donor CMP in the nucleus. The high energy donor molecule is
transported to the cytoplasm and eventually to the Golgi, where its addition to acceptor
glycan substrates are carried out by members of the sialyltransferase family(76). This
group of enzymes exhibits remarkable specificity in linkage conformation and acceptor
substrates; they may as well be sensitive to chemical modifications occurring on the
donor sugar. Neu5Ac may be linked to other sugars (or itself) through three different
anomeric configurations, with each linkage the result of specific sialyltransferases(76,77).
The α2-3 and α2-6 linkages are found in both N- and O-glycans, where sialic acid is
added on terminal galactose or GalNAc residues. Glycans bearing α2-3 linked sialic acid
may act as substrates for the addition of other sugars on interior residues or inhibit further
chain elongation(73). α2-6 configurations have additionally been identified in linkages to
GlcNAc (terminal and non-terminal) as well as internal GalNAc
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monosaccharides(73,78). This type of bond generally hinders supplementary sugar
extensions, with a notable exception being the addition of α2-8 linked sialic acid. The
final connection, α2-8, is initiated on α2-3 or α2-6 linked sialic acid for the production of
polymeric chains of the sugar composed of up to 200 residues. The product of this
linkage, polysialic acid (PSA), is rarely found outside of the biological process of
embryogenesis or in neuronal development; however, one α2-8 sialyltransferase, ST8SiaIV, is expressed in various tissues through adulthood(73,79). Sialic acid residues can be
found in any tissue where O- and N-glycans are produced, however tissue-specific
expression of certain sialyltransferases may limit the types of attachments present at a
given site. The general biological properties influenced through sialic acid attachments
are related to the electronegative charge of this sugar at physiological pH(76). At the
cellular level, the charge state of Neu5Ac impacts protein conformation, which in turn
regulates protein-protein interaction, receptor-ligand affinity and protein turnover. Sialic
acid may also facilitate binding of glycan epitopes to lectins or even mask antigenic
sequences from recognition. In a broad sense, the chemical attributes of this sugar affect
cell-environment interactions through its distribution on both cell-membrane and ECM
glycoprotein populations. Altered states of sialic acid biosynthesis and degradation are as
well implicated in pathological conditions. The inborn errors of metabolism, as well as
neurological disorders such as Parkinson's disease, Schizophrenia, and Alzheimer's
disease, are all hypothesized to be impacted by sialylation(75,76). Furthermore, a general
increase cell-surface sialylation and a shift toward production of α2-6 linkages are
frequently observed on transformed cells and several lines of evidence suggest a role for
Neu5Ac in tumor cell progression(63,76,78,80–83).
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1.3.4 Glycosylation Alterations in Cancer
Aberrant glycosylation on cell-membrane and secreted glycoproteins is
inherently tied to the progression of carcinoma. Alterations in the abundance, structure,
and sites of glycosylation contribute to the acquisition of invasive phenotypes through
effects on cell-cell adhesion, cytoskeletal dynamics, and extracellular matrix
properties(53,63,78,84,85). Cancer cells acquire the ability to produce a selected subset
of glycans configurations, including incomplete/truncated structures, changes in N-glycan
branching patterns, and the altered presentation/secretion of mucins. In addition,
increased sialylation, fucosylation, and the reappearance of embryonic-associated glycan
structures (oncofetal antigens) are correlated with poor prognoses in several different
cancers(63,86–89).
β1-6 branching on the core structure of N-glycans, catalyzed by the enzyme GnTV, produces a scaffold upon which other sugars may be added for the production
complex tetra-antennary oligosaccharides. While this process is a normal part of the Nglycan biosynthetic pathway, transformed cells often exploit this mechanism to overproduce these "bulky" molecules on cell surface-associated proteins. Hypotheses on how
neoplastic cells carry out this function include direct transcriptional regulation of the gene
MGAT5 during carcinogenesis. This gene, which codes for the GnT-V
glycosyltransferase, contains 5' promoter region sequences which may be functionally
regulated by downstream effectors of common cancer-cell signaling pathways including
V-Src, Her-2, and H-Ras(63,85). In addition, TGFβ1 has been shown to increase the
stability of MGAT5 transcripts in melanoma cells, although the mechanism for this effect
has yet to be uncovered(90). Various models of cancer show that these large
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oligosaccharide groups may be attached on proteins including integrins, cadherins,
cytokine/growth factor receptors, and other classes of membrane-bound
glycoproteins(52). The biological consequence for the over-production of these
structures varies with the function of the underlying protein. For example, increased β1-6
branching on E-cadherin in a mouse mammary tumor model resulted in decreased
homotypic interaction of the cell-cell adhesion proteins(91). The molecular rationale for
these observations is most likely increased turnover of E-cadherin from the cell
membrane and/or decreased protein-protein interaction conferred from the steric effects
on the underlying protein. Alternatively, increased branching of N-glycans attached on
cytokine receptors, like EGFR and TGFβR, has been shown to reduce endocytosis of
these molecules from the cell membrane(92,93). This outcome is hypothesized to be
carried out by the stabilization of these receptors at the cell surface through lattice
formation via increased interaction of these molecules with galectin-3; allowing
continued signaling through these pathways. Interestingly, this specific example
highlights a potential positive feedback mechanism to amplify cell programs for invasive
phenotypes, granted the stabilizing effect of TGFβ1 on MGAT5 transcripts discussed
previously. The α5β1 integrin, a receptor for fibronectin, is a heavily N-glycosylated
membrane-bound protein integral to cell-cell and cell-ECM interactions. Guo et al.
elegantly demonstrated that the over-expression of GnT-V in fibrosarcoma cells resulted
in increased β1-6 branching of the β1 subunit of this cell adhesion protein(85). The
authors established that through this mechanism cells were able to decrease attachment to
fibronectin and increase migration/invasion. Furthermore, this group showed that
inhibition of GnT-V catalyzed β1-6 linkages, by the addition of swainsonine, reversed
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these phenotypes and restored attachment to fibronectin. The glycosyltransferase GnT-III
is responsible for adding a β1-4 linked GlcNAc moiety to the central mannose residue of
core GlcNAc N-glycan structures. The addition of this "bisecting GlcNAc" prevents
complex glycan formation by blocking the action of downstream core trimming enzymes.
Studies using various models of cancer have identified paradoxical roles for the GnT-III
catalyzed product associated with metastatic phenotypes. For example, GnT-III
expression and the presence of increased bisecting GlcNAc in ovarian cancer and
hepatocellular carcinoma were able to differentiate tumor from adjacent normal tissue
and were associated with higher rates of metastasis in these models, respectively(94,95).
However in mouse models of melanoma, the overexpression of GnT-III resulted in a
decrease of β1-6 branching and correlated with less-aggressive tumor phenotypes(96,97).
The production of truncated or incomplete O-glycan structures are another feature
associated with cancer-induced glycosylation changes. The normal biosynthesis of Oglycans begins with the attachment of GalNAc to Ser/Thr residues on polypeptides as
they progress through the secretory pathway. Further sugar extensions are typically added
to produce core and extended core O-glycans structures; which may be further modified
by capping sugars such as sialic acid and/or fucose. Shorter, intermediate O-glycan
architectures, such as the T and Tn antigens and their sialyated forms (sT and sTn), are
almost exclusively expressed in association with pathologies such as cancer(63,84).
These types of structures are often ubiquitously attached on various membrane-associated
protein populations and therefore described as a generalized phenomenon rather than an
effect on specific proteins. The Tn antigen (GalNAc-Ser/Thr) is considered a pancarcinoma marker, being expressed on virtually all epithelial-based tumors(63,72,98).
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This particular glycan epitope may be found on both membrane-associated and
extracellular (luminal) proteins during carcinogenesis and is correlated to poor outcomes
in multiple cancer types. Several mechanistic theories have been formed to explain the
production of this biosynthetic intermediate. Following the addition of GalNAc to
Ser/Thr by ppGalNAcT, the resulting Tn antigen may be extended by either T-synthase
or C3GnT for the production of core-1 or core-3 structures, respectively. T-synthase is a
widely expressed enzyme that requires the chaperone protein COSMC for appropriate
Golgi localization and full catalytic activity(71,99). Reports using various models of
cancer show that the loss of T-synthase or C3GnT activity, as well as COSMC mutation
and epigenetic silencing, provide a means for accomplishing the overproduction of Tn
antigen during tumor progression(100,101)). Unlike the Tn antigen, the sialylated form of
this epitope (sTn) does not serve as a precursor in the construction of other O-glycan
configurations(71). sTn is produced by the action of ST6GalNAc-1 within the Golgi,
where this enzyme catalyzes the α2-6 linkage of Neu5Ac to the initiating GalNAc
carbohydrate. sTn expression is thought to occur as a byproduct of increased Tn
production through the same mechanisms described above, because both epitopes are
often identified in parallel. Investigations into alternative pathways for its accumulation,
such as the over-expression or increased activity of ST6GalNAc-1, demonstrate mixed
results as a means to accomplish this outcome(102–104). The T antigen ("core-1") is
composed of a galactose molecule attached to the GalNAc residue of the Tn antigen
(Galβ1-3GalNAc-Ser/Thr). Fates of the T antigen in normal O-glycan processing include
GlcNAc addition for core-2 production and/or the attachment of Neu5Ac for mono-/disialylated T antigens(71) . Increased expression of the T-antigen has been detected in
-
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various epithelial-based tumors, usually in association Tn and sTn epitopes. However,
difficulty in differentiating T antigens from similar glycan attachments on lipid substrates
has hindered efforts to define the prognostic significance of these molecules in cancer
progression(72). The functional relevance for the production of these incomplete Oglycan structures in cancer is evidenced by their roles in immune detection and cell
adhesion. Ogata et al. established that tumor cells are able to evade natural killer cell
induced lysis through the production of sTn antigens(105). In addition, others have
shown that these glycan structures may inhibit interaction with cytotoxic T-lymphocytes
and prevent the accumulation of antigen-presenting cells in the tumor
microenvironment(106,107). A potential role for these molecules affecting cell adhesion
properties has been demonstrated using prostate and breast cancer cell lines. Glinsky et
al. showed a critical requirement for T antigen-mediated binding to galectin-3 on
endothelial cells as a potential means of promoting metastasis(108). Another study
showed that pancreatic cancer cells genetically modified to over-produce Tn antigens
manifest with enhanced growth, migration, and invasive capabilities relative to controls.
In this particular study, a knockout model of the COSMC chaperone incited these
phenotypes which were reversed upon its re-expression(100). Studies targeting the
expression of sTn have identified it on adhesion-related proteins such as CD44, integrin
β1, Muc1, and osteopontin; where its presence is correlated with increased metastatic
potential(78). However, a few conflicting reports exist regarding these substrates and this
trend between different models of cancer(109,110). Clarification of the functional
mechanisms and substrate specificity for sTn attachment is therefore of great interest
because of potential implications in biomarker identification and therapeutic-intervention.
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The increased production of the sialyl LewisX antigen (SLex) by tumor cells also
contributes to attainment of invasive characteristics. The SLex motif, a tetrasaccharide
structure defined by α1-3 fucose linked to GlcNAc and α2-3Neu5Ac to galactose,
functions as a ligand for selectin-mediated cell adhesion during inflammatory
responses(111). The epitope is expressed at low-levels on N- and O-linked glycans for
non-transformed epithelial cells. However a generalized increase in the abundance of
these structures, typically on O-GalNAc glycans, has been noted for several carcinomas
with aggressive phenotypes. Hypotheses on how cancer cells gain a selective advantage
for metastasis through this alteration are based on its function as a ligand for P-, L-, and
E-selectin(63,73,78,84). Specifically, SLex/selectin interaction is thought to promote
aggregate formation of tumor cells with leukocytes and platelets in the blood stream,
facilitating interactions with activated endothelium and decreasing the likelihood of
immune detection(63,112). The mechanistic-underpinnings of SLex over-expression may
be rooted in dysregulated signaling from the inflammatory tumor microenvironment or
the incomplete synthesis of more complex structures. From a molecular perspective,
alterations in sialyltransferase/fucosyltransferase expression, epigenetic modification of
genes required for further processing of these structures, and possible contributions from
hypoxia-regulated pathways are all implicated in cancer-associated SLex
production(6,111,113).
Finally, transformed cells may alter the topology of mucins and display a
generalized increase in cell-surface sialylation during cancer progression. Mucin
1(MUC1) is an integral membrane glycoprotein bearing both O- and N-linked glycans,
which extend outward into the extracellular space. The O-glycan structures of MUC1,
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which greatly outnumber N-linked, are typically configured as core-2 structures that are
extended and capped with fucose and sialic acid. These extended configurations mediate
an essential function of MUC1 on non-transformed epithelial cells: they provide highlevels of negative charges which allow for the formation of a gel-like, protective barrier
on the luminal surface of secretory tissue(69,74). Transformed cells may exploit Oglycosylation biosynthetic machinery for the preferential production of incomplete or
over-sialylated structures on MUC1. For example, breast cancer cell-derived MUC1 has
been identified carrying T-antigen or sialylated Lewis structures rather than extended
core-2 O-glycans(114). As a result of altered glycosylation, MUC1 may be
inappropriately internalized and redistributed on basal cell surfaces where its charge state
may influence cell adhesion(74,115,116). Additionally, hypo-glycosylated forms of
MUC1 are suspected to allow increased access of extracellular proteases to the
underlying peptide structure, resulting in liberation of the N-terminus to systemic
circulation. This observation, which is also noted in states of inflammation, led to the
development of a breast and pancreatic biomarker utilized in monitoring cancer treatment
regimens (CA15-3)(117,118). Interestingly, the shedding of N-terminal MUC1 is
thought to leave a remnant C-terminal peptide protruding from the cell membrane, which
some studies suggest may propagate a signaling mechanism promoting stemness(119).

1.3.5 Sialic Acid in Cancer
Including, but not limited to, the expression of specific O-glycan sialylated
structures (sT, sTn, SLe), is the observation that aggressive tumors often present with
global increases in cell-surface sialylation. Early studies targeting the properties of
cancer-cells first demonstrated the increased propensity of sialic acid-specific lectins in
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binding to transformed models. Subsequent investigations aimed at clarifying a role for
up-regulated Neu5Ac demonstrated that induced deficiency in its expression at the cellsurface decreased invasive characteristics and returned cells to normal growth
dynamics(63,76,78). Further probing into this phenomenon identified alterations in
sialyltransferases and sialidases which utilize N- and O-linked glycans, as well as lipids,
as substrates(81). Furthermore, an apparent tendency for tumor cell glycoconjugates to
carry sialic acid in a α2-6 linkage-dependent manner was observed(78). Hypotheses
formed to explain the rationale for increased sialylation highlight the potential
implications of this molecule on several biological processes, including: cell adhesion,
receptor-ligand interactions, masking of glycan epitopes, and retention time of molecules
at the cell surface(76,78,81). Specifically, these biological roles for sialic acid are thought
to be conferred from the chemical nature of the molecule; at physiological pH, Neu5Ac
carries a negative charge and may therefore mediate charge repulsion and/or influence
protein conformation. Mechanistic research has provided insights into cancer-pathway
regulation of sialic-acid modifying enzymes which may be partially responsible for its
increased abundance. For example, the RAS oncogene has been shown to induce the
expression of the sialyltransferase ST6Gal-I in a cell model of colon cancer(78,120).
Other efforts demonstrate the feasibility for sialidase down-regulation in the propagation
of invasive phenotypes. Uemura et al. used a transgenic model of colon cancer, capable
of either NEU1 over-expression or knock-down, to show that there was an inverse
relationship between sialidase levels and invasive properties(121). The identification of
differentially regulated enzymes may also explain the inclination of tumor cells to
preferentially catalyze α2-6 sialic acid linkage conformations. The relevance of this
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attachment is evident as a means for decreased binding of extracellular glycan-binding
proteins, such as galectins, to cell-surface glycoproteins bearing sialic acid in this
configuration. Integrin β1, for example, is a specific target for the α2-6 sialic acid linkage
in cancer progression(120,122). Importantly, this cell adhesion receptor connects binding
to the ECM with cytoskeletal elements through various heterodimeric interactions with
other integrin subunits. In addition, the integrin molecules mediate vital intercellular
signaling pathways that help cells respond dynamically to alterations in binding states.
Multiple studies have highlighted differential glycosylation of the integrins occurring in
parallel with altered biological scenarios, including pathological states(123,124).
However, only recently have these changes been tied to specific outcomes, such as the
modified binding affinity for extracellular substrates by integrin heterodimers containing
Neu5Ac α2-6 linked to β1 subunits(120,125–128). Other observed changes in sialic acid
dynamics, associated with aggressive phenotypes, include the appearance of Nglycolyneuraminic acid (Neu5Gc) and polysialic acid chains. Neu5Gc is a variant form of
sialic acid in which the acetyl group on C5 of Neu5Ac is hydroxylated. This sub-type of
sialic acid is not synthesized by humans due to homozygous loss of the gene responsible
for the conversion of Neu5Ac to Neu5Gc; however it is produced by other mammalian
species(76). Early observations indicating the presence of this structure in humans during
embryogenesis and carcinogenesis led to hypotheses regarding a specific role for this
molecule as an oncofetal antigen. However, further investigation indicated the presence
of low-levels of anti-Neu5Gc antibodies in adults without any pathology(129).
Subsequent studies showed that humans are capable of incorporating Neu5Gc into
endogenous glycans by cellular uptake and processing of foreign glycans. Current
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theories suggest that Neu5Gc is detected at higher levels during malignancy due to
dietary intake of animal products in conjunction with the altered sialylation profiles these
cells commonly exhibit. As a consequence, reactivity of endogenous antibodies to
increased Neu5Gc epitopes could promote chronic inflammation and thereby serve to
propagate tumor progression(82). Polysialic acid is a negatively charged linear chain of
α2-8 linked sialic acid residues normally restricted to expression on select proteins in
neural and immune cell populations. The structure may be linked to N- or O- glycans and
is thought to influence biological functions through charge repulsion due to its polyanionic nature. For example, during brain development the addition of these large
polymers on NCAM and SynCAM1 mediate neurite outgrowth and synapse formation
through inhibition of homophilic interactions between adjacent cells(79). PSA synthesis
is a highly regulated process, with temporal and cell-specific expression mediated
through the dynamic regulation of the polysialyltransferases ST8Sia-II and ST8SiaIV(130). Under normal circumstances, brain PSA levels are down-regulated following
specific developmental cues, leaving the PTM only in areas critical to neural plasticity.
Outside of the brain, an additional role for PSA in dendritic cell chemotaxis has recently
been resolved(131). The presence of PSA on tumor cell NCAM of has been detected in
several forms of aggressive disease, including small and non-small cell carcinomas,
pituitary tumors, neuroblastoma, and Wilms tumor(130,132–135). Hypotheses formed to
explain why tumor cells might express PSA are primarily based on the monosaccharides
ability to interrupt cell adhesive processes. Subsequent examinations into the relationship
between PSA and cancer progression have revealed correlations between
polysialyltransferase levels, PSA abundance, and invasive properties in lung cancer and
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tumors of neuroendocrine origin(132,134). Furthermore, inhibition of
polysialyltransferase activity was demonstrated as a feasible approach to decrease
migratory capabilities in some tumor models(136).

1.3.6 Introduction to Glycoprotein Cancer Biomarkers
The mechanisms by which tumor cells manipulate glycosylation pathways for the
production of specific structures are an area of intense research. Recent studies have tied
transcriptional regulation and epigenetic modification of fundamental glycogenes to
commonly dysregulated cancer-signaling networks; yet, much remains to be elucidated in
this realm(45,120). In the past, the functional redundancy of the glycosyltransferases was
a key roadblock to dissecting how specific genetic programs could be modified for
altered glycosylation. However, progress is being made through the production of highly
specific transgenic cancer cell models, capable of over-expression or knockdown of
specific glycan-related enzymes in combination with various oncogenic drivers.
Additional efforts are focused on defining the biological consequences of altered
glycosylation on specific protein targets. Importantly, it should be considered that some
cancer-specific glycan structures are likely a "side-effect" of carcinogenesis and may not
have functional relevance. Regardless, elucidation of the mechanisms and outcomes of
dysregulated glycosylation will likely have implications for the identification of
potentially targetable pathways for therapeutic intervention. Integral to these functional
investigations are continued efforts to catalog cancer-specific protein glycoforms. This
research is significant for diagnostic/prognostic stratification and will likely feedback to
provide insights into mechanistic/functional research. Several cancer biomarkers in use
today are glycoproteins, including CA15-3, CA19-9, prostate-specific antigen, CEA, and
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CA-125(137). As well, therapeutic strategies based on the antigenic-properties of cancerspecific glycan epitopes have resulted in the production of anti-cancer vaccines(51). In
light of newer research methods and technologies, capable of detailed characterization of
complex oligosaccharides and their carriers, a resurgence of interest in identifying
cancer-associated glycoforms as putative biomarkers has emerged.

1.3.7 Current Glycoprotein Cancer Biomarkers
MUC1, as discussed in section 1.3.4, is a transmembrane glycoprotein highly
decorated with core-2 O-glycans capped with sialic-acid or fucose. In non-pathological
states, MUC1 carries out an essential function in glandular tissues by facilitating the
production of a mucinous layer for protection and lubrication of underlying epithelial
cells. Observations that MUC1 was alternatively glycosylated and could be detected in
circulation during inflammation/cancer initiated investigations into its clinical utility as a
biomarker. As a result, assays were developed for the quantification of the shed portion
of extracellular MUC1, which was termed Carbohydrate Antigen 15-3 (CA15-3)(118).
The relevance of CA15-3 as a prognostic indicator is exemplified by the increased
circulating levels of the molecule typically associated with the progression of various
adenocarcinomas(138–141). For example, following surgical or chemotherapeutic
intervention of breast cancer, rising levels of CA15-3 may indicate the presence of
otherwise undetected micro-metastases(118,142). Unfortunately in this particular case,
earlier detection of disease recurrence does not translate into delayed time to progression
or improvements in quality of life for these patients. Therefore the recommendations for
use of CA15-3 in breast cancer prognosis is limited to monitoring therapy in advanced
disease states as a supplemental indicator for loss of response(118,142).
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The identification of specific glycan epitopes have also been utilized in
development of biomarker assays. For example, the detection of glycolipids or
glycoproteins carrying sialylated-Lewisa structures (SLea) may be of prognostic value in
advanced gastric, colorectal, and pancreatic adenocarcinomas(143–145). SLea is a
structural isomer of the SLex pentasaccharide whose production may be favored during
carcinogenesis due to inefficient production of extended core O-glycans(111). The SLea
epitope, also termed CA19-9, was first evaluated for use as a biomarker in colon cancer
following the production of cancer-specific monoclonal antibodies in the 1970’s(146).
Since that time, clinical utility for CA19-9 has perhaps been most well defined for
pancreatic cancer; where it may be used in diagnostic and/or prognostic criteria,
evaluation of therapy response, or in predicting recurrence. In reference to the diagnosis
of pancreatic cancer, a comprehensive review by Ballehaninna and Chamberlain indicates
values for the sensitivity and specificity of CA19-9 as 79-81% and 82-90% (respectively)
in symptomatic patients(144). Low positive-predictive values generated in these studies
were alleviated by incorporating imaging studies for targeted evaluation of patients
presenting with pancreatic masses(147). In addition, pre-operative CA19-9 levels have
been shown to correlate with pathological grade which may be useful for predicting
resectable disease(148,149). Furthermore, several studies have evaluated CA19-9 use in
pre- and post-operative prognostic stratification. Although multiple experimental designs
were employed and variations in CA19-9 values became evident, these studies
overwhelmingly support the use of this biomarker as an independent predictive value for
survival(150–152). Despite the applicability of this biomarker in several clinical contexts,
caution for its use is urged due to a number of limitations. Low sensitivity/specificity and
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the potential for false positives preclude the use of CA19-9 as a stand-alone parameter for
the diagnosis of pancreatic cancer in non-symptomatic patients. Several non-cancerous
conditions, including chronic pancreatitis, gall bladder-related disease, and diverticulitis,
may result in elevated levels of CA19-9(147,153). In addition, approximately 5-10% of
the population are incapable of producing SLea epitopes due to genetic variation affecting
the production of an enzyme critical for its synthesis(73,144). Therefore, there is a wide
range of applications for CA19-9 testing in pancreatic cancer, however the potential for
false positives/negatives limit the information it provides and require guarded use in a
clinical setting.
CA125, or Mucin16, is the most thoroughly explored biomarker for ovarian
cancer. The molecule was first identified in the 1980's from a highly aggressive model of
ovarian cancer using a monoclonal antibody(154). Subsequent investigations into the
binding specificity of the Ab revealed targeting against the tandem repeat core of Muc16;
in an area of heavy O-glycosylation similar to MUC1. Further development of antibodies
to this peptide region resulted in the production of commercial assays for the
quantification of CA125, which in turn facilitated research into its utility as a serum
biomarker. Since that time, CA125 has been extensively studied in the contexts of seroustissue based cancers, including lung and gastrointestinal; however current applications
are most well defined for ovarian cancer. For this disease, examinations of CA125 levels
in screening/early diagnosis indicate a positive correlation between biomarker levels and
advanced disease state(155). However, as with CA19-9, clinicians are cautioned against
using CA125 as a single entity for diagnosis in non-symptomatic patients due to low
sensitivity/specificity(142). Efforts introduced to circumvent this limitation include
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combinatorial approaches which integrate other biomarkers and imaging approaches, as
well as longitudinal surveillance of CA125 levels(142,155,156). Another utilization of
CA125 is in the stratification of post-menopausal women presenting with pelvic masses.
For this patient population, increasing levels of the biomarker, in conjunction with other
clinical criteria, may indicate the presence of malignant disease(142). However, the
potential for false positives due to benign fluctuations of CA125 during
ovulation/menstruation prevents its application to the pre-menopausal
population(157,158). In addition, non-cancerous pathological conditions such as liver
disease, inflammatory conditions, or even recent surgery may affect CA125 abundance in
circulation. Relevance to monitoring therapeutic response and detection of recurrent
disease have also been investigated and are currently accepted in clinical
practice(142,157). Serial measurements of CA125 before, during, and after chemotherapy
may be used in treatment decisions as a factor indicating the efficacy of response. For
example, a decrease in 50% or more of pre-treatment levels for 28 days or greater is
considered a positive indicator for therapeutic efficacy(159,160). Additionally, elevated
levels of CA125 following treatment may predict relapse and help guide appropriate
intervention. Finally, prognostic significance of CA125 in ovarian cancer, as an
independent indicator, has demonstrated utility in predicting outcomes following
surgical/therapeutic intervention. In this context, both the rate of change of CA125 levels
and the amount of time the changes are observed for appear to correlate with trends in
overall survival(142,157).
Alpha-Fetoprotein (AFP), a 70kDa N-linked glycoprotein, has been extensively
researched as a biomarker for hepatocellular carcinoma (HCC). In normal physiological
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contexts AFP is synthesized by the fetal liver and is detectable in maternal circulation
during pregnancy. Following birth, AFP levels drop dramatically in both the infant and
the mother and remain within a precise range in the absence of pathological
circumstances. The biological functions of the molecule, while still under investigation,
are hypothesized to be similar to that of albumin for fetal circulation(161). Observations
that increased AFP levels are associated with hepatic pathologies in adults were first
noted more than 50 years ago, prompting investigations into the clinical utility for
monitoring. Initial examinations demonstrated promising results as elevated AFP levels
tend to correlate well with larger liver tumors (>2cm). However upon continued
evaluation, it was revealed that fluctuations in serum AFP were also occurring due to
benign liver disorders(hepatitis, cirrhosis) and a low sensitivity for early-stage tumors
(<2cm) also became evident. Therefore the quantification of AFP in serum for HCC
surveillance was hindered by the potential for false positives due to chronic liver disease
and false negatives due to inconsistent AFP elevation with small tumors(161,162). In the
1990's, glycoproteomic evaluations of AFP's single N-linked glycan, using lectin affinity
methods, discerned differential binding of the molecule between alternative disease
states(163). This data supported the hypothesis that differential glycan structures were
preferentially attached to AFP in various pathological contexts. Ensuing investigations
focused on quantification of a “cancer-specific” AFP glycoform (AFP-L3), in
combination with total AFP and other biomarkers, resulting in modest increases in
sensitivity for detecting early HCC(161). Current diagnostic applications of AFP utilize
the biomarker as an adjunct to imaging-based methods for surveillance of patient
populations at risk for HCC development. Additionally, AFP may be utilized in
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monitoring in post-surgical/therapeutic contexts as well as an indicator for recurrence of
undetected disease(161,164).
The advantage of monitoring glycoproteins as disease biomarkers is rooted in the
nature of these molecules to dynamically respond to changes in physiological states. In
addition, their inherent biosynthesis along the secretory pathway provides a convenient
route for collection (e.g. serum/secreted fluids). Current biomarker assays primarily focus
on assessing quantitative changes in the underlying substrate rather than directly
accounting for alterations in the glycans they carry. While this approach has
demonstrated value, it often fails to achieve levels of sensitivity and specificity required
for confident clinical use(89,137). To overcome these limitations, efforts have been set
forth to re-focus biomarker discovery research towards the elucidation of site-specific
and structural glycan changes that accompany pathogenesis. A recent increase in
analytical technologies available for glycoproteomic analyses, now capable of detailed
characterization of the underlying peptide, glycosylation sites, and glycan compositions,
has facilitated a renewed vigor in this type of approach. For example, newer mass
spectrometry (MS) platforms and data-acquisition strategies provide a highly-sensitive
method for global and protein-specific characterization of disease associated
glycosylation changes. These innovative MS-based analyses provide a means for highthroughput, confident identification of peptides, glycans, and/or glycopeptides from
samples stemming from minute amounts of complex starting materials. Together with
advances in separation chemistry, enrichment/affinity/labeling techniques, and the
development of bioinformatic glycan databases, detailed characterization of
glycoforms/glycosites is underway.
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1.4 Mass Spectrometry Methods for Glycoproteomics
1.4.1 Introduction to MS-based Glycoproteomics
Mass spectrometry based proteomic and glycoproteomic evaluations are integral to
discovery phase biomarker research for several reasons. First, this approach allows for
the characterization of either intact proteins or peptides, enriched or in complex mixtures,
from a host of starting materials. A variety of MS instruments are available, each suited
to specific applications, which may be combined with up-front techniques for
optimization of experimental parameters. Modern platforms are capable of providing
comprehensive qualitative and quantitative data as well as information on posttranslational modifications and protein-protein interactions(165). In addition, decreased
turn-around-time and moderate up-front sample preparation make this methodology wellsuited for discovery-phase efforts. Previous approaches to glycoproteomics, such as 2D
gels or lectin microarrays, failed to achieve the depth of coverage or sensitivity inherent
to current MS systems(165). Furthermore, older MS technologies lacked the ionization
efficiency and mass accuracy required to make high confidence identifications of glycan
species. Newer, hybrid-type mass spectrometers, like the OrbiTrap, are capable of
providing detailed glycan structural (anomeric linkages, branching patterns) and site
specific information, as well as evaluating the underlying peptide backbone(166–168). In
addition, modern ionization and fragmentation strategies out-perform previous methods
in producing glycan fragment ions amenable to high-resolution characterization. Further
supporting the use of MS for glycoproteomic applications are an abundance of options
for enrichment, chemical derivatization, and chromatographic separations prior to
analysis. The implementation of these techniques before MS acquisition increases the
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likelihood for successful analysis by reducing sample complexity and/or modifying
glycan structures so that they can be more efficiently analyzed. Several variations in MS
workflows have been described, often involving different combinations of sample
preparation, MS acquisition (ionization techniques, fragmentation strategies, various
mass analyzers), and data processing(166,169–175) . Each unique configuration has
)

distinct advantages and disadvantages for glycoproteomic analysis and therefore should
be carefully considered during experimental design.

1.4.2 Enrichment Strategies for Glycoproteomics
One of the greatest challenges in MS-based glycoproteomics is derived from the
fact that proteins are not equally distributed in biological fluids. This observation, known
as the “dynamic range problem”, describes how a limited number of proteins dominate
the proteome of secreted matrices such as serum. This may result in the inability to
effectively characterize low-abundance proteins, such as those carrying PTMs, unless
pre-fractionation of the starting material is carried out(176,177). Several strategies exist
for the enrichment of glycoconjugates prior to MS analysis, typically targeting the
chemical properties of the carbohydrate moieties as a means to selective isolate these
molecules. These methods have been optimized for both bottom up (glycopeptides) or
top-down (glycoproteins) approaches, allowing increased flexibility in experimental
design. For example, lectin affinity, hydrazide chemistry, titanium dioxide (TiO2) and
hydrophilic interaction liquid chromatography (HILIC) are all feasible means to
accomplish this end.
Lectin affinity enrichment is based on the innate ability of these plant and animalbased molecules to recognize and selectively bind to particular glycan structures(89,178).
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To date, over 150 lectins have been characterized with results demonstrating both broad
and narrow-spectrum specificity for different glycoforms(178). For example,
concanavalin A (con A) targets oligomannose structures, inferring a broad specificity of
this lectin for N-glycans. Others, like Sambucus nigra (SNA) and L-phytohemagglutinin
(L-PHA) are extremely specific in their preference for epitopes like sialic acid α2-6
linked to terminal galactose and β1,6 branched N-glycans, respectively(176). Lectins may
also be combined for use in one preparation to increase the robustness of initial screening
efforts. Alternatively, sequential lectin affinity enrichments may be of value if a
particular glycan species is of interest. Important considerations for this strategy include
the experimental conditions (pH, metal co-factors) and appropriate elution strategies
(competing sugars, ↓pH, glycosidases) for optimal results.
Hydrazide chemistry is another means to accomplish selective isolation of
glycosylated substrates from complex starting materials. This procedure, often carried out
in a solid-phase extraction format (SPE), relies on the chemical conversion of
monosaccharide cis-diol functionalities to aldehydes, which then react with hydrazide
groups on an immobilized support(14). Following the covalent linkage glycans to the
hydrazide resin, glycosidase digestion is used to release glycan-carrier substrates for MS
analysis. Although hydrazide approaches provide higher selectivity for isolating total
glycan fractions relative to lectin affinity, there are a few inherent drawbacks to this
method. Perhaps most obvious is the lack of information that downstream analysis can
provide on glycan structure. Typical protocols use enzymatic digestion with Peptide-Nglycosidase-F (PNGase-F) to liberate the proteins/peptides, leaving the glycans bound to
the immobilized support. PNGase-F treatment, which cleaves N-linked glycan structures
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at the initial GlcNAc linkage to asparagine (except where α1,3 fucose is linked), results
in a detectable deamidation reaction at former sites of N-linked glycosylation (179).
Therefore this approach has utility for identifying underlying carrier peptides and Nlinked glycosites. However, the lack of an equivalent glycosidase for releasing O-linked
glycans and the irreversible chemical modification of oligosaccharide structure during the
reaction limit the resourcefulness of this approach. Several reports have described the use
of hydrazide chemistry in combination with other strategies, such as depletion of high
abundance proteins, multiple protease digestions, and isotopic labeling methods, to
successfully increase the range of information derived from single experiments(180–
183).
Hydrophilic interaction chromatography (HILIC) exploits the polar nature of
monosaccharide moieties for isolation of glycopeptides. This technique utilizes
zwitterionic-based stationary phases which facilitate hydrogen bonding and electrostatic
interactions with glycan moieties in the presence of organic solvents(184). Importantly,
HILIC is amenable to downstream glycan structural analysis because no chemical
alterations to the sugar structures are necessary for binding/elution(185). Subsequently
this method may be used for glycomic, intact glycopeptide, and formerly-glycosylated
peptide evaluations. As a drawback, a bias towards N-linked glycans may occur because
of the nature of the molecules to be longer and more complex than O-glycans.
Additionally, non-specific binding of peptides carrying hydrophilic amino acids, other
polar biological molecules, or the presence of salt in sample preparations may reduce the
efficiency of enrichment(185).
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The use porous graphitized carbon (PGC) for selective enrichment of glycosylated
species also has demonstrated relevance for MS applications. This method is based on the
interaction of hydrophilic glycopeptides with a crystalline carbon structure through
adsorption and may be used for glycomic or intact glycopeptide analyses(186). Benefits
of this technique include the ability to separate isomeric glycan structures, durability, and
tolerance to mobile phase pH range fluctuations(168,186). Another enrichment approach
targets the chemical nature of sialic acid-containing glycans for binding and isolation of
carrier substrates. Titanium dioxide (TiO2) is an affinity strategy originally described for
phosphoproteomic applications because of its ability to bind molecules with the
characteristics of a Lewis base(187). The overall negative charge carried by sialic acidcontaining glycopeptides facilitates multi-point interaction with TiO2. Therefore the use
of low pH mobile phases and pre-treatment of samples with broad-specificity
phosphatases are important experimental considerations. Bound substrates are eluted with
increasing concentrations alkaline solutions and may be directly interfaced for MSanalysis. TiO2 chromatography is tolerant to the presence of salt and detergents in sample
preparations and has been successfully combined with other enrichment methods for
increased coverage of sialic-acid containing glycopeptides(188,189).

1.4.3 Glycan Metabolic Labeling
Glycan metabolic labeling strategies represent an alternative means to interrogate
the glycoproteome for in vitro studies(190). These methods are typically based on the
stable conjugation that occurs between azide and alkyne functional groups in the presence
of copper(I) (“Click Chemistry”). For this type of experiment, cells are incubated with
analog sugars bearing either the alkyne or azide functionality. Because these chemical
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groups are small and biologically-inert, the modified sugars are incorporated onto nascent
glycoproteins by normal biosynthetic pathways (Figure 1). Following labeling, selective
enrichment/detection of modified glycoconjugates proceeds through reaction with
exogenous substrates fixed with the reciprocal chemical group in the presence of copper.
For example, azido-sugars may be reacted with alkynes bound to agarose beads, biotinconjugated materials, or various fluorophores. Accordingly, this technique has
applications in MS-analysis, imaging, and flow cytometry(190). Several glycan precursor
analogs, including GlcNAc, GalNAc, sialic acid, and fucose, are commercially available
and an increasing number of studies have taken advantage of this technology to detect
alterations in both N- and O- glycosylation(191–193).. This method is of particular utility
in studies of secreted glycoproteins, making it highly suitable for efforts in biomarker
discovery. For example, our group used the sialic acid analog (ManNAcAz) to
successfully capture and quantify low-abundance glycoproteins in prostate cancer stromal
cell secretomes. Remarkably, our approach maintained efficacy in MS analysis without
the complete removal of serum protein supplements from the culture media(194).
Similarly, Slade et al. profiled secreted glycoproteins using an azido-GalNAc analog for
the detection of mucin type O-glycans stemming from CHO cell cultures(192). For MSbased applications, metabolic labeling and affinity enrichment precludes detailed glycan
structural elucidation because of the irreversible nature of the Click reaction. Therefore a
typical proteomic workflow relies on proteolytic release (trypsin) of non-glycosylated
peptides from bound glycoproteins followed by MS identification /quantification of
captured species.
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From: Invitrogen https://tools.lifetechnologies.com/content/sfs/manuals/mp10186.pdf

Figure 1: Tetraacetylated Azido-Sugar Incorporation Onto Nascent Glycoproteins
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Further utility of this strategy by might be attained through the application a secondary
digest, such as with PNGase-F, to release the bound glycopeptides for determination of
potential N-linked glycosites(191). Newer developments in glycan metabolic labeling
design include introduction of copper-free ligation techniques, which negates cytotoxicity
and therefore may allow use of this method for in vivo studies(195).

1.4.4 Strategies for MS-based Glycoproteomics
The abundance of options to selectively isolate/separate glycosylated
proteins/peptides has greatly facilitated progress in MS-based biomarker endeavors.
These up-front preparations may be used as stand-alone entities or in combination, offline
or directly-interfaced to MS instrumentation, and approaches may be modified to suit the
experimental goal. Ultimately, these techniques reduce the complexity of biological
samples and thereby allow for more focused MS evaluations of glycan/peptide structures.
In parallel to these advances, are improvements to MS instrumentation and novel data
acquisition strategies. Importantly, these breakthroughs overcome previous analytical
limitations which hindered detailed, high-throughput characterization of intact
glycopeptides.
Current approaches to MS-based global glycoproteomics generally follow the
scheme of: glycoprotein enrichment→ enzymatic digestion of glycoproteins →
chromatographic separation → MS analysis → bioinformatics. Depending on the
available instruments and the experimental goal, one of two sample preparations is
typically adopted: 1. Enzymatic/Chemical release of glycans from carrier peptides and
separate MS acquisitions for each species (glycans and formerly glycosylated peptides)
or 2. Intact glycopeptide analysis. Previous approaches to MS-based glycoproteomics
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have favored the former because of difficulties in ionizing hydrophilic intact
glycopeptides and inefficient detection of low m/z glycan fragment ions(196). This
separate analysis approach has resulted in the development of glycomic (i.e. glycan only)
MS strategies for elucidation of monosaccharide compositions and linkage
conformations. As well, the formerly glycosylated peptides may be analyzed by
traditional tandem mass spectrometry techniques (MS/MS) to determine amino acid
sequence and localization of N-linked glycan sites. One of the major failures of the
separate analysis design results from the lack of an equivalent enzyme to PNGase-F for
the release O-glycans. Chemically-induced techniques, including β-elimination,
trifluoromethansulfonic acid, and hydrazinolysis have been employed for this purpose,
however low-specificity and irreversible modification to glycan/peptide structures impair
characterization(171,178,197,198). In addition, chemical derivatization is almost always
a necessity for glycomic analyses, adding additional time to sample preparation. The two
major MS ionization strategies for glycomics, matrix-assisted laser desorption ionization
(MALDI) and electrospray ionization (ESI), both benefit from derivatization methods
such as permethylation. This process decreases the hydrophilicity of glycans entering the
mass spectrometer, resulting in more efficient ionization and decreasing the chances for
loss of labile substituents, such as sialic acid, from the oligosaccharides(175). At the
same time, formerly-glycosylated peptide analysis suffers from the potential for false
identification of N-linked glycan sites. The release of N-glycans by PNGase-F results in a
deamidation reaction on Asn residues carrying the oligosaccharides, producing a mass
shift of .9840Da. Although this change is easily detectable by MS, the potential for
random deamidations, from sample preparation procedures, limits the utility this method
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for glycosite assignment(199,200). Intact glycopeptide analysis is employed to
simultaneously acquire information on glycan site/structure and peptide identification.
Challenges to this type of MS approach owe principally to the differing chemical
properties between the peptide and the attached glycan(s). This may result in preferential
data acquisition of only one of the species or complicated mass spectra containing
information derived from both types of molecules. In addition, complex mixtures of
glycopeptides and non-glycosylated peptides may result in the suppression of signal from
the analytes of interest. Subsequently, several of MS strategies have been instituted for
intact glycopeptides, including combinations of MALDI or ESI-based ionizations, singlestage or tandem MS ion fragmentations, and data acquisition with various mass
analyzers(178,196). As well, bioinformatic platforms have evolved to keep pace with this
type of experiment. For example, the development of glycomic and glycoproteomic data
analysis softwares and curated databases containing information on N- and O- linked
structures identified from various MS methods(201,202).
Of the available approaches for intact glycopeptide studies, tandem MS platforms
are of particular utility because they allow for repeated cycles of precursor ion selection
and fragmentation(178,203). This translates into efficient coverage of ion species
representing the diversity of glycoforms present in biological samples. A general scheme
for Tandem MS analysis begins with the ionization of molecules (“precursor ions”),
followed by selection and fragmentation of precursor ions of interest (now called
“product ions”) and finally the detection of mass to charge ratios (m/z). The resulting m/z
can then be searched against databases of known values to identify various molecular
species with high confidence (amino acid sequences, sugars, lipids, etc.). Importantly, the
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application of various fragmentation techniques for intact glycopeptides is used to gain
information on glycan structures or site localization/peptide sequences. For example,
collision-induced dissociation (CID) is a relatively low-energy approach which tends to
cleave labile glycosidic bonds. The production of glycan-based spectra, with low or no
fragmentation of the underlying peptide structures, makes CID suitable for glycan
structural information but not for glycosite or peptide identification(173,203). Alternative
CID-based methods utilize the detection of glycan-specific product (oxonium) ions for
the selective isolation and secondary evaluation of precursor molecules from which they
were derived(167,173,203). For example, oxonium ions produced from a first round of
CID may be used to trigger a second fragmentation to acquire complementary
information on glycosylation site and peptide sequence. This type of approach requires
instrument capabilities to detect low m/z diagnostic ions and therefore has previously
been limited to triple quadrupole and quadrupole-time-of-flight (Q-TOF) type systems;
which are not ideal for discovery phase efforts. It should also be noted that the
normalized collision energy used for CID approaches will influence the preferential
dissociation of glycan and/or peptide structures and may therefore be modified to suit the
experimental goal(173,203). Electron transfer dissociation (ETD) and electron capture
dissociation (ECD) are higher energy fragmentation methods which preferentially cleave
peptide backbones, leaving glycan structures intact. These MS/MS modes produce
ionization patterns distinct from CID, making them favorable for peptide sequencing and
identifying glycosylation sites, rather than glycan structural information(178,196,203).
ECD is often carried out on Fourier Transform Ion Cyclotron Resonance (FT-ICR)-type
instruments while ETD may be applied in ion-trap type mass analyzers. Both techniques
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operate using similar molecular mechanisms and have utility for PTM localization studies
including N- and O-glycosylation and phosphorylation(196,203). More recently, higherenergy collisional dissociation (HCD) has been employed for intact glycopeptide
analysis. This type of fragmentation is specific to OrbiTrap-type hybrid MS/MS systems
and may be used to attain information on glycosylation sites as well as some glycan
structural information(167,204). OrbiTrap mass spectrometers combine linear ion trap
and Fourier transform mass analyzers for the production of high resolution/high mass
accuracy measurements. Technological advances in these systems allow for the detection
of low m/z glycan oxonium ions from HCD; which CID-based ion trap only instruments
fail to achieve. On these instruments, data acquisition strategies implementing HCD
combined with CID or ETD have been used to determine glycan structure, site, and
peptide sequencing in a single run(167,204,205). For discovery phase efforts, hybrid
instruments are preferable over triple-quadrupole instruments because they combine high
trapping capacity for ions over a wide range of masses, low mass product ion detection,
and high resolution accurate mass analyzers for confident identifications.

1.4.5 Bioinformatics for Glycoproteomics
Critical to the analytical advances facilitating MS glycomic and glycoproteomic
investigations are developments in bioinformatic databases and software for interpreting
this data. Various approaches to searching acquired mass spectra of peptide ions against
known/theoretical values have been developed, each having distinct
advantages/disadvantages. Proteomic databases, such as the UniProt Knowledgebase,
contain information regarding amino acid sequences, PTMs, functional descriptions, and
taxonomy identification. Options within this database allow users to select from manually
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annotated (Swiss-Prot) or computationally-analyzed (TrEMBL) records of proteins
stemming from multiple species. The application of search engine programs, such as
Mascot or Sequest, facilitates comparison of experimentally-observed mass spectra
against databases for the identification of peptides/proteins. However these search engine
programs are limited in their ability to simultaneously consider multiple peptide
modifications and have failed to keep pace with the high resolution type of data
commonly acquired in modern MS systems(202). Advancements in search engine
software for intact glycopeptide analysis have been made through the production of
programs which consider multiple fragmentation strategies and data derived from high
resolution/accurate mass systems. For example, Byonic™ software allows users to
examine acquired spectra considering multiple or unexpected peptide modifications, as
well as having a dedicated glycopeptide search function(202). Importantly, analyses may
be set to consider data derived from multiple fragmentation strategies including HCD and
ETD as well as allowing users to define monosaccharide masses or apply softwareincluded theoretical masses. In addition to the search engine innovations for MS-based
glycoproteomics has been the development of glycan structural databases. The
Consortium for Functional Glycomics (CFG) contains a library of N- and O-linked
oligosaccharide structures identified and validated from experimental observations. This
public resource provides a platform for researchers to both query and submit data related
to glycosyl transferase expression, glycan structures, protein-glycan interaction from
various tissue and cell-based samples(201,206,207). The CFG glycan database be utilized
to identify for glycan structures based on monosaccharide content, molecular weight
values, specific glycan motifs, or linear nomenclature
(http://www.functionalglycomics.org/glycomics/molecule/jsp/carbohydrate/carbMoleculeHome.jsp).
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Importantly, these options provide a means for interpreting data derived from various MS
approaches (ESI-MS/MS or MALDI-MS) and sample preparations (native or derivatized
glycans).
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Chapter 2
Hypothesis
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The goal of this research project was to assess the application of novel
glycoproteomic and glycomic workflows in experimental approaches useful for NSCLC
biomarker discovery. These methods include: 1. Azido-sugar metabolic labeling, alkyneagarose bead enrichment and LC-MS/MS to identify proteins undergoing differential
sialylation, 2. Sialic acid linkage-specific esterification and high-resolution mass
spectrometry for glycan structural studies, and 3. MALDI-MS imaging of N-glycans in
human lung tissue to both identify glycoforms and discern their spatial distribution.
The rationale for this work is seeded in the critical need for biomarkers to
predict the disease course of NSCLC. Glycosylation is one of the most common posttranslational modifications and has a well-established influence on the biological
properties of glycoproteins associated with the acquisition of invasive phenotypes.
Several lines of research suggest that altered glycosylation accompanies NSCLC
progression and metastatic dissemination. In particular, glycans carrying sialic acid
moieties are thought to contribute to the invasive properties of lung tumors through
interruption of cell-cell and cell-matrix contacts. Previous efforts to attain detailed
characterization of sialoglycoproteins during tumor progression have been hindered by
laborious sample preparations and inefficient techniques for the selective study of these
molecules. Recent advances in experimental approaches and instrumental analyses are
now capable of defining glycan microheterogeneity in workflows conducive to highthroughput investigations. Cumulatively, these innovations are capable of defining
glycoprotein properties including quantity, sites of glycan attachment, oligosaccharide
composition, monosaccharide linkage conformations, and the architecture of glycans
within tissues. Importantly, all of these characteristics could be considered when
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assessing the specificity of putative glycoprotein biomarkers. Therefore, we
hypothesized that the application of new mass spectrometry-based glycoproteomic and
glycomic methods can provide a detailed characterization of sialoglycoproteins in nonsmall cell lung cancer. This hypothesis will be tested by the following specific aims:
Aim 1: Evaluate the utility of azido-sugar metabolic labeling, alkyne-agarose bead
enrichment, and LC-MS/MS for identifying differentially sialylated glycoproteins in a
cell model of NSCLC.
This aim entails:
A. Optimization of the azido-sugar labeling, gene induction, enrichment, on-bead
trypsin digest, and LC-MS/MS workflow. These experiments will evaluate the
incorporation of the analog sugars for sialic acid (ManNAcAz) and Nacetylgalactosamine (GalNAcAz), the use of cell lysate and supernatant
fractions as starting materials, and provide initial data regarding differentially
captured glycoproteins following the induction of TGFβ1, Zeb, or empty
vector.
B. Double metabolic labeling of H358 cells (SILAC and ManNAcAz), alkyneagarose bead enrichment, and LC-MS/MS. This approach provides very
reliable quantitative data on captured sialoglycoproteins following TGFβ1 or
empty vector induction.
C. SILAC quantification of non-alkyne agarose bead enriched H358 cell lysate.
Data from these experiments can used to identify protein level changes which
may be contributing to the differential capture of sialoglycoproteins.
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D. A secondary digestion using PNGase-F to release the sugar-conjugated
peptides attached to the previously-trypsin digested alkyne beads. LC-MS/MS
analysis of released peptides provides information on the specific
glycosylation sites where ManNAcAz is being incorporated. In addition,
proteins not detected following trypsin digest may also be revealed by this
method.
E. Permethylation and sialic acid linkage specific esterification of cleaved Nlinked carbohydrates from H358 cell lysate followed by MALDI-FT-ICR
analysis of derivatized structures. This approach will identify preliminary
trends in the expression of specific sialylated N-glycans in the TGFβ1 and
EV-induced cells.
Aim 2: Investigate NSCLC-associated N-linked glycan structures in a set of matched
human lung tissues and proximal fluids using a novel sample preparation and highresolution MS analysis workflow.
Experiments include:
A. Proteomic evaluation of Bronchoalveolar lavage fluid by in-solution trypsin
digestion, LC-MS/MS, and label-free quantification. This catalogues the
protein content of BAL which will be useful as a reference for future studies
targeting the specific carriers of N-linked structures identified from glycomic
evaluations.
B. Sialic acid linkage-specific esterification and MALDI-FT-ICR structural
analysis of N-glycans in pooled samples of bronchoalveolar lavage fluid and
saliva. These experiments provide evidence for the feasibility of performing
63

glycomic studies in lung cancer proximal fluids. In addition, initial trends in
the expression of sialylated structures, and their anomeric configurations, will
be catalogued for reference as more samples are procured.
C. On-tissue PNGase-F digest and MALDI-FTICR mass spectrometry imaging
of N-linked glycans from human lung. Concurrent histological assessment
will be performed to define regions of interest in these tissues. Direct
comparison of spatial distribution of glycans to defined pathological features
will be useful to identify putative cancer-specific oligosaccharide structures.
D. Evaluate trends in the expression pattern of N-glycans between the tissues and
proximal fluids. This will be useful as a preliminary assessment of how the
expression of glycan structures translates between tissues of origin and
associated proximal fluids.
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Chapter 3

Glycoproteomic and Glycomic Approaches to
Evaluate TGFβ1-induced effects on
Sialoglycoproteins in a Cell Culture Model of
NSCLC
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3.1 Introduction
Glycosylation is the most common post-translational modification, estimated to
occur on approximately 50% of all proteins. Glycans influence protein-folding,
localization, protein-protein interaction, and alterations in the expression/structure of
specific moieties have been identified in several disease states, including cancer(63). The
identification of specific glycan motifs has previously demonstrated utility for
prognostic/therapeutic monitoring of various malignancies. For example, current
biomarkers based on this principle include CA15-3, CA19-9, CA125, and AFPL3(118,144,155,157,161). Despite the abundance of information these molecules carry,
the clinical value of these assays are hindered by low sensitivity/specificity.
Consequently, newer approaches to evaluating putative glycoprotein biomarkers are
emphasizing the detection and quantification of specific glycosylation sites and
structures. This work is in-part being driven by advances in up-front analytical
techniques, which have multiple applications for discovery phase endeavors. For
instance, glycan metabolic labeling and click chemistry-based enrichment has recently
emerged as an efficient method for assessing glycosylation from in vitro
models(190,195). This type of approach is based on the incorporation of analog sugars,
bearing small, inert chemical functional groups, onto nascent glycoproteins. Following
experimental procedures, glycoproteins which have incorporated the analog sugars are
covalently bound to a solid-support and digested directly for the evaluation of proteins
which incorporated them. Additionally, this method may be further employed for the
identification of N-linked sites of glycosylation following the release of glycopeptides by
PNGase-F digestion. In parallel to this type of experimental approach are workflow
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developments and technology innovations capable of discerning individual glycan
structures and, in some cases, anomeric linkages of the constituent monosaccharides. By
combining these approaches for a total assessment of the glycoproteome, a more
comprehensive view of how pathology influences these processes might be attained.
Therefore, we set forth to define alterations in sialic-acid containing glycoprotein
populations in a cell culture model of NSCLC. An azido-sugar metabolic labeling
approach was instituted, allowing biorthogonal incorporation of the analogs onto nascent
glycoproteins followed by the induction of TGFβ1, Zeb, or an empty vector control (EV).
To increase the breadth of the initial screen, alterations in O-linked glycosylation were
profiled by including a sample set treated with an N-acetylgalactosamine analog
(GalNAcAz). Glycoproteins incorporating the azido-sugar analogs were selectively
pulled down by reaction with alkyne agarose beads (i.e. “Click reaction”) and digested
with trypsin. Peptides were analyzed by LC-MS/MS and normalized spectral counts were
generated for quantitative evaluation of proteins incorporating the analog sugars. Next, a
double metabolic labeling strategy (SILAC and ManNAcAz labels) was implemented as
a secondary means to quantify captured glycoproteins following the induction of TGFβ1.
This approach was also useful for assessing if protein level changes were contributing to
differential capture. To this end, we applied SILAC relative protein quantification before
and after alkyne-agarose bead enrichment in TGFβ1 and EV-induced cells. Further
utility of for our methods was achieved by applying a PNGase-F digest to the previously
trypsin-digested beads; allowing us to investigate the localization of N-linked glycans
incorporating the azido-sugar label. Finally, the N-linked glycan structures from TGFβ1
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and EV-induced cells were evaluated using two different derivatization strategies and
MALDI-FT-ICR acquisition.

3.2 Materials and Methods
3.2.1 Cell Culture
H358 non-small cell lung cancer cells were kindly provided by Dr. Robert
Gemmill. Cells were grown at 37⁰C, 5% CO2 in RPMI-1640 media supplemented with
10% fetal bovine serum and 1x Penicillin/Streptomycin/Amphotericin (MP Biomedicals).
Tetracycline/Doxycycline-inducible TGFβ ligand 1, Zeb, or Empty Vector (EV) genes
were stably-integrated using the Flp-In T-Rex system (Invitrogen) prior to receipt.
Selection was maintained by the addition of Blasticidin (Fisher Scientific) at 5µg/ml and
Hygromycin (Fisher Scientific) at 100µg/ml to media throughout culturing and
experiments.

3.2.2 Azido-Sugar Metabolic Labeling
The workflow for H358 Azido-Sugar metabolic labeling is depicted in Figure 2.
1 x 106 cells were plated on 10cm polystyrene tissue culture dishes (Corning) in 6ml of
RPMI-1640 media with supplements for 48 hours. At the 48 hour time-point, culture
media was removed and cells were gently washed with sterile 1x PBS. Fresh media and
40µM azido sugar analog, either tetraacetylated N-azidoacetyl-D-mannosamine
(ManNAcAz) (Life Technologies) or tetraacetylated N-azidoacetyl-D-Nacetylgalactosamine (GalNAcAz) (Life Technologies), were added and allowed
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Doxycycline-inducible: TGFβ1, Zeb, or Vector

Figure 2: Azido-Sugar Metabolic Labeling Workflow

ManNAcAz

incorporation for 48 hours. At the 96 hour time-point culture media was discarded,
replaced with fresh media containing 1% FBS, and 100ng/ml Doxycycline hydrochloride
(MP Biomedicals) was added to the appropriate sample groups. 24 hours later, cells were
loosened by non-enzymatic dissociation and the resulting culture media/intact cell
mixture was centrifuged at 800rpm, 4⁰C, for 5 minutes in 15ml conical tubes.
Supernatant was allocated to new 15ml conical tubes and immediately stored at -80⁰C.
Cell pellets were washed with 5ml sterile 1xPBS, centrifuged, and the supernatant was
discarded. The resulting cell pellets were immediately stored at -80⁰C. Three biological
replicates were prepared for ManNAcAz -treated cells and two for GalNAcAz-treated.

3.2.3 Agarose-alkyne Bead Enrichment of Azido-Sugar bearing
Glycoproteins
3.2.3.1 Sample Preparation
Cell pellets were processed for enrichment by combining technical replicates were
combined and thawed on ice for 10 minutes in 1ml urea lysis buffer (8M Urea, 200mM
Tris pH8, 4% CHAPS, 1M NaCl). Complete cell lysis was achieved through probe
sonication (Fisher Scientific) at 30% power using 6x 3 second pulses while the samples
remained on ice. Cell lysates were then centrifuged at 800 rpm, 4⁰C, 5 minutes and
800µL of the resulting supernatant was used as input for the enrichment. Conditioned cell
media samples were thawed on ice and technical replicates were combined. The media
samples were concentrated using Amicon Ultra 3000Da MWCO filter units (EMD
Millipore) by serial centrifugations at 4⁰C, 2683 x g, for 45-60 minutes until the entire
volume had been processed. 800µL of the resulting concentrated media was used as input
for enrichment. Sample groups included in are listed in Table 1.
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H358 TGFβ
1. +40µM ManNAcAz
2. +40µM GalNAcAz
3. No Azido-Sugar
4. +40µM ManNAcAz
5. +40µM GalNAcAz
6. No Azido-Sugar

H358 Empty Vector
1. +40µM ManNAcAz
2. +40µM GalNAcAz
3. No Azido-Sugar
4. +40µM ManNAcAz
5. +40µM GalNAcAz
6. No Azido-Sugar

100ng/mL Doxycycline
Induction

No Doxycyline Induction

4. +40µM ManNAcAz
5. +40µM GalNAcAz
6. No Azido-Sugar

1. +40µM ManNAcAz
2. +40µM GalNAcAz
3. No Azido-Sugar

H358 Zeb

Table 1: H358 Sample Groups for Azido-Sugar Metabolic Labeling
and Enrichment, LC-MS/MS, and Label-Free Quantification

3.2.3.2 Enrichment
For the enrichment of glycoproteins bearing the tetraacetylated azide sugar
analogs, the Invitrogen Click-iT® Protein Enrichment Kit (#C10416) was used(208).
This method encompasses a 3 day procedure in which glycoproteins bearing the azide
functionality are bound to alkyne functional groups on agarose beads in the presence of a
copper catalyst, producing a 1,4 disubstituted 1,2,3-triazole linkage. On the second day,
agarose bead-bound samples are reduced, alkylated, and subjected to a set of stringent
washes to remove unbound/non-specifically bound constituents followed by overnight
digestion with trypsin. On day 3, samples are acidified, desalted, concentrated, and stored
at -20°C until analysis. Reduction was performed using 10 mM Dithirothreitol (DTT)
(Sigma) at 70⁰C and alkylation with 40 mM Iodoacetamide (IAA) (Sigma) in the dark.
Washing was carried out as prescribed by the Click-iT® Enrichment protocol: 5x 2ml
wash with SDS wash buffer, 5x 2ml wash with 8M Urea (Sigma), and 5x 2ml wash with
20% acetonitrile (Fisher). On-bead digestion was performed with 5μl of 0.2μg/μl
proteomic grade trypsin (Sigma) for 16 hours at 37°C. Peptides were acidified by the
addition of 2µL Trifluoroacetic acid (Sigma) and desalted using Waters Sep-Pak® C18
cartridges. The resulting peptides were vacuum-concentrated and stored at -20°C until
LC-MS/MS analysis. Enrichment procedures are depicted in Figure 3

3.2.4 Azide-Sugar Incorporation Western Blot
H358 whole cell lysates (TGFβ and EV) derived from the ManNAcAz metabolic
labeling (section 3.2.2) were lysed in RIPA buffer (10mM Tris-Cl pH 8, 1mM
Ethylenediaminetetracetic acid (EDTA), 140mM Sodium Chloride, .1% Sodium dodecyl
sulfate (SDS), .1% Sodium Deoxycholate, 1% Triton X-100) on ice with intermittent
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Alkyne-agarose beads after trypsin digest
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Figure 3: Workflow of Click-Chemistry Enrichment and On-bead Trypsin Digest

Day 2 and 3

Day 1

probe-sonication. Protein concentration was measured by Bichinoninic acid (BCA) assay
from a commercially available kit (Pierce #23227). 50µg total protein was allocated for
biotinylation of ManNAcAz-bearing glycoproteins by the Click-iT® Biotin glycoprotein
detection kit (Invitrogen) as prescribed by the manufacturer. Biotinylated samples were
speedvac concentrated and reconstituted in RIPA buffer prior to denaturation. Samples
were separated by electrophoresis through 4-12% Bis-Tris SDS-PAGE (Life
Technologies) and protein was transferred to a nitrocellulose membrane (LiCor
Biosciences) for blotting. Following transfer, the membrane was blocked in 1:3 Licor
blocking buffer diluted with 1x PBS and incubated with 1:5000 Streptavidin-IR800
(LiCor Biosciences) in blocking buffer containing .1% SDS for one hour at room
temperature with rocking. The membrane was washed 5 times with 1x PBS containing
.1% Tween (Fisher) and a final wash with 1xPBS without detergent. A LiCor Odyssey
infrared imager (LiCor, Lincoln, NE, USA) was used to visualize the membrane. To
assess consistency of protein loading, an identical SDS-PAGE gel was run and blotted
with 1:5000 rabbit anti-GAPDH (Cell Signaling Technology) and 1:20,000 goat antirabbit IR-800 (LiCor Biosciences).

3.2.5 LC-MS/MS and Bioinformatics for Label-Free Quantification
Concentrated digests were resuspended in 15μl buffer A (97.8% HPLC-grade
H2O, 2% acetonitrile, 0.2% formic acid), the entire contents of which was loaded onto a
25cm x .0075mm C-18 reversed phase LC column (packed in house, Waters ODS C18).
Liquid chromatography (LC)-electrospray ionization (ESI) -tandem mass spectrometry
(MS/MS) on a linear ion trap mass spectrometer (LTQ, ThermoFischer) coupled to a LC
Packings nano-LC system was performed utilizing a 120 minute linear gradient from 5%
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acetonitrile, 0.2% formic acid to 50% acetonitrile, 0.2% formic acid. Data-Dependent
Analysis was selected to perform MS/MS on the 10 most intense ions in each MS spectra
with a minimum ion count of 1000. Acquired data were searched using Mascot (version
2.4.1, Matrix Science, London, UK) via Proteome Discoverer (version 1.4.0.288, Thermo
Scientific). The data were searched against a UniProt SwissProt Homo sapien database
(2014_07 release) containing both canonical and isoform entries, which was concatenated
with entries from the common Repository of Adventitious Proteins (40,872 entries).
Precursor mass tolerance was set to 2 Da and fragment mass tolerance to 1 Da. Enzyme
specificity was trypsin, allowing for two missed cleavages. Carbamidomethyl (Cys) was
specified as a fixed modification and protein N-term acetylation, deamidation (Asn, Gln),
Gln→pyro-Glu (N-term Gln), and oxidation (Met) were set as variable modifications.
False positive rates were determined by searching against an automated decoy database
within Mascot. Protein identifications were confirmed using ProteoIQ (version 2.3.08,
Premier Biosoft, Palo Alto, CA) by specifying >1 peptide and protein false discovery rate
(FDR) <5%. Protein FDR was calculated within ProteoIQ using separate searches against
target and reverse decoy databases. The decoy database was the target database reversed.
ProteoIQ was used to generate normalized spectral counts (nSCs) for use as relative
quantification of protein expression levels for comparisons between cell groups.
Designation of “Glycoproteins” was done by cross-referencing identified proteins against
the glycoprotein keyword, KW-0325, in the UniProt Knowledge Base. A moderated t-test
(limma package, R) was used to determine significant changes, which was defined as p<
0.05. These significant proteins were uploaded to the WebGestalt
(http://bioinfo.vanderbilt.edu/webgestalt/) in order to perform pathway enrichment
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analysis. Enrichment was performed against the KEGG database with the entrez proteincoding genes as a background. A hypergeometric test was used and required a minimum
of two proteins for a pathway. Significant pathways were identified if BenjaminiHockberg (BH) adjusted p<0.05.

3.2.6 Double Metabolic Labeling
TGFβ and EV-inducible H358 bronchoalveolar adenocarcinoma cells were
selected for a double-metabolic labeling approach encompassing: 1. Stable-isotope
labeling of amino acids in cell culture (SILAC), followed by 2. Azido-sugar metabolic
labeling using ManNAcAz. For SILAC labeling, cells were cultured using Pierce®
SILAC protein quantitation kits (#89982) with 13C6-L-Lysine and 13C6-15N4-L-Arginine
(“Heavy”) or non-isotopic L-Lysine and L-Arginine (“Light”) in T75 tissue culture flasks
for 6 doublings. Incorporation of heavy amino acids was verified >95% by MS prior to
beginning the azido-sugar metabolic labeling procedures. Azido-sugar metabolic labeling
was carried out as described in section 3.2.2, with the following changes: 1. Cells were
maintained in full (dialyzed) serum SILAC media throughout and, 2. 40ng/ml
Doxycycline was used for induction of TGFβ or EV. A total of three biological
replicates, including a label-swap, were prepared for these experiments (Table 2).
3.2.6.1 Sample Processing for Double Metabolic Labeling
The rationale for our double metabolic labeling experiments is depicted in Figure
4. Following double metabolic labeling procedures, cells were collected and stored at 80⁰C as described in section 3.2.2. Pellets were processed for either: 1. SILAC relative
quantification before agarose-alkyne bead enrichment (“SILAC-Only”), or 2. SILAC
relative quantification after agarose-alkyne bead enrichment (“SILAC+Click”). SILAC76

Table 2: H358 Sample Groups for Double
Metabolic Labeling and Protein Quantification
(Before and After Enrichment)
All samples:
+40ng/mL
Doxycycline

H358 Empty Vector

H358 TGFβ

1. SILAC Heavy Label
+40µM ManNAcAz
2. SILAC Light Label
+40µM ManNAcAz

1. SILAC Heavy Label
+40µM ManNAcAz
2. SILAC Light Label
+40µM ManNAcAz
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TGFβ1
SILAC Heavy

Vector
SILAC Light

ManNAcAz labeling

“SILAC Only” group

Mix 1:1

MS/MS Before Click enrichment to
determine protein quantity only

Alkyne-Agarose bead
enrichment

“SILAC+CLICK” group
MS/MS After Click enrichment to
determine protein or glycan change

Figure 4: Rationale for Double Metabolic-Labeling Approach. SILAC-Incorporated
TGFβ1 and EV cells undergo the 120 hour azido-sugar metabolic labeling and gene
induction procedure and are then mixed at a 1:1 ratio. Two fractions are prepared
for MS acquisition:1. Without enrichment (“SILAC-Only”) and 2. With enrichment
(“SILAC+Click”)
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Only pellets were thawed on ice in 500µL RIPA buffer for 10 minutes followed by probe
sonication at 30% power for 6 seconds with three repeats. Samples were centrifuged
800rpm, 4⁰C, for 5 minutes and approximately 450µL of the resulting supernatant was
saved to 1.5ml microcentrifuge tubes (Axygen) on ice. Protein quantification was
achieved using the BCA assay and 100µg SILAC pair aliquots were prepared (50µg
SILAC Heavy + 50µg SILAC Light) for in-solution trypsin digestion. Samples were
reduced at 95⁰C with 10mM DTT for 5 minutes followed by alkylation with 40mM IAA
in the dark for 30 minutes. 2µg of Trypsin was added to each SILAC pair sample and
digestion proceeded at 37⁰C overnight. The resulting peptides were desalted using Pierce
C18 spin columns (#89870), speedvac concentrated, and stored at 4⁰C until LC-MS/MS.
For SILAC+Click samples, normalization of input for Heavy and Light pairs was
accomplished by cell counting immediately following non-enzymatic dissociation. 5 x
106 total cells (2.5 x 106 Heavy + 2.5 x 106 Light) were prepared for agarose-alkyne bead
enrichment by the addition of 500µL Urea lysis buffer to each pellet, vigorous pipetting,
and combining pairs to attain 1000uL total sample volume. Enrichment of ManNAcAzbearing glycoprotein was carried out as described in section 3.2.3 and samples were
stored at 4⁰C until LC-MS/MS analysis.

3.2.7 LC-MS/MS and Bioinformatics for Double Metabolic Labeling
Concentrated digests were resuspended in 7µL buffer A (97.8% HPLC-grade
H2O, 2% acetonitrile, 0.2% formic acid) for online 2-dimensional liquid chromatography.
Samples were first loaded onto a strong cation exchange column (Biobasic, 50 x .5mm,
Thermo) using a Dionex U3000 nano-LC system (Thermo Scientific). For SILAC-Only
samples, 10-step SCX separation was carried out using increasing concentrations of
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ammonium acetate (0, 5, 10, 20, 40, 50, 60, 75, 100, and 500mM) for 10 minutes at each
concentration. For SILAC+Click samples, a 5-level SCX fractionation was utilized (0, 5,
10, 50, 500mM). Peptides were eluted at each step directly onto a C18 trap column (C18
pepMap 100, 5µm, 300µm x 5mm ID, Thermo) followed by a C18-reverse phase
analytical column (75mm ID, 15cm) packed in-house with Waters YMC-ODS C18-AQ
5mm resin. Peptides were eluted from the analytical column to an OrbiTrap Elite
instrument (Thermo Scientific) using a 120 minute linear gradient of 2-50% buffer B
(97.8% acetonitrile, 2% HPLC-grade H2O, .2% formic acid) at a flow rate of 200nL/min
via a Nanospray Flex Ion source (Thermo Scientific). Data-dependent analysis was
selected to perform MS/MS on the 20 most intense ions in each MS spectra with a
minimum ion count of 1000. The survey scan was performed in the Orbitrap at a
resolution of 60,000. For ion trap based CID, the normalized collision energy was set to
35% and dynamic exclusion was set to a repeat count of 2, repeat duration of 30 seconds,
and exclusion duration of 180 seconds. Acquired data was searched using MaxQuant
quantitative proteomics software (version 1.5.1.0) against a UniProt Swissprot Homo
sapiens database (2014_7 release), which was concatenated with entries from the
common Repository of Adventitious Proteins (40,872 entries total). Precursor mass
tolerance was set to 4.5 ppm and fragment mass tolerance to 0.5 Da. Enzyme specificity
was trypsin and 2 missed cleavages were allowed. Carbamidomethyl (Cys) was selected
as a fixed modification and protein N-term acetylation, deamidation (Asn, Gln), pyro-Glu
(N-term Gln), and oxidation (Met) were specified as variable modifications. The false
discovery rate was set to 1% using a reversed target database generated in MaxQuant.
Heavy SILAC labels were designated as Arg 10 and Lys 6 with a maximum of 3 labeled
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amino acids per peptide. Protein quantification required a minimum ratio count of 2
peptides, including all unmodified and variably-modified peptides (protein N-term
acetylation and oxidized methionines). SILAC ratios generated in MaxQuant were postprocessed using Perseus statistical software (version 1.4.0.8). Reverse, contaminant, and
“identified by site only” hits were filtered and removed. Replicate trimming was applied
by calculating ±2 standard deviations of the mean of the log2 ratio distribution for every
label-swap comparison (Heavy/Light*Light/Heavy) and discarding proteins falling
outside of that range(209,210). Ratios were inverted so that all data was reported with
respect to TGFβ expression and log2 transformed. A moderated t-test (limma package, R)
was used to determine significant changes (n≥2 of 3 ratios), which was defined by
Benjamini-Hockberg corrected p values. KEGG analysis of significant proteins in
SILAC+Click group was carried out as described in section 3.2.5.

3.2.8 PNGase-F Mediated Release of N-linked Glycopeptides
Agarose-alkyne beads retaining ManNAcAz-bearing glycopeptides following onbead trypsin digestion (section 3.2.3.2) were stored at -20⁰C until processing. Beads were
initially washed with 100µL RIPA buffer, vortexed, briefly centrifuged, and the
supernatant was aspirated with a gel-loading tip and discarded. 100µL of HPLC H2O and
1µg of recombinant Peptide-N-glycosidase-F (See Powers et al for enzyme information
(211)) were added followed by incubation for 16 hours at 37⁰C. Following digestion, the
supernatant was collected and the beads were washed with an additional 100µL of HPLC
H2O, which was added to the supernatant. The resulting 200µL aliquots were centrifuged
briefly to pellet any carryover beads and the supernatant was speedvac concentrated.
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3.2.9 LC-MS/MS and Bioinformatics for PNGase-F Mediated Release of Nlinked Glycopeptides
Concentrated peptides were reconstituted in 7µL Buffer A and analyzed on the
OrbiTrap Elite using the parameters described in section 3.2.5; with the exception that
only a single dimension of chromatography was carried out (RPLC). Acquired data was
searched using MaxQuant as described in section 3.2.7, with one peptide being required
for protein identification. Post-processing using Perseus software was used to generate
categorical headings (i.e. peptide sequence, deamidation site, protein ID) and data was
exported to external data-processing software for the identification of putative N-linked
glycosylation sites by manual annotation.

3.2.10 H358 Global N-linked Glycomics
3.2.10.1 Linkage-Specific Sialic Acid Esterification
TGFβ and EV inducible H358 cells (+/- Doxycycline induction) were prepared as
described in section 3.2.2, with the exception that no azido-sugar metabolic label was
added. Samples were incubated at 4⁰C in 200µL of lysis buffer (1% SDS, 5mM EDTA,
25mM Tris Base) for 1 hour. Probe sonication was performed at 30% power, 10 seconds
and samples were centrifuged for 5 minutes, 800rpm, 4⁰C. Supernatant was transferred to
new tubes and protein quantification was carried out by BCA assay. 250µg of protein was
allocated to a fresh tube and total sample volume was brought up to 100µL in water.
Protein precipitation was achieved by adding 400µL methanol (Fisher), 100µL
chloroform (Fisher), 300µL HPLC H2O (Fisher), vortexing, and centrifugation at 14,000
x g for 2 minutes. Supernatant was discarded and 400µL of methanol was added to the
protein pellet followed by vortexing and centrifugation at 14,000 x g for 3 minutes. The
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entire solution was decanted and protein pellets were allowed to air dry for 10 minutes.
100µL of reducing solution (10mM DTT, 1% SDS) was added and dissolution of protein
pellets proceeded by rigorous pipetting and vortexing. Samples were boiled for 10
minutes and cooled to room temperature. Nonidet P-40 (Boehringer) was added to a final
concentration of 1%, as well as 1µg of PNGase-F. Digestion was carried out at 37⁰C for
16 hours. On the next day, protein was re-precipitated by the addition of 400µL methanol,
15 minute incubation at -80⁰C, and centrifugation at 15,000 x g for 10 minutes. At this
point, the supernatant (containing released N-linked glycans) was collected and speedvac
concentrated. 2µL of HPLC H2O and 40µL of Ethylating reagent ( 250mM 1-ethyl-3-(3(dimethylamino)propyl)-carbodiimide hydrochloride (EDC), 250mM 1Hydroxybenzotriazole hydrate (HOBt)) (Oakwood Chemical) were added, followed by
incubation at 37⁰C for 1 hour. After incubation, 40µL of Acetonitrile was added and
samples were incubated at -20⁰C for 20 minutes. Cotton tip HILIC solid-phase extraction
of N-glycans was performed using the procedure described by Reiding et al and samples
were eluted in 10µl HPLC H2O (212).
3.2.10.2 Permethylation
H358 TGFβ and EV cell pellets (+/- Doxycycline induction) were probe-sonicated
in 1x PBS at 30% power for 10 seconds on ice. Protein was precipitated by the addition
of cold methanol (80% final concentration) and centrifugation at 20,000 x g, 4°C, for 30
minutes. Supernatant was removed and the protein pellets were reconstituted in 200µl 1x
PBS. Protein was re-solubilized by vigorous pipetting and each sample was split into two
100µl aliquots: one for PNGase-F (2.7µg per sample) digest and one as a no-enzyme
control. Following overnight incubation at 37°C, 400µl of cold methanol was added and
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samples were centrifuged at 20,000 x g, 4°C, for 30 minutes. The supernatant, containing
the glycans, was speedvac concentrated and permethylation was carried out as described
by Mechref et al.(213). Following permethylation, samples were speedvac concentrated
and reconstituted in 10µl of 50% methanol.

3.2.11 MALDI-FT-ICR Analysis and Bioinformatics of N-linked Glycans
5µL of the Cotton tip HILIC eluate were spotted on an Anchorchip MALDI plate
(Bruker Daltonics) with .3µL DHB matrix (5mg/ml 2,5-Dihydroxybenzoic acid (Sigma)
in 50% acetonitrile, 1mM NaOH (Sigma)). After each spot dried, .2µL of ethanol (Fisher)
was added for recrystallization. For Permethylated glycans, 1µl of sample and 1µl of
DHB were spotted and allowed to air dry. Spectra were acquired on a Solarix dual source
7T FT-ICR mass spectrometer (Bruker Daltonics) in positive mode (m/z= 500-5000). A
SmartBeam II laser was operated at 1000 Hz in random walk mode for the acquisition of
10 average scans per spot, 75µm laser spot size. Acquired spectra were visualized using
FlexImaging 4.1 (Bruker Daltonics) and exported to DataAnalysis 4.0 (Bruker Daltonics)
for peak selection. Annotation of glycans was carried out using GlycoWorkbench 2.1 by
searching spectra against the glycan structures database from the
CFG(http://www.functionalglycomics.org/glycomics/molecule/jsp/carbohydrate/carbMoleculeH
ome.jsp)(214). Sialic acid linkage specificity was determined by identifying mass shifts of

-18Da (α2-3) and +28Da (α2-6) relative to the non-derivatized mass of identified species
as described by Reidling et al.(212).
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3.3 Results
3.3.1 Initial Quantification of Glycoproteins in TGFβ1, Zeb, and EVinduced NSCLC Cells
We first sought to identify how the induction of TGFβ1, Zeb, or EV would affect
glycoprotein populations bearing either sialic acid or O-GalNAc moieties in the H358
NSCLC cell line. An azido-sugar metabolic labeling strategy and alkyne-bead enrichment
was utilized for the selective incorporation and pull-down of proteins potentially
undergoing alternative glycosylation following induction of these genes. The workflow
for these experiments can be summarized as: 1. Metabolic labeling of the TGFβ1, Zeb,
and EV-inducible cells with either tetraacetylated N-azidoacetyl-D-mannosamine
(ManNAcAz) or tetraacetylated N-azidoacetyl-D-N-acetylgalactosamine (GalNAcAz) and
induction of gene expression, 2. Ligation of cell-lysate derived glycoproteins bearing the
azido-sugars to alkyne-agarose beads via Click chemistry and removal of non-specific
proteins, 3. Trypsin digest off of beads, LC-MS/MS, and label-free quantification bound
glycoproteins (Figure 5).
Prior to MS/MS analysis, an assessment of azido-sugar incorporation efficiency in
the H358 cells was carried out. Cells were incubated in the presence of ManNAcAz for
48 hours followed by doxycycline-induction of genes for 24 hours. Cell lysate was
incubated with biotin-alkyne, separated via SDS-PAGE, and blotted using streptavidin-IR
dye. As illustrated in Figure 6, the incorporation of ManNAcAz is evidenced by the
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Metabolic Labeling
H358 NSCLC

Cell lysate

-/+ TGFβ1, Zeb, or Vector

Culture Media

Alkyne bead capture
Trypsin digest

Proteomics
Quantification
Label-free

Statistics and Pathway Analysis

Figure 5: Cumulative Sample Workflow for H358 Azido-Sugar Metabolic Labeling,
Enrichment, and LC-MS/MS
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Figure 6: H358 Cells Incorporate ManNAcAz. Cell lysate from the azido-sugar
metabolic labeling procedure was incubated with biotin-alkyne. Approximately
12.5µg was separated by 4-12% Bis-Tris PAGE, transferred to nitrocellulose, and
incubated with streptavidin-IR800.
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presence of a broad smearing in both doxycycline-induced and non-induced TGFβ and
EV H358 cells.
For MS/MS-based label-free quantification of captured glycoproteins, a total of
1091 proteins were identified from all samples, including cell lysate and supernatant
fractions, TGFβ, Zeb and EV-induced cells, and labeling with both ManNAcAz and
GalNAcAz (Table 3, suppl. materials). Of the 1091 proteins, 387 matched the UniProt
knowledge base keyword “glycoprotein” (KW-0325), 24 were isoform-specific
identifications, and 17 proteins were identified as both canonical and isoform-specific.
From this data, individual comparisons were nade between the cell-lysate derived
experimental groups by applying a moderated t-test to the averaged log2 fold change of
normalized spectral counts (nSC). Because significance was being deemed by the
averaged fold change metric, 50% of the minimum observed nSC value (MOV) was
applied for any protein which was not quantified in at least one biological replicate of a
given comparison, so that no value would be zero. Table 4 summarizes the total number
of proteins quantified, those reaching statistical significance (p< 0.05), and how many
were up or down regulated for all comparisons.
The induction of TGFβ following ManNAcAz-labeling resulted in the
quantification of 598, 611, and 558 proteins relative to induced-EV, non-induced TGFβ,
and induced-Zeb expression, respectively (Tables 5 – 7, suppl.. materials). The
corresponding numbers of proteins which were captured at significantly different levels
were 10, 16, and 57, respectively. The proportion of glycoproteins identified in these
experiments was 46% for both TGFβ vs. EV and induced vs. non-induced TGFβ and
47% for TGFβ vs. Zeb. KEGG analysis revealed 3 enriched pathways (BHp<.05) from
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Experimental Groups Compared
Group 1
Group 2
H358_TGFβ1
H358_EV
+Dox
+Dox
+ManNAcAz
+ManNAcAz
H358_TGFβ1
H358_TGFβ1
+Dox
No Dox
+ManNAcAz
+ManNAcAz
H358_TGFβ1
H358_Zeb
+Dox
+Dox
+ManNAcAz
+ManNAcAz
H358_TGFβ1
H358_EV
+Dox
+Dox
+GalNAcAz
+GalNAcAz
H358_TGFβ1
H358_TGFβ1
+Dox
No Dox
+GalNAcAz
+GalNAcAz
H358_Zeb
H358_EV
+Dox
+Dox
+ManNAcAz
+ManNAcAz
H358_Zeb
H358_Zeb
No Dox
+Dox
+ManNAcAz
+ManNAcAz

457

57
14
9
50
51

558
455
463
543
525

145

90

188

195

295

16

611

297

10

598

1

0

3

6

57

9

4

380

453

275

260

99

316

301

50

50

6

8

0

7

6

Relative to Group 1 Induction:
Total # of Proteins Quantified # Significant (p<.05) Total # Up-regulated # Up-regulated p<.05 Total # Down-regulated # Down-regulated p<.05

Table 4: Summary of H358 Cell Lysate Label Free Quantification Results

the proteins captured at significantly different levels in induced TGFβ vs. induced-EV, 4
pathways with induced vs. non-induced TGFβ, and 27 for TGFβ vs. Zeb expression.
When TGFβ was induced in GalNAcAz-labeled cells, 455 and 463 proteins were
quantified, relative to EV and non-induced TGFβ cells (Tables 8 and 9, suppl.
materials). Of these quantified proteins, 14 and 9 were captured at significantly different
levels, respectively. A total of 31% and 30% of the total quantified proteins matched the
UniProt keyword search for glycoprotein and KEGG analysis identified three
significantly enriched pathways related to TGFβ induction in the GalNAcAz-based
experiments. Comparisons of ManNAcAz-labeled induced-Zeb versus induced-EV and
non-induced Zeb cells (Tables 10 and 11, suppl. materials) resulted in a total of 543
and 525 proteins quantified, respectively. Statistical significance was reached for 50 and
51 of the proteins quantified in these comparisons. The proportion of total glycoproteins
was 48% and 54%, and KEGG analysis identified 19 and 27 significantly enriched
pathways for these experiments, respectively.

3.3.2 Double Metabolic Labeling
Several proteins potentially undergoing differential glycosylation following the
induction of TGFβ were identified from the label-free quantification experiments. We
next wanted to ascertain whether changes in underlying protein expression were
contributing to the differential capture quantity. Therefore, SILAC metabolic labeling, for
relative protein quantification, was included in the workflow prior to ManNAcAz
labeling and gene induction. A total of 700 cell lysate-derived proteins were quantified in
three biological replicates of SILAC and ManNAcAz labeled H358 TGFβ and EV
induced cells without alkyne-agarose bead enrichment (“SILAC-Only”) (Table 12,
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suppl. materials). Of the 700 quantified proteins, 11% were identified as glycoproteins.
For the equivalent three replicates which underwent the alkyne-agarose bead enrichment
(“SILAC+Click”), 392 total proteins were quantified; 76% of which matched the UniProt
glycoprotein keyword search (Table 13, suppl. materials). Comparison of proteins
identified with and without enrichment revealed a total of 91 shared proteins between
experiments (Table 14, suppl. materials). We next wanted to identify which shared
proteins were significantly changing in the SILAC+Click experiments while not
significantly changing in the SILAC-Only experiments. Three Benjamini-Hockberg
corrected p-value cutoffs (BHp= 0.05, 0.10, and 0.15) were applied to the averaged log2
fold-change of the SILAC ratios (Table 15). At BHp = 0.05, 665 SILAC-Only and 58
SILAC+Click proteins met this criteria. There were 5 proteins shared in this assessment,
including CD276, Transmembrane emp24 domain-containing protein 9, Neutral amino
acid transporter B, Aspartyl/asparaginyl beta-hydroxylase, and Sodium/potassiumtransporting ATPase subunit alpha-1. For BHp = 0.10, there were 651 SILAC-Only and
77 SILAC+Click proteins; the same 5 proteins were identified in the overlap between
groups. At BHp = 0.15 cutoff, 644 SILAC-Only and 92 SILAC+Click proteins remained.
In addition to the 5 proteins shared from the lower BHp values, Host cell factor-1,
Granulins, and Sodium/potassium-transporting ATPase subunit beta-1 fit our criteria at
this significance level.
An assessment of proteins significantly changing in both SILAC+Click and
SILAC-Only experiments was also carried out. Two proteins, Integrin beta-4 and
Transforming growth factor-beta-induced protein ig-h3, met this criteria at BHp <0.05. In
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Significance BHp<0.05

0.016990901

0.016969599

BHp value

SILAC+CLICK

0.011849181

BHp value

SILAC Only

5 Shared Proteins, BHp<0.05
Log2 FC

-0.9321607

-0.746520067

0.016941724

Protein name

-0.830429633

Uniprot Acc #

0.950530752

0.277631528

-0.763383867

-0.425741833

0.273458668

-0.045584177

0.580121971

Sodium/potassium-transporting
ATPase subunit alpha-1

-0.5304869

Aspartyl/asparaginyl betahydroxylase

-0.33044835

P05023

Neutral amino acid transporter B(0)

Q12797

CD276 antigen

0.044077622

Q15758

-0.7868279

Q5ZPR3

0.808151645

Transmembrane emp24 domaincontaining protein 9

-0.202251755

Q9BVK6

Log2 FC

Table 15: Shared Proteins Significantly Different in SILAC+Click and Not Significantly Different in SILAC-Only
Fraction at 3 Benjamini-Hockberg P-value Cutoffs
Significance BHp<0.10

5 Shared Proteins, BHp<0.10

0.016990901

BHp value

0.011849181

SILAC+CLICK

-0.9321607

0.016941724

Log2 FC

-0.830429633

BHp value

0.950530752

-0.763383867

SILAC Only
Protein name

-0.425741833

0.273458668

Log2 FC

Uniprot Acc #

-0.045584177

0.580121971

0.016969599

Sodium/potassium-transporting
ATPase subunit alpha-1

-0.5304869

-0.746520067

Aspartyl/asparaginyl betahydroxylase

-0.33044835

0.277631528

P05023

Neutral amino acid transporter
B(0)

Q12797

CD276 antigen

0.044077622

Q15758

-0.7868279

Q5ZPR3

0.808151645

Transmembrane emp24 domaincontaining protein 9

-0.202251755

Q9BVK6
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93

-0.1458968
-0.206671985
-0.0158968

Sodium/potassium-transporting
ATPase subunit beta-1
Granulins
Host cell factor 1
P05026
P28799
P51610

-0.5304869
-0.33044835

-0.045584177

-0.202251755

Q15758
Q5ZPR3

Q12797

P05023

0.866053587
0.798426727
0.986642932

0.808151645

0.273458668
0.580121971

0.950530752

-0.9321607

-0.513125533
-0.5789029
0.6508421

-0.7868279

-0.830429633
-0.763383867

0.126914523
0.147500776
0.105684875

0.044077622

0.011849181
0.016941724

0.016990901

0.016969599

SILAC+CLICK
BHp value

-0.746520067

Log2 FC

0.277631528

SILAC Only
BHp value

-0.425741833

Log2 FC

Q9BVK6

Protein name
Sodium/potassium-transporting
ATPase subunit alpha-1
Aspartyl/asparaginyl betahydroxylase
Neutral amino acid transporter
B(0)
CD276 antigen
Transmembrane emp24
domain-containing protein 9

Uniprot Acc #

8 Shared Proteins, BHp<0.15

Significance BHp<0.15

an equivalent examination at BHp <0.10 and BHp<0.15, a third protein, Myoferlin, was
also significant in both groups.
Finally, the 58 SILAC+Click proteins captured at significantly different levels
(BHp <0.05) were submitted for pathway analysis (Table 13). Enriched pathways
represented by these proteins included: Metabolic processes (5 proteins), cell adhesion
molecules (4 proteins), ECM-receptor interaction (2 proteins), Mucin type O-glycan
biosynthesis (2 proteins), Folate biosynthesis (2 proteins), malaria (2 proteins), p53
signaling pathway (2 proteins), complement and coagulation cascades (2 proteins), and
phagosome (2 proteins).

3.3.3 PNGase-F Release of N-linked Glycopeptides
The previously-trypsin digested alkyne-agarose beads from our SILAC+Click
experiments were retained to assess N-linked glycosylation sites where ManNAcAz was
being incorporated (Figure 7). Following the removal of any carryover tryptic peptides,
the beads were incubated with PNGase-F and evaluated the peptides by LC-MS/MS. We
observed a total of 553 deamidated (Asn or Gln) peptides representing 224 unique
proteins, of which 77% matched the UniProt glycoprotein keyword search. Peptide data
was filtered to include only those with a deamidated Asn (411 peptides) and at least one
N-linked glycan consensus sequence (N-X-S/T), narrowing the list to 385 peptides
(Table 16, suppl. materials). From these 385 peptides, 170 unique proteins were
represented, with 91% matching the glycoprotein keyword. We next cross-referenced a
randomly selected subset of 55 observed peptides against the known glycosylation sites
in the UniProt knowledge Base. In this selected set, 7 of the peptides were discovered to
be overlapping in identifying specific N-linked sites, differing only in where N- or C94
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Deamidated

= GSANGTVQK

UniprotKB known Nglycan site?

Figure 7: PNGase-F Release of N-linked Glycopeptides from Alkyne-Agarose Beads.
PNGase-F catalyzes a deamidation of Asn residues (Asn→Asp) where N-glycans are
attached. Detection of deamidated Asn within an N-linked consensus sequence
constitutes a putative N-linked glycosylation site where ManNAcAz was incorporated.

PNGase-F

LC-MS/MS Peptide ID

terminal trypsin cleavage had occurred. Furthermore, 3 peptides were deamidated at Asn
residues outside of their N-linked consensus sequence and 3 were observed having
multiple deamidated Asn in their sequence (both within and outside of consensus
sequences). A total of 43 of the 55 peptides had deamidation localizations which matched
documented UniProt KB sites of glycosylation and 3 sites were identified in nonannotated N-linked consensus sequences (Table 17, suppl. materials).
In addition to sequence assessments, a comparison of the representative proteins
from PNGase-F released peptides to those of the equivalent samples digested with trypsin
(SILAC+Click experiments) was performed (Table 18, suppl. materials). A 63%
overlap of proteins derived from PNGase-F peptide release was observed in the trypsin
data. Glycoprotein content was 51%, 67%, and 92% in the identifications unique to
PNGase-F, unique to trypsin, and the shared proteins, respectively.

3.3.4 H358 Global N-linked Glycomics
Global changes in the N-linked glycome of H358 cells induced or non-induced to
express of TGFβ or EV were screened. Cell lysate-derived N-glycans were released by
PNGase-F and prepared by one of two methods of derivatization prior to MALDI-FTICR analysis: Permethylation or Linkage-specific sialic acid esterification. For the
Permethylated glycans, evaluation was initially carried out in the 500-5000 m/z mass
range from PNGase-F digested or no-enzyme controls (Figure 8). Obvious differences in
the distribution of spectra from PNGase-F digested samples relative to no PNGase-F
controls were observed; notably the presence of peaks above 2000 m/z in treated samples.
We next compared the spectra of induced TGFβ and EV in the 1150-5000 mass range
(Figure 9). Several shared structures were identified, including oligomannose and bi-,
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tri-, and tetra- antennary complex structures between the TGFβ and EV induced samples.
Notably, one species, Hex6HexNAc5 (m/z = 2519.3), was observed only in the TGFβinduced sample. In addition, mono- and tri-sialylated complex glycans were noted in the
upper mass ranges of both samples. For the linkage-specific sialic acid glycan analysis,
spectra were assessed from 1150-2600m/z (Figure 10). Several of the low-mass
oligomannose species, including Hex6HexNAc2 through Hex9HexNAc2 shared
identification in the permethylated data, including both TGFβ and EV groups. The
anomeric configuration of sialic acid on seven different bi-antennary complex glycans
was resolved. These included Neu5Acα2-6 Hex5dHex1HexNAc4 (m/z = 2128.7) and
Neu5Acα2-61Hex5dHex2HexNAc4 (m/z = 2275.8), which were also noted in the
permethylated spectra. As a general observation, α2-6 linkages were predominant on
mono-sialylated species, while di-sialyated glycans displayed a combination of α2-3 and
α2-6. Relative peak abundance suggests the major species present in TGFβ and EV
induced H358 cell lysate were Neu5Acα2-3Neu5Acα2-6Hex5dHex1HexNAc4 (m/z
2402.8). However, a clear increase in the proportion of Neu5Acα26Hex5dHex1HexNAc4 (m/z 2128.7) relative to m/z 2402.8 is evident in the TGFβinduced sample.
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Figure 8: H358 Permethylation +/- PNGase-F
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3.4 Discussion
Our initial experiments evaluated glycoprotein quantities following azido-sugar
metabolic labeling and alkyne-agarose bead capture of H358 cell lysate following the
induction of TGFβ, Zeb, or EV. We compared experimental groups by LC-MS/MS and
label-free quantification by calculating the average log2 fold change of nSCs and
applying a moderated t-test to deem significance (p<0.05). Of note, the induction of
TGFβ in ManNAcAz-labeled cells resulted in significant differences of the captured
quantity of several glycoproteins relevant to processes such as cell adhesion, cytoskeletal
regulation, ECM-receptor interaction, N- and O-glycan biosynthesis, solute transport, and
metabolic pathways (Tables 5 -7). For example, relative to Zeb, TGFβ-induction resulted
in the increased capture of Macrosialin, Cub-domain containing protein-1, Integrin alpha2, and Integrin beta-6. In addition, differences were apparent in several glycosyl
transferase enzymes, including GALNT10, MGAT2, B4GALT1, and GALNT6, in the
same comparison. Furthermore, the TGFβ1 ligand, which harbors three N-linked
glycosylation sites, was the most significantly increased glycoprotein captured in all
comparisons where its expression was induced. Experiments utilizing the GalNAcAz
label with TGFβ induction identified significant differences in known O-linked
glycoproteins such as SLC31A1 copper transporter and CD44. Moreover, the cell
membrane-associated glycoprotein Basal cell adhesion molecule and cytoskeletal
organization protein PDZ and LIM domain protein-7 were captured at altered levels with
GalNAcAz labeling. In the final two comparisons, based on ManNAcAz labeling and
Zeb-induction, we observed decreased capture of cell adhesion proteins (Intercellular
adhesion molecular-1, Cadherin-3, Tetraspanin-13, Dystroglycan, Syndecan-1), ECM101

based proteins (Thrombospondin-1 and Laminin), and cell surface receptors (Plexin-B2,
Receptor tyrosine protein phosphatase alpha and Epidermal growth factor receptor).
Further examination of data from comparisons where the Zeb gene was induced
(Tables 7, 10 and 11) revealed a trend suggesting a bias towards lower nSC values for
this experimental group. A review of the data for all of the individual samples indicates
that this may be due to changes in the quality of MS acquisitions over the 14 month time
period in which these experiments were carried out. This assertion is based on the total
acquired spectra and normalization factor for each sample provided by the ProteoIQ
software used for nSC generation (Table 3; rows 3 and 4). For example, within
experiments performed at individual time-points (as indicated by the dates and colors on
table 3 row 5), the total spectra and normalization factors are relatively consistent.
However, large variations in these values are apparent when equivalent samples acquired
at different time-points are compared. In this regard, it is quite possible that the quality
of online chromatographic separations varied over time because analyses were performed
on a highly-operated core-facility mass spectrometer. We were prepared for this
possibility and addressed it in the design of our data analysis. For each comparison
(Tables 5-11), the equivalent replicates for each group were selected from experiments
carried out at the same time-point (see Table 3: row 1). For example, if group A was
being compared to group B, replicate 1 for group A was selected from the same
experiment as replicate 1 for group B; the same being true for replicate 2 and replicate 3.
This approach accounts for variability in instrument performance and alleviates any bias
which would have been introduced from using data acquired over a long period. For our
goal of initially assessing azido-sugar labeling, enrichment, and LC-MS/MS
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quantification, this strategy was an appropriate choice for a rapid, preliminary analysis
prior to implementing a more reliable quantification method.
The experimental groups studied in our label-free quantification served to
establish the feasibility of our experimental procedures prior to double metabolic
labeling. Two concentrations of doxycycline for induction (data not shown), two azido
sugars (ManNAcAz and GalNAcAz), and samples derived from both cell lysate and
secreted protein fractions were evaluated. In addition, glycoprotein capture following the
induction of the gene Zeb, as well as non-induced controls, was assessed. We were able
to identify significant differences in captured glycoproteins using label-free
quantification and utilized this data as a guide for selection of TGFβ1 and EV
experimental groups only in our double metabolic labeling experiments.
Next, protein level changes were gauged to determine if this was contributing to
differential capture of azido-sugar labeled glycoproteins. SILAC relative protein
quantification was used in these experiments, rather than label-free quantification,
because of the increased reliability of data associated with this method(215). Three
biological replicates of SILAC and ManNAcAz metabolic labeling were performed on
TGFβ and EV- induced H358 cells and proteins were quantified both before (SILACOnly) and after alkyne-agarose bead capture (SILAC-Click). In order for this strategy to
have merit, candidate proteins must be quantified in both of these fractions. Therefore a
two-dimensional chromatographic separation (SCX and Reverse phase) of peptides was
applied to maximize the number of identifications made in both groups. As a result, 700
and 392 proteins were quantified in the SILAC-Only and SILAC+Click groups
(respectively), however a relatively small subset of proteins were shared between the
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fractions (91 total). To investigate this low overlap, a GO Analysis was performed on
total proteins quantified in each fraction (data not shown). The SILAC-Only group
contained a diverse set of proteins representative of broad biological processes derived
from intercellular, macromolecular complexes, and organelle-based components.
Conversely, the majority of quantified hits from the SILAC+Click fraction stemmed from
membrane-based and cell surface components. In addition, there was an obvious
discrepancy in the proportion of glycoproteins identified for each fraction (11% v s.
76%). Therefore, the lack of overlap between SILAC-Only and SILAC-Click may be
explained by the efficiency with which the Click chemistry based enrichment selectively
pulls down azido-sugar incorporated-glycoproteins. A more prudent approach to assess
protein quantity prior to enrichment would be Western blot analysis. Candidates captured
by alkyne-agarose beads at significantly different levels following TGFβ1 induction, with
relevant biological functions to invasive phenotypes, could be specifically assayed for
this purpose without the necessity of time consuming LC-MS/MS acquisitions and
bioinformatics analyses.
For statistical analysis of our double metabolic labeling, a moderated t-test was
applied to the averaged log2 fold change of the SILAC ratios with respect to TGFβ1
induction. Assessment of significance at BHp-values of 0.05, 0.10, and 0.15 was carried
out to evaluate shared proteins which were significantly changing in SILAC+Click while
not reaching significance in SILAC-Only. The same five proteins were observed meeting
this criteria at both BHp = 0.05 and BHp = 0.10; however, an additional 3 proteins were
included at BHp = 0.15. A UniProt search of these proteins indicated that seven of the
eight are known glycoproteins; with only Sodium/potassium-transporting ATPase subunit
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alpha-1 not meeting the designation. Interestingly, the beta-1 subunit of this protein also
fit inclusion criteria at BHp = 0.15, where it was observed to be decreasing about 30%
following TGFβ1 induction and alkyne-agarose bead capture (Table 15). The Na/K
ATPase is composed of heterodimeric alpha and beta subunits; where alpha carries out
the catalytic role and beta functions in regulating plasma membrane localization of the
pump. Recently, a role for the beta-1 subunit in epithelial cell polarity and cell-cell
adhesion was identified and shown to be modulated by N-linked glycosylation (216,217).
The authors conclude that hypo-glycosylated beta-1subunits resulted in decrease cell-cell
contacts through modification of the ATPase’s stability within the adherens junction.
Regarding the detection of the alpha-1 subunit in our SILAC+Click fractions, it is
plausible that the intact, heterodimeric form of the ATPase was captured through
ManNAcAz incorporation within the beta-1 subunit. Consistent with this is the absence
of sequenced peptides identified from the alpha subunit in our PNGase-F mediated
release of glycopeptides from the alkyne-agarose beads; whereas two unique beta-1
peptides, covering two N-linked glycosylation sites, were identified (Table 16) .
Another putative candidate identified from this work was CD276, which was
captured at significantly decreased levels following the induction of TGFβ. This
membrane-based-glycoprotein, also known as the T-cell B7-H3 co-stimulatory molecule,
has previously been implicated in the progression of cancer through effects on anti-tumor
immunity(218,219). However, very little information exists regarding the biological role
of its 6 potential N-linked glycosylation sites. One recent methods-based study uncovered
two sites of altered sialylation in CD276 stemming from hepatocellular carcinoma cells
treated with doxorubicin(220). Another study indicates that the B7 family of co-
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stimulatory molecules are constitutively expressed on airway epithelial cells and may
contribute to increased immune surveillance and inflammation at these surfaces(221).
Unfortunately, an assessment targeting the sialylation status of CD276 in lung cancer has
yet to be carried out.
The aspartyl/asparaginyl beta-hydroxylase (ASPH) was observed having the
lowest relative change in protein expression following TGFβ induction while
simultaneously having the largest significant difference following ManNAcAz capture
(47% decrease following TGFβ1 induction). This glycoprotein is found in the ER plasma
membrane where it functions in the hydroxylation of EGF-like domains of transient
proteins. The expression of ASPH has previously been noted as up-regulated at the
mRNA level in several tumor cell lines and has therefore been suggested for further
scrutiny as a putative biomarker(222). A UniProt search of ASPH indicates that it has
two predicted N-linked glycosylation sites based on its amino acid sequence, however no
published reports have confirmed this. In addition, Granulins was also identified from
double metabolic labeling experiments as a possible candidate of altered sialylation. This
secreted protein has functions in wound healing/tissue repair, inflammation,
embryogenesis and has been implicated in the progression of multiple cancers (223,224).
There are 5 predicted sites of N-linked glycosylation on granulins and a recent
publication has characterized 4 of them(225). Interestingly, although the authors noted
the presence of several different fucosylated complex N-glycans, none of the species
were sialyated.
The lack of protein-level data on the remainder of the significantly different
SILAC+Click proteins does not preclude further investigation of these candidates. KEGG
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analysis of these 58 proteins identified that they were enriched in pathways related to
metabolic processes, cell adhesion, extracellular matrix-receptor interaction, and other
pathways with relevance to the acquisition of invasive tumor phenotypes. Targeted
studies of each individual species may therefore be a warranted. For example, immunoprecipitation could be used to attain more-purified starting material for intact
glycopeptide analysis or glycomic studies. This approach would be contingent on the
availability of highly-specific antibodies for each target and MS instrumentation capable
of these types of acquisitions. These methods, however, have the potential for providing
detailed characterization of glycan structures and glycosylation site occupancy
information which could then be assessed as differentiating characteristics, alone or in
combination with other parameters, for biomarker development.
Following the double metabolic labeling experiments, we next investigated the
value of LC-MS/MS analysis of PNGase-F released glycopeptides from previously
trypsin-digested alkyne-agarose beads. This approach was used to specifically survey the
N-linked glycopeptides which incorporated ManNAcAz; as a means to potentially
identify the sites where this was occurring. The principle of these experiments was based
on the enzymatic specificity of PNGase-F, which cleaves the linkage between the core
GlcNAc and the asparagine residue of all N-glycans (with the exception of those bearing
a core (α1,3) linked fucose). During this reaction, the asparagine to which the glycan was
attached is deamidated (converting it to Aspartic Acid), resulting in a 1Da mass shift
detectable by MS. This approach to glycosylation site identification has previously been
applied to N-glycan enrichment strategies including hydrazide capture and lectin affinity
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chromatography, but never utilizing Click-chemistry-based alkyne bead enrichment
(179,180,226).
Over 500 deamidated peptides were initially identified from the PNGase
experiments. Sequential data filtering, from all deamidated peptides (Asn + Glu) →
deamidated Asn only → deamidated Asn only and at least one N-linked consensus
sequence, was applied to reduce the list to the most probable group for harboring Nglycans. This process brought the number of peptides down to 385, representing 170
unique proteins (91% glycoproteins). A subset of these peptides were selected for crossreference to assess how our putative site localizations compared to those on UniProtKB.
This approach was selected because of the large list of peptides and the requirement of
manual annotation. We discovered that, for some individual proteins represented by
multiple peptides in our list, the same deamidation site was being identified. This
phenomenon appears to be a consequence of slight variation in where N- or C-terminal
trypsin cleavage occurred. As expected, deamidated Asn outside of N-X-S/T sequences
were identified for a few of the peptides, reiterating the potential for false site
identifications due to random deamidations(227). Modern approaches to circumvent this
are focused on performing PNGase-F digest in the presence of isotopically-labeled water
for the incorporation of 18O into Asp following glycan release. This method, termed
Isotope-coded glycosylation site specific tagging (IGOT) has demonstrated utility for
increasing the fidelity of putative N-linked sites(228). We also evaluated how
deamidation sites from our selected list were annotated in UniProtKB. This database
makes use of two designations for the assignment of glycosylation: Published or
Sequence analysis. Published sites are derived from experimental observations while
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sequence analysis are predicted sites based on the presence of an extracellular consensus
sequence and confirmation from an external prediction service such as NetNGlyc
(http://www.cbs.dtu.dk/services/NetNGlyc/). Of the 43 non-repetitious peptides queried
in our selected list, 24 matched UniProt listed sites by sequence analysis, highlighting the
lack of existing information on N-linked glycan localizations. Therefore experimental
approaches capable of cataloguing these sites will be useful for creating libraries from
which experimental data may be compared.
An additional comparison of the protein identifications made following PNGase-F
release to those discovered from the original trypsin digest was performed.
Approximately 63% of the total proteins represented in the PNGase-F based experiments
had already been observed in the Trypsin fraction. Several potentially relevant
glycoproteins were uniquely identified with either enzyme; however this may be the
result of non-equivalent chromatographic separation and/or data processing steps used for
either analysis. For example, the trypsin based experiments were carried out using a 5step 2D-LC chromatographic separation prior to LC-MS/MS, while only a single
dimension was used for PNGase-F release acquisitions. The 392 trypsin-based
identifications were made based on the application of our quantification criteria; which
included the requirement of ≥2 SILAC ratios from the 3 biological replicates. In addition,
trypsin data was not limited to deamidated peptides only, whereas PNGase-F data was
immediately filtered to include only peptides with this variable modification. Therefore a
more even gauge of protein content might be attained by the application of standardized
chromatographic separation and data processing parameters prior to comparison.
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To provide a more comprehensive analysis of the glycosylation profile of the
H358 cells induced to express TGFβ or EV, we explored the N-linked glycoforms
detectable by PNGase-F release and MALDI-FT-ICR analysis. Two experiments were
performed, each utilizing a different glycan derivatization strategy. Permethylation was
carried out to optimize FT-ICR settings for the detection of sialic acid-bearing moieties
and linkage-specific sialic acid esterification to increase the detail of identified structures.
From this cumulative effort, a wide range of N-glycans were acquired, including
oligomannose, bi- tri- and tetra- antennary complex glycans, mono- and tri-sialylated, and
core-fucosylated species. We observed one glycan which was detected only in the
permethylated TGFβ-induced group (figure 9, m/z = 2519.3). Furthermore, inferences
regarding relative glycan abundance led us to discover a disproportionate increase one of
the sialylated N-glycans in TGFβ relative to EV in the linkage-specific derivatization
(figure 10, m/z = 2128.7).
One of the limiting factors to our H358 total N-glycome data is that only one
replicate for each derivatization method was examined. This was primarily due to
excessive difficulties in attaining high-intensity spectra with the H358 cell lysate. For the
linkage specific work, two protein precipitation methods were tested, two protein
concentrations for PNGase-F digest, and serial cotton tip HILIC enrichment prior to
attaining the presented spectra. Despite lack of demonstrated reproducibility, we believe
that the application optimized methods used here will be beneficial for future
glycoproteomic biomarker discovery endeavors. For example, by utilizing two distinct
derivatization methods we were able to identify a more diverse set of glycans than would
have been evident from either preparation alone. Permethylation data identified two tetra-
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antennary and three tri-antennary species which were not observed in the linkage-specific
experiment. At the same time, four distinct bi-antennary complex glycans, and their sialic
acid linkages, were discerned exclusively in the esterification fraction.
Finally, the use of high-resolution/high mass accuracy MS analysis greatly
facilitated the structural characterization of these glycans. This acquisition strategy is
based on the sensitivity of the FT-ICR mass analyzer for resolving the individual
monosaccharide constituents of a given glycan moiety(230). Importantly, this type of
mass analyzer has demonstrated utility for use with various ionization techniques
including ESI, MALDI, and fast-atom bombardment. Thus, FT-ICR analysis of N-linked
glycans is an ideal platform for rapid, sensitive studies which can be carried out on vast
array of MS instrumentation.
In summary, we demonstrated approaches for evaluating glycoproteins
incorporating an analog of sialic acid, glycoform structures, and the identification of
putative N-linked glycosylation sites from the H358 NSCLC cells. A workflow was
explored utilizing the incorporation of azido-sugars and gene induction followed by
enrichment of glycoproteins bearing these analogs (Figure 11). LC-MS/MS and labelfree quantification was applied to gain an initial look at targets which may be undergoing
alternative glycosylation as a result of TGFβ1 or Zeb induction. The approach was
narrowed to assess only TGFβ-influenced alterations in sialylated proteins and included
SILAC metabolic labeling. In these experiments, relative protein quantity was calculated
both before and after alkyne agarose bead enrichment so that inferences could be made
regarding how protein expression levels were affecting captured targets. Further utility
from the alkyne-bead capture format of these experiments was gained by performing a
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secondary digest, with PNGase-F, to identify site localizations of where ManNAcAz was
being incorporated. Finally, a preliminary analysis of the global N-glycome of the H358
was carried out. Two separate derivatization methods were implemented and glycans
were resolved by high-resolution/high mass accuracy MALDI-FT-ICR to ascertain if
TGFβ1 was influencing the glycoforms and/or types of sialic linkages present. The
combined use of these methods provided multi-faceted insight as to how TGFβ1
influenced the glycoproteome of this model and we therefore assert that these techniques
have merit for future biomarker discovery endeavors.
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4.1 Introduction
The initial stages of glycoproteomic biomarker discovery are most often carried
out using materials derived from in vitro or animal models of disease, tissue lysates, or
serum/plasma (14,231). Each discovery substrate has distinct advantages and
disadvantages, therefore sample availability and experimental strategy are often deciding
factors for selection. For example, plasma/serum matrices are easily obtainable and have
established utility in clinical testing. However, these samples may not be ideal for the
study of low-abundance proteins or post-translational modifications because of the need
for extensive pre-analytical preparations to remove high-abundance proteins. Cell culture
models provide a cheap, abundant source of materials and are compatible with metaboliclabeling to confidently quantify large numbers of analytes. However, these systems may
not truly be representative of the in vivo tumor microenvironment, often restricting the
applicability of findings. To circumvent these limitations, several approaches for
biomarker discovery have shifted towards analyzing biofluids in direct contact with the
tissue of interest (“Proximal fluids”)(15,232–234). These fluids contain tissue-specific
leaked and secreted proteins at higher concentrations than found in serum. In addition,
many proximal fluids are readily accessible (saliva, urine, tears) or routinely collected
during diagnostic procedures (Bronchoalveolar lavage fluid (BAL), cerebrospinal fluid,
gastric secretions). Furthermore, these types of samples are ideal for glycoproteomic or
glycomic studies because of the frequency with which this PTM occurs along the
secretory pathway.
Another useful strategy for biomarker discovery has been the analysis of tumor
tissue-lysate(235). These studies bypass several of the limitations of other starting
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materials because of their direct nature; without dilution of analytes in heterogeneous
substrates. In the past, workflows for the preparation of tissue-derived samples required
laborious processing steps and were incompatible with concurrent examinations to define
histological features. More recently, methods have been developed for intact tissue
profiling and spatial resolution of proteins, lipids, and glycan species(211,236,237).
Importantly, these imaging mass spectrometry procedures can be used to define the
distribution of various analytes in fresh-frozen or formalin-fixed paraffin embedded
tissues and may be carried out in parallel to pathological examinations.
At the same time as biomarker efforts using proximal fluids and tissue-imaging
approaches are moving forward, innovations in pre-analytical sample preparations and
MS-instrumentation have come about. These advances have been integral in facilitating
glycomic-based biomarker studies(230). For example, evolving derivatization methods
have synergized with the development of high-resolution and mass accuracy MS systems
to provide a robust means for the structural characterization of sialylated carbohydrate
molecules. One such procedure, recently described by Reiding et al., encompasses
chemical modification of sialic acid for the discrimination of anomeric linkages(212).
When this method is combined with highly sensitive instrumentation, such as a MALDIFT-ICR, a more detailed structural evaluation can be performed than previously possible.
While the use of MALDI-FT-ICR is not novel for oligosaccharide analysis,
implementation of this strategy for investigations based on proximal fluid derived
glycans has not been previously investigated.
Therefore, we implemented a novel approach to the characterization of diseasespecific glycan alterations in clinically-relevant biofluids using linkage-specific sialic
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acid derivatization and MALDI-FT-ICR analysis. Pathologically-defined matched
human samples, including BAL fluid and saliva, as well as fresh frozen lung tissue
(tumor and adjacent normal) were obtained from the lung cancer bio-specimen repository
network. Fluids were pooled and processed for derivatization and cotton-tip HILIC
enrichment of N-linked glycans. Fresh frozen tissues were sectioned at 5µm thickness
and processed on-slide prior to MALDI-FT-ICR acquisition of N-linked glycans;
duplicate slides were prepared for histological evaluation by a board-certified pathologist.

4.2 Materials and Methods
4.2.1 Samples Description
10 de-identified, matched sets of human samples (5 benign, 3 squamous cell
carcinoma, 2 adenocarcinoma) were obtained from the Lung Cancer Bio-specimen
Resource Network (LCBRN). The included bio-specimens, and a link to the LCBRN
website where the methods for collection are describe, can be found in Table 19. All
samples were stored at -80⁰C until processing.

4.2.2 Bronchoalveolar Lavage Fluid Proteomics
4.2.2.1 Sample preparation and In-solution digest
The 10 BAL samples were thawed on ice and 75µl aliquots were prepared as a
working solution. 3µl of each samples was visualized by polyacrylamide gel
electrophoresis (SDS-PAGE) (4-12% NuPage ®Bis-Tris Gel, Life Technologies) and
silver stained (SilverQuest™, Life Technologies) to approximate total protein quantity.
Normalized samples were brought up to 75µL total volume in 50 mM NH4HCO3
(Sigma), 10mM DTT, and allowed to reduce at 95⁰C for 10 minutes. After cooling to
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room temperature, IAA was added to a final concentration of 20mM and alkylation
proceeded for 30 minutes in the dark. Samples were digested at 37⁰C for 16 hours with
2µg proteomics grade trypsin. Following digestion, samples were desalted by µC18 ZipTip (Milipore), speedvac concentrated, and stored at -20⁰C until LC-MS/MS.
4.2.2.2 LC-MS/MS and Bioinformatics
LC-MS/MS, Bioinformatics, and generation of normalized spectral counts for
BAL samples were performed as described in section 3.2.5. Gene Ontology (GO)
analysis of proteins uniquely identified in cancer-associated BAL fluid was performed
using Web-based gene set analysis toolkit (Webgestalt:
http://bioinfo.vanderbilt.edu/webgestalt/)(238,239). Protein identifications were
compared to the normal distribution of genes in the human genome to identify biological
processes and cellular components which were enriched (BHp <0.05) relative to expected
distribution. Specifications included: Organism = Homo sapiens, Id Type =
uniprot/swissprot accession, Ref Set = entrezgene, Significance Level = Top10, Statistics
Test = Hypergeometric, Multiple test correction = Benjamini Hockberg, Minimum
number of genes = 2.

4.2.3 N-linked Glycomics of Human Biofluids
Pooled BAL samples were prepared from each diagnostic group (Benign, SCC,
AC) at 100µL total volume. Two saliva pools were prepared at 200µL total volume: 1.
Benign- 40µL of each benign sample and, 2. Metastatic- 40µL from each of the
metastatic groups (SCC+AC). Linkage-specific sialic acid esterification proceeded as
described in section 3.2.10.1. MALDI-FT-ICR N-glycan analysis and bioinformatics
were carried out as described in section 3.2.11.
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4.2.4 N-linked Glycan Imaging of Lung Tissue
4.2.4.1 Sample preparation
Flash frozen lung tissues were prepared for MALDI-Imaging Mass Spectrometry
(MALDI-IMS) by the formalin-fixed paraffin embedded method described by Powers et
al.(240). Tissues were sectioned at 5µm and mounted onto positively charged glass slides
compatible with the Bruker FT-ICR adaptor plate. Citraconic anhydride (Thermo) was
used for antigen retrieval. Following buffer exchange and desiccation, .2µL of
recombinant PNGase-F were applied uniformly using an ImagePrep spray station (Bruker
Daltonics) and slides were incubated at 37⁰C for 2 hours in a humidified chamber. Slides
were desiccated for 10 minutes and matrix (0.021g α-Cyano-4-hydoxycinnamic acid
(Sigma) in 3 ml 50% acetonitrile/50% water and 12µl 25% trifluoroacetic acid) was
applied using the TM-sprayer™ (HTX Technologies). Duplicate slides of each tissue
were prepared for hematoxylin and eosin staining, and definition of histological features
was performed by a board-certified pathologist.
4.2.4.2 N-glycan MALDI Imaging Mass Spectrometry
Released N-glycans were acquired directly on tissue with a Solarix dual source 7T
FT-ICR mass spectrometer (m/z= 500-5000). A SmartBeam II laser operating at 2000 Hz
was used to acquire spectra across at a raster width of 50µm. Detected glycan species
were viewed using FlexImaging 4.1 software. Identifications were made by searching
spectra in the range of m/z = 1000-4000 against the glycan structures database of the
Consortium for Functional Glycomics. Glycan structural annotations were produced in
GlycoWorkbench 2.1.
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Diagnosis:
ID#:
Specimens:

Paired Tissue:

Table 19: Lung Cancer Bio-speciment Resource Network Sample Types

Squamous Cell Carcinoma (SCC)
V0229
V0232
V0233
Urine
Urine
Urine
BAL
BAL
BAL
Cell pellet
Cell pellet
Cell pellet
Serum
Serum
Serum
Saliva
Saliva
Saliva
Lung (tumor)
Lung (tumor)
Lung (tumor)
Lung (fibrosis)
Lung (normal)
Lung (fibrosis)
Bronchus (normal) Bronchus (normal) Bronchus (normal)

Adenocarcinoma (AC)
V0231
W0216
Urine
Urine
BAL
BAL
Cell pellet
Cell pellet
Serum
Serum
Saliva
Saliva
Lung (tumor)
Lung (tumor)
Lung (normal)
Lung (normal)
Bronchus (normal) Bronchus (normal)

Collection protocol for each specimen can be found at http://avillage.web.virginia.edu/LungBio/standard-operating-procedures
Benign
S0081
W0099
V0034
W0005
W0086
Urine
Urine
Urine
Urine
Urine
BAL
BAL
BAL
BAL
BAL
Cell pellet Cell pellet Cell pellet Cell pellet Cell pellet
Serum
Serum
Serum
Serum
Serum
Saliva
Saliva
Saliva
Saliva
Saliva

BAL= Bronchoalveolar Lavage Fluid
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4.3 Results
4.3.1 Bronchoalveolar Lavage Fluid Proteomics
We examined the proteomic contents of 10 human BAL fluids for an initial
survey of constituents detectable by LC-MS/MS. These samples were derived from a
pathologically defined set of matched biofluids and tissues, including 5x benign, 3x
squamous cell carcinoma (SCC), and 2x adenocarcinoma (ADC). In addition, we gauged
the relative abundance of identified proteins by label-free quantification to provide a
well-annotated resource from which future studies may be compared.
Total protein abundance of each sample was estimated by SDS-PAGE and silver
staining (Figure 12). Darker banding patterns were observed in the cancer relative to
benign samples, with the exception of sample W0099. This visual assessment was used to
gauge individual sample input for an in-solution trypsin digest and LC-MS/MS analysis
of proteomic content. A total of 332 proteins were quantified from all samples following
the application of post-processing parameters for the production of normalized spectral
counts (Table 20, suppl. materials). Of the total proteins discovered, 35% matched the
Uniprot glycoprotein keyword search. Grouping of the individual samples into two
categories (Cancer and Benign) for comparison resulted in the identification of 25
proteins distinctly quantified in cancer-associated BALs and 12 unique to Benign (Table
21, suppl. materials). Glycoproteins identified only in the cancer group included
Osteopontin, Clusterin, and Mucin-4. Conversely, Sialic acid synthase was quantified
only in the benign group. For
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Benign

Cancer

Figure 12: Bronchoalveolar Lavage Fluid Protein Content. 3µl
BAL fluid separated by 4-12% Bis-Tris PAGE and Silver-Stained.
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shared proteins, discrepancies were obvious in the nSC quantity of cell adhesion and
extracellular glycoproteins including an increase in CD59, Galectin-3 binding protein,
Mucin-5, and Mesothelin, as well as decreases in the redox-related proteins Catalase,
Peroxiredoxin-6, and Thioredoxin reductase-1, in the cancer group relative to benign.
GO analysis of proteins uniquely identified from cancer BALs revealed significant
enrichment of intracellular non-membrane-bounded, extracellular, and cytoskeletal
cellular components, amongst others (Table 22). In addition, biological processes
represented included protein-DNA complex assembly, chromatin assembly, and
nucleosome organization.

4.3.2 N-linked Glycomics of Human Bio-fluids
Matched human biofluids, including BAL and saliva, were processed for N-linked
glycan profiling by linkage-specific sialic acid esterification and FT-ICR analysis. Total
acquired spectra from each BAL pool (Bn, SCC, and ADC) were first evaluated from
1200- 3250 m/z (Figure 13). We observed abundant spectra (>108 intensity) in each pool
and therefore annotated individual peaks to assess differences between groups (Figures
14-16). A peak at m/z = 2301.8, correlating to a di-α2-6-sialylated bi-antennary complex
glycan, was the most prevalent species observed in all BAL samples. Within the benign
pool, there was an increased abundance of Hex9HexNAc2 (m/z = 1905.7),
Hex5dHex2HexNAc4 (m/z = 1955.7), and Hex5dHex1HexNAc4 (m/z = 1809.7) relative
to SCC and ADC (Figure 14). The ADC pool had a distinct increase in an α2-6-monosialylated bi-antennary complex glycan (Figure 14: m/z = 1982.8) as well as an apparent
decrease in the relative peak height of two di-sialylated bi-antennary complex glycans
(Figure 15: m/z = 2355.9 and 2401.9).
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Table 22: Gene Ontology Analysis of Proteins Unique to Cancer Bronchoaveolar
Lavage Fluid Samples

5.13
0.1
5.13
0.4

# of genes matched
4
4
4
4
4

11
2
11
3

0.0024
0.0024
0.0059
0.0237
0.0474

adjP value
0.0023
0.0023
0.0023
0.0023
0.0023

0.0373
0.0373
0.0373
0.0398

adjP value
0.0018
0.0018
0.0028
0.0028
0.0159
0.0159
3800
77
3800
296

# Expected
0.21
0.16
0.18
0.19
0.21

4
4
4
2
2

# of genes matched
7
8
3
10
3
8

GO:0043232
GO:0005796
GO:0043228
GO:0000785

Biological Process
# Genes in category
137
107
117
128
138

0.23
0.23
0.28
0.04
0.07

# Expected
1.15
1.48
0.09
2.89
0.15
2.41

ID
GO:0065004
GO:0006334
GO:0031497
GO:0034728
GO:0006333

152
152
188
29
44

Cellular Component
# Genes in category
856
1099
67
2140
111
1790

Category
extracellular space
extracellular region part
nucleosome
extracellular region
protein-DNA complex
cytoskeleton
intracellular non-membrane-bounded
organelle
Golgi lumen
non-membrane-bounded organelle
chromatin

GO:0071824
GO:0006323
GO:0071103
GO:0018149
GO:0031424

ID
GO:0005615
GO:0044421
GO:0000786
GO:0005576
GO:0032993
GO:0005856

Category
protein-DNA complex assembly
nucleosome assembly
chromatin assembly
nucleosome organization
chromatin assembly or disassembly
protein-DNA complex subunit
organization
DNA packaging
DNA conformation change
peptide cross-linking
keratinization
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Figure 13: BAL Pool total FT-ICR Spectra (m/z = 1200 –3250 )
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Pooled saliva samples were next examined over the mass range of m/z = 11603250 (Figure 17). Clear differences in the spectra of the benign and cancer were
apparent, therefore we assessed which structures were predominant in each group
(Figures 18 - 20). In the benign pool, the tri-antennary complex glycan
Hex3dHex1HexNAc5 (m/z = 1688.7) was the most prevalent. This species was followed
by a near equal distribution of m/z = 1850.7 and 2101.8, correlating to a core-fucosylated
tri-antennary and a tri-fucosylated bi-antennary glycan, respectively (Figure 18 and 20).
There was also an apparent increase in an α2-6-mono-sialylated tri-antennary glycan (m/z
= 2169.8) and a decrease in a di-fucosylated tri-antennary complex species (m/z =
2320.9) in the benign pool relative to the cancer (Figure 20). The cancer pool presented
with a slightly higher mass tri-antennary glycan, Hex4dHex1HexNAc4 (m/z = 1809.7)
dominating peak height. In addition, the increased relative abundance of bi-antennary
Hex5dHex2HexNAc4 (m/z = 1955.7) and tri-antennary Hex6dHex1HexNAc5 (m/z =
2174.9) in the cancer samples (Figures 19 and 20).
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4.3.3 N-linked Glycan Tissue Imaging of NSCLC Tissue
Human lung tissue was sectioned and processed for on-slide PNGase-F digest,
matrix application, and MALDI-FT-ICR acquisition of released N-glycans (Figure 21).
These included tumor and adjacent normal tissue from one adenocarcinoma and two
squamous cell carcinomas. A duplicate slide of each was stained with hematoxylin and
eosin and histological features were confirmed by a pathologist (Figure 22). The
distribution of individual peaks was compared against defined regions to determine how
their expression correlated to histology (Figures 23a and 23b). From this effort, we
identified three glycans whose presence was increased in the tumor tissues (both ADC
and SCC) relative to normal adjacent (m/z = 1419.5, 1743.6, and 2174.8). These
structures correspond to Hex6HexNAc2, Hex8HexNAc2, and Hex6dHex1HexNAc5,
respectively. In addition, three other species appeared to be up-regulated exclusively in
the defined cancer region of ADC (m/z = 1955.7, 2320.8, and 2686.0). These glycans
correlated to a set of di-fucosylated structures including Hex5dHex2HexNAc4,
Hex6dHex2HexNAc5, and Hex7dHex2HexNAc6. There was also a single spectra,
correlating to Hex3dHex1HexNAc4, which was selectively dominant in SCC tumor
tissues (m/z = 1485.5). In addition, we identified several N-glycans whose expression did
not appear to differentiate tumor from normal lung tissue (Figure 23a; m/z = 1257.4).
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Histological Evaluation
By Pathologist

Adapted from Powers et al. PLOS ONE. Vol.9 (9). Sept. 2014.

Figure 21: Workflow for Lung Tissue Imaging of N-glycans
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Figure 22: Lung Tissue H&E with Pathology Notes
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Figure 23a: Distribution of N-glycans in Lung tissue by MALDI imaging MS (m/z=1250-1750)
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Figure 23b: Distribution of N-glycans in Lung tissue by MALDI imaging MS (m/z=1950-2700)
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4.4 Discussion
Here the application of recently-developed methods for N-linked glycomics on
pathologically-graded, clinically-relevant NSCLC samples was assessed. A pre-analytical
sialic acid linkage derivatization approach was applied to biofluids, including BAL and
saliva, and acquired mass spectra using a high resolution accurate mass instrument. We
also performed an on-tissue PNGase-F digest and imaging mass spectrometry to spatially
resolve glycans on tumor and adjacent normal tissues. The rationale for these
experiments was seeded both in the methodology employed and the types of samples
analyzed; to gauge their collective utility for future biomarker discovery efforts.
The proteome of human BAL pools (benign and cancer) was first evaluated to
catalogue the components detectable in each diagnostic group by LC-MS/MS. This
substrate has previously demonstrated relevance as a tool for diagnostic/prognostic
evaluations of various pathologies, however explorations of its proteomic content are still
rather new(15,233,234,241). We discovered over 300 proteins across the 10 samples
analyzed and applied label-free quantification as a means initially assess relative
abundance of each. General trends were observed in protein abundance based on the
application of label-free quantification which would likely be of value exploring using
isotopic labeling techniques such as, iTRAQ, or TMT methods. In addition, based on the
high nSC values obtained for albumin, IgG, and transferrin-related proteins, the
application of up-front depletion/enrichment strategies would likely increase the depth of
identifications for sub-proteomic investigations.
The N-linked glycome of BAL fluid was analyzed using sialic acid linkage
specific esterification and MALDI-FT-ICR. This was the first assessment of N-linked
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glycoforms derived from this proximal fluid that we know of. In addition, we profiled
structures present in matched saliva pooled samples to increase the breadth of
investigation and discern the utility of these substrates for glycomic-based biomarker
discovery efforts in NSCLC. An obvious difference in the distribution of peaks
associated with N-linked glycan structures was apparent between BAL pools. The glycan
structural database from the consortium for functional glycomics was utilized to make
identifications based on FT-ICR accurate mass detection. Several bi- and tri-antennary
complex structures, including core-fucosylated and mono-, di-, and tri-sialylated forms,
were shared between pools. Based on relative peak intensity, we discovered the
predominant species present in each group was a di-α2-6-sialylated bi-antennary complex
glycan (Figure 13; m/z = 2301.8). Three glycans, including an oligomannose structure,
appeared to be uniquely up-regulated within the benign pool (Figure 14). As well, there
was apparent down regulation of two structures (Figure 15; m/z = 2355.9 and 2401.9) in
the ADC pool relative to benign and SCC. Furthermore, the application of linkage
specific sialic acid esterification resolved the presence of di- and tri- sialylated complex
glycans, displaying multiple anomeric configurations, in the higher mass ranges of these
samples (Figure 16). For saliva pools, there was a generalized decrease in the number of
spectra correlating to sialylated glycan moieties relative to the BALs. Structures
identified in saliva-based benign and cancer groups were predominantly lower mass biand tri- antennary complex glycans. Relative peak height suggested that the predominant
species in the benign pool was by far a core fucosylated tri-antennary moiety, while the
cancer group appeared to have a more even distribution of 3 main structures (Figure 17).
Interestingly, 11 shared glycan structures were identified in both the saliva and BAL
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pools. These included four of the most abundant peaks identified in saliva representing
three fucosylated bi-antennary and one fucosylated tri-antennary complex glycans
(Figures 18 and 19; m/z = 1793.7, 1809.7, 1850.7, and 1955.7).
Intact lung tissue MALDI-FT-ICR imaging mass spectrometry was used to
spatially profile the distribution of native N-glycans in tumor and normal-adjacent
tissues. Eight oligomannose structures were presented as a demonstration of how this
data could be useful for defining specific features of histology. In addition, we crossreferenced several peaks from the imaging data which had previously been identified in
the proximal fluid studies. These included species whose localization appeared to
correlate to increased expression in ADC only (Figure 24a and 24b; m/z = 1955.7), SCC
only (Figure 25a and 25b; m/z = 1485.6), or within both cancer groups cancer (Figure
26a and 26b; m/z = 1419.5). Conversely, we assessed potentially interesting spectra
from the proximal fluids in the imaging data. For example, based on visual assessment of
peak height, the core-fucosylated tri-antennary glycan (m/z = 1688.7) was the prevalent
species in the benign saliva pool (Figure 17) .However, the spatial distribution of this
species, and peak height in the BAL pools, did not correlate with this observation (Figure
27). In a similar manner, the high-mannose glycan (m/z = 1905.7) appeared to be more
abundant in the benign BAL pools relative to SCC and ADC; yet imaging data suggested
a higher association with tumor tissues (Figure 28).
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Obvious caveats limit the ability to assess trends in glycan expression between
substrates as presented. These include the use of pooled proximal fluid samples and the
low number of tissues used for imaging. In addition, statistical analysis for evaluating
differences in relative peak height was not performed and reproducibility has yet to be
investigated. Furthermore, the release of glycans from dominant endogenous
glycoproteins in these substrates may overpower the detection of lower abundance
species. Another limiting factor related to these investigations was the use of linkagespecific sialic acid derivatization for proximal fluids only. This approach was adopted to
both protect sialic-acid containing glycans during ionization and discern their anomeric
configurations. However, an equivalent method for on-tissue derivatization has yet to be
developed; precluding extensive detection of sialylated species for on-tissue experiments.
As an alternative, increased identification of these glycans might be achieved by imaging
mass spectrometry carried out in negative ionization mode(242).
Bronchoalveolar lavage fluid and saliva are appropriate substrates for the
discovery of disease-specific glycosylation patterns in NSCLC. These fluids are abundant
sources of secreted/shed glycoproteins and are frequently collected during routine
diagnostic or follow-up procedures. Saliva may be acquired regularly in copious volumes
with minimum patient risk, while BAL fluids are typically available from patients
presenting with a respiratory mass following bronchoscopy. Although BAL has been
probed for diagnostic and prognostic utility based on cytological and (more recently)
proteomic content, investigations of N-linked glycoforms in this fluid are
novel(233,234,243,244). Similarly, efforts to utilize saliva for biomarker discovery have
demonstrated promising results in lung, head and neck, and breast cancer(245–249).

150

Saliva is known to be an rich source of carbohydrate molecules stemming from mucins
and high molecular weight glycoproteins, however explorations into the types of glycan
structures it carries, and how they relate to specific pathologies, are
limited(188,247,249,250). In addition, the presented methods could also be applied to
proximal fluids such as exhaled breath condensate or pleural fluid. These materials
contain proteomic content derived from the respiratory epithelium and early studies have
demonstrated their feasibility for use in biomarker evaluations(251,252). While all of
these fluids may be potent reservoirs of glycan molecules related to disease,
consideration must be given to collection and processing procedures in order to reliably
assess reproducibility of findings. This potential limitation will be addressed in our ongoing studies by continuing to use bio-repository maintained samples with welldocumented collection/processing procedures. The use of this sample resource will also
provide us with follow-up patient data which will likely be of value for correlating glycan
structures to specific outcomes such as disease recurrence and mortality rates.
In relation to the MALDI tissue imaging approach presented, one of the limiting
factors was the inability to attain spatial resolution at cellular and sub-cellular levels. This
constraint has the potential to decrease the specificity of detected glycans because of the
heterogeneous cell populations present in and adjacent to tumor tissues. Efforts to address
this have successfully used an overlapping laser shot approach where repeated ablation of
tissue resulted in improved resolution down to approximately 25µm(253). Alternatively,
the use of smaller diameter lasers combined with a “transition geometry” method, where
the MALDI laser is fired from behind the tissue, has also achieved higher definition in
uncovering the distribution of tissue analytes at sub-micron levels(254). The feasibility of
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incorporating these strategies into our workflow was principally constrained by the time
and analytical requirements necessary to carry out these approaches. The selection of a
raster width of 50µm was therefore an appropriate compromise to attain moderately high
resolution images in a time frame conducive to high-throughput studies.
Another factor to consider for the glycan imaging studies was the discovery of
inflammation and immune cell infiltrate within the tissues during histological assessment.
This finding was unsurprising granted the established role for immune activation and
inflammation in the pathogenesis of NSCLC(255). Importantly, several studies have
taken advantage of the presence of such infiltrating cells to research the prognostic
significance specific populations may confer (7,256). Further utility of our approach
might therefore be achieved by incorporating a phenotypic evaluation of these infiltrating
cells as an additional metric for prognostic considerations. Additionally, the discovery of
immune cell and/or inflammatory-associated glycan epitopes from tissue imaging studies
would be useful for this purpose, particularly if they could be translated into biofluids
with relevance for clinical assays.
In summary, the assessment of a combined approach to identify N-glycans
derived from matched lung tissues and proximal fluids was presented (Figure 29).
Oligosaccharides were released from BAL and saliva pools and underwent a sialic acid
linkage-specific derivatization strategy. This procedure serves to both protect from the
loss of labile sialic acid residues during ionization and allow for discernment of linkage
conformations. At the same time, tumor and normal lung tissues matched to the proximal
fluids were sectioned for histological analysis and on-tissue acquisition of N-glycans.
This approach facilitated discernment of the spatial distribution of N-glycan species to
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relevant histological features of the tissue. All MS analyses were carried out on a
MALDI-FT-ICR instrument, providing high-resolving power to differentiate a variety of
oligomannose and complex glycans from each sample type. The implementation of these
analytical strategies carried out on a set of matched samples was conducive to directly
cross-referencing distinct glycan structures between tissues and biofluids. Therefore, ongoing studies focused to increasing the throughput, applying statistical analyses, and
assessing reproducibility from these methods are likely to result in a whole new paradigm
for approaches to glycomic biomarker discovery.

.
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Figure 29: Summary of Workflows for NSCLC Biofluids and Tissue Imaging Glycomics
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Chapter 5
Conclusions and Future Studies
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5.1 Glycoproteomic and Glycomic Approaches to Evaluate
TGFβ1-induced effects on Sialoglycoproteins in a Cell
Culture Model of NSCLC
5.1.1 Conclusions
We hypothesized that the development of mass spectrometry-based
glycoproteomic and glycomic workflows could be used to identify detailed characteristics
in sialylated glycoproteins in NSCLC. To test this, investigations were carried out in the
H358 cells using an azido-sugar metabolic labeling, alkyne agarose bead enrichment, and
LC-MS/MS quantification strategy. Differential capture of glycoproteins incorporating
ManNAcAz following TGFβ1 induction was assessed by both label-free and SILAC
relative quantification. The double metabolic labeling strategy was also utilized to
examine relative protein expression levels influenced by TGFβ1. In addition, the utility of
a secondary digest using PNGase-F was gauged for surveying N-linked glycosylation
sites. Finally, the global N-glycome of TGFβ1-induced H358 cells was acquired using an
innovative pre-analytical strategy and MALDI-FT-ICR analysis. The application of these
approaches revealed that:
1. We developed a robust method for the interrogation of sialylated glycoproteins in a
cell culture model of NSCLC by mass spectrometry. A multi-faceted approach, including
quantification of glycoproteins incorporating a sialic acid analog following the induction
of TGFβ1, elucidation of N-linked glycosylation sites, and structural evaluations of
global N-linked glycans, was presented using the cell lysate fraction of H358s. Initial
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assessments of these strategies also demonstrated feasibility for the methods with the
GalNAcAz label and cell culture supernatant fractions.
2. H358 cells efficiently incorporate the ManNAcAz label onto nascent glycoproteins as
demonstrated by WB analysis of cell lysates using biotin-alkyne/streptavidin-IR dye. The
induction of TGFβ1 appears to increase the presentation of the analog dramatically.
3. ManNAcAz labeling and Click-chemistry alkyne-agarose bead enrichment are an
efficient means to selectively study low-abundance glycoproteins. This was evidenced by
the high proportion of glycoproteins identified in SILAC+Click experiments (76%)
relative to SILAC-Only experiments (11%).
4. The induction of TGFβ1 expression in ManNAcAz-labeled cells resulted in significant
differences in the captured quantities of glycoproteins relevant to the acquisition of
invasive phenotypes. Supporting this was KEGG enrichment analysis of proteins
captured at significantly different levels representing cell adhesion, extracellular matrix,
and cytoskeletal-related functions.
5. The inclusion of SILAC with the azido-sugar metabolic labeling procedures provided a
reliable means for quantifying the large number of glycoproteins identified. Even after
the application of stringent post-processing parameters and replicate trimming, over 390
proteins were quantified from Click enriched samples and 700 from non-enriched.
6. The double metabolic labeling strategy provided limited information regarding how
TGFβ1-influenced protein expression levels were contributing to differential capture
quantities. This was evident from the low number of proteins shared between the SILACOnly and SILAC+Click fractions (91 total). Furthermore, only 5 proteins were found to
be significantly enriched in the SILAC+Click while not significant in SILAC-Only at
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BHp = 0.05 and 0.10. A more prudent approach to assess protein expression may be to
perform WB analysis on selected glycoproteins relevant to invasive biological processes.
7. The utility of the alkyne-agarose bead enrichment procedure can be extended by the
application of a secondary digest to release bound N-linked glycopeptides. This strategy
is useful for verification of N-linked sites where ManNAcAz was incorporated and may
reveal additional glycoproteins not detected by the initial digest.
8. MALDI-FT-ICR analysis of H358 N-linked glycoforms, using two derivatization
methods, identified an array of the most prominent oligosaccharide structures from TGFβ
and EV-induced cells. The permethylation approach was useful for identification of
oligomannose and tri- and tetra-antennary complex glycans. The linkage-specific
esterification method resulted in elucidation of anomeric configurations of sialic acid on
several bi-antennary complex glycans.

5.1.2 Limitations of Azido-sugar Metabolic Labeling Studies
The azido-sugar metabolic labeling, alkyne-agarose bead enrichment and LCMS/MS approach is a powerful tool for analyzing characteristics of sialylated
glycoproteins, however there were some inherent technical and conceptual limitations
associated with this strategy. These shortcomings are introduced here and discussed in
more detail in the future studies section (5.1.3).
One limitation is the inability to release bound glycans from the alkyne agarose
beads for structural evaluations. This limitation is due to the covalent nature of the Click
reaction between the azide and alkyne functional groups. The strength of this reaction is
an advantage for proteomic evaluations of captured glycoproteins, because it allows
stringent washes of the beads to remove non-specifically bound molecules. At the same
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time, however, the glycans which incorporated the azido-sugar remain permanently
bound to the beads and there is currently no method available to release them. Therefore,
the presented approach provides proteomic and N-glycan site data on captured
glycoproteins without concomitant information on the glycan structures which
incorporated the analog sugars.
Another drawback is the lack of information that can be obtained regarding Olinked glycosylation sites. This weakness is more related to the lack of an enzyme for Oglycan release from the alkyne beads than it is to the azido-sugar labeling and enrichment
methodology. Further adding to this constraint is the lack of an amino acid consensus
sequence for the attachment of O-linked sugars. Peptides attached to the beads linked via
an O-glycosylation linkage could be released by beta-elimination, but there is no way to
verify what site was modified, or how many sites were modified, for a given protein.
Therefore, the presented approach is currently only amenable to identifying sites of Nlinked glycosylation where the azido sugars are being incorporated, without equivalent
information on sites of O-linked glycosylation.
Another weakness related to N-linked glycosylation site identification is the
inability to differentiate random deamidations on asparagine residues from PNGase-Fmediated deamidations. Random deamidations may occur on asparagine or glutamine due
to proteolytic degradation or because of side-chain reactions with glycine or
serine/threonine residues. As a result, it is possible that some of the N-linked glycan sites
identified were result chance occurrences; however the high proportion of peptides in
which Asn was deamidated within an N-linked consensus sequence argues more for a
PNGase-F specific deamidation.
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Conceptual constraints also limit the relevance of information obtained in the
presented approach. For example, in our demonstration of the methods, only one cell
model of lung cancer was assessed. In addition, a single time-point of gene-induction and
only one mechanism for inducing invasive phenotypes was carried out during
experimental procedures. Therefore the findings presented do not adequately represent all
relevant changes in sialylation that occur during the entire time-course of TGFβ1-induced
NSCLC progression; rather, our method provided a “snapshot” of sialylation changes
occurring in a limited representation of the disease.
Another conceptual concern relates to the inability of the presented strategy to
measure absolute protein and sialylation changes between experimental groups. Because
the presented approach is based on relative quantification of captured glycoproteins, it is
possible that differences in sialylation where missed when a given glycoprotein’s
incorporation of the azido sugar was in opposition to changes in protein quantity. For
example, if TGFβ1 caused increased sialylation while simultaneously decreasing protein
quantity for a given glycoprotein (relative to empty vector cells), then no difference in
captured quantity would be seen between the groups. Therefore, the presented method is
limited in that some of the differences in sialylation were likely over- or under-estimated.

5.1.3 Future Studies
The goal of this work was to develop methods and evaluate experimental
approaches tailored to future glycoproteomic/glycomic biomarker studies in NSCLC. The
initial experiments using azido sugar labeling and Click chemistry enrichment with labelfree quantification demonstrated feasibility for the use of both ManNAcAz and
GalNAcAz labels in cell lysates and supernatant fractions. However statistical analysis
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and subsequent investigations were carried out only for ManNAcAz-labeled cell lysate
fractions following TGFβ1 induction. Therefore a more in-depth investigation into cell
culture supernatant glycoproteins (i.e. secreted products) may be beneficial for translating
in vitro findings into frequently used clinical fluids. An added benefit for this type of
approach is that this method has previously been shown to maintain selectivity for low
abundance glycoproteins without the complete removal of serum supplements from cell
culture media(194). Furthermore, we have carried out preliminary assessments of this
approach for the detection of exosomal glycoproteins (data not shown). These nonclassical secreted vesicles have shown promise as a cancer biomarker discovery source as
they carry tumor-specific protein products and may be isolated from multiple biological
fluids(257,258). Therefore we additionally propose to implement the SILAC double
metabolic labeling strategy for the quantification of exosomal glycoprotein cargo as a
future direction.
Other variables to the presented strategy that will be addressed by future studies
include a dedicated approach centered on the use of other sugar analogs, such as those for
Fucose, GalNAc, or GlcNAc. These studies may provide a more comprehensive view of
how other classes of glycoproteins respond to specific stimuli such as TGFβ1. As well,
for increasing the likelihood that in vitro findings will be representative of in vivo
disease, additional studies would benefit from applying these methods to multiple cell
models. For the presented work, parallel investigations using A549 or HCC4006 cells
may have highlight inconsistencies or uncover common trends with the H358 model.
Similar to this, utilization of alternative mechanisms for the production of specific
phenotypic properties will be critical if claims will be made that observed glycosylation
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changes are truly of a consequence these processes. For example, as an alternative to the
use of TGFβ1 to induce invasive characteristics, future studies might use hepatocyte
growth factor or epidermal growth factor treatments, knockdowns of miR200, or the
modification of E-cadherin to achieve this outcome.
The primary workflow utilized for azido sugar labeling and TGFβ1 induction (Figure
2) was based on a previously optimized procedure described by Yang et al with slight
modifications (193). Specifically, cells are incubated with the analog sugars for 48 hours,
followed by a media change and the addition of doxycycline for 24 hours prior to
collection of lysates and cell culture media. In order to gain a better perspective as to
how sialylation is affected by TGFβ1 expression, different gene induction time-points
should be utilized. For example, studies with extended exposure to TGFβ1 or
experimental approaches where analog sugar metabolic labeling occurs after doxycycline
treatment would be worthwhile endeavors.
In chapter 3, we utilized a broad-approach to identify large populations of
glycoproteins potentially undergoing alternative sialylation in response to TGFβ1
stimulation. The logical next step from these investigations would be to critically
evaluate the individual proteins identified from this work. Future studies will therefore
employ approaches such as immunoprecipitation to selectively focus on the glycosylation
of specific targets. Glycoproteins captured at significantly different levels from
SILAC+Click will be individually evaluated for protein expression levels by WB prior to
moving forward. Mass spectrometry analyses such as HCD-PD-ETD will be employed to
simultaneously gauge individual glycans and their site localizations on a given
glycoprotein of interest. Preliminary studies in our lab, in collaboration with Dr. Robert
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Gemmill, have already begun assessing the utility for this type of approach on putative
targets such as Neuropilin-2. Furthermore, PNGase-F based release of N-glycans and
utilization of linkage-specific derivatization methodology can be used as a parallel
approach to both verify oligosaccharide structures and attain sialic acid linkage
information from the individual targets.
Modifications to our strategy for glycosylation site assessment would also be an
appropriate endeavor for future work. One of the central limitations to the method
presented was that only N-linked glycopeptides were released. Implementing an approach
for release of O-linked glycopeptides, such as beta elimination or hydrazinolysis, would
be useful for assessing additional glycoproteins incorporating the analog. For O-linked
site elucidation, difficulties arise because of the lack of consensus sequence for these
glycans. Therefore, for this specific goal, exoglycosidase release of bead-bound
glycopeptides followed by intact glycopeptide analysis would be the best approach.
Another avenue worth exploring would be accounting for the SILAC labels
incorporated into peptides released from the alkyne beads by PNGase-F. This strategy
would allow us to record the ratios of peptides derived from either experimental
condition (TGFβ or EV) because the samples are mixed at 1:1 ratio prior to alkyne bead
enrichment. This strategy has the potential to provide quantitative information on
sialylation occurring at distinct glycosylation sites.
Quantitative glycomic studies may also be carried out using the cell culture model of
NSCLC. These investigations have the potential to uncover trends in the expression of
specific glycan structures which warrant further exploration in clinically-relevant samples
(for example, by using lectin affinity enrichment to pulldown sialylated glycans of
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interest in human biofluids/tissues). In an experimental approach similar to SILAC,
isotopic detection of amino sugars with glutamine (iDAWG), has shown promise for the
quantification of N- and O-glycan structures (259,260). This method is based on the
metabolic incorporation of isotopically labeled nitrogen into GlcNAc, GalNAc, and sialic
acid monosaccharides, which all rely on the side chain of glutamine as their source of
nitrogen for biosynthesis.

5.2 Glycomic Assessment of Human NSCLC Biofluids and Tissue
5.2.1 Conclusions
In aim 2, we tested the application of new glycomic mass spectrometry
acquisition strategies in human biofluids and lung tissues to investigate their utility in
clinically-relevant sample types. A set of matched proximal fluids and tissue representing
cases of benign disease, adenocarcinoma, and squamous cell carcinoma were utilized for
“proof-of-concept” experiments. The proteome of BAL fluids was characterized by LCMS/MS and preliminary trends were highlighted between the diagnostic groups. N-linked
glycans from pooled samples of BAL and saliva were subjected to a linkage-specific
sialic acid esterification method prior to acquisition on a high resolution/high mass
accuracy instrument. Normal and tumor lung tissue were sectioned for histological
analysis and tissue imaging mass spectrometry of native N-glycans. The application of
these methods demonstrated that:
1. A detailed characterization of N-linked glycan structures present in proximal fluids and
tissues of lung cancer can be accomplished by using a combination of recently-developed
MS glycomic strategies. These included methods for discerning the anomeric linkages of
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sialylated N-glycans in biofluids and the application of tissue imaging mass spectrometry
to correlate specific oligosaccharides to histological features of the tissues. The use of
MALDI-FT-ICR for all MS acquisitions provided a high level of precision and mass
accuracy for resolving structures in each starting material. The use of matched samples
allowed for direct comparison of structures between the fluids/tissues, representing a
whole new paradigm in biomarker discovery efforts. Furthermore, this was the first
demonstration of feasibility for the use of BAL fluid as glycomic biomarker reservoir that
we know of.
2. Bronchoalveolar lavage fluid contains a diverse set of proteins representing biological
processes such as wound healing, inflammatory response and coagulation. Over 300
proteins were identified, approximately 35% of which matched the Uniprot keyword for
glycoprotein. The application of label-free quantification was a convenient means for
assessing preliminary trends in the quantity of proteins between cancer and benign
samples.
3. BAL and saliva contain a repertoire of N-linked glycan structures composed of
oligomannose and bi-/ tri-antennary complex glycans. The presented approach resulted in
the identification of 24 glycans in BAL from m/z = 1200-3185 and 16 glycans from
saliva from m/z =1400-2375. The derivatization method resolved the anomeric
configurations for 11 and 5 sialylated glycans in BAL and saliva, respectively. A total of
11 glycans shared identification in both BAL and saliva in the m/z = 1400-2375 range.
4. The application of imaging mass spectrometry methodology was amenable to defining
spatial distribution of N-glycans within tumor and normal adjacent lung tissue. The
compatibility of this strategy with concurrent histological assessment facilitated
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comparison of oligosaccharide localization to pertinent histological features as well as
cross-reference in BAL and saliva.

5.2.2 Limitations of Human Biofluids and Tissue Imaging Glycomic Studies
The implementation of sialic acid linkage specific esterification and MALDI-FTICR analysis of BAL and saliva was an efficient method for identifying sialylated glycan
structures in these fluids. In addition, our workflow for MALDI imaging mass
spectrometry of human lung facilitated cross-reference of prevalent N-glycans to defined
histological features of the tissue, as well as against matched proximal fluids. While these
methods and biofluids carry great potential for future biomarker studies, there are some
limitations associated with the presented workflow. These potential drawbacks are
introduced here and alternative approaches are discussed in the future studies section
(5.2.3).
The first constraint is related to the depth of coverage for BAL proteomic studies.
This data was acquired following an in-solution trypsin digest, linear-ion trap mass
spectrometry, and label-free quantification of detected proteins. This was an appropriate
strategy to initially catalogue the protein-carriers of glycan structures present in this fluid.
However, high-abundance metabolic proteins in the fluid, and the relatively-low
resolution MS instrument used for acquisitions, likely hindered the identification of
lower-abundance species. Furthermore, the application of a label-free quantification
strategy is not the preferred method for analyzing starting materials containing a wide
range of protein concentrations.
The next limitation relates to the incompatibility of the sialic acid linkage specific
esterification procedure with the tissue imaging workflow. When this procedure is carried
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out on fluid-based starting materials, the final step before MS is to enrich for sialylated
glycans using cotton-tip HILIC. However, because the workflow for imaging MS relies
on the analysis of intact (non-homogenized) tissues, no equivalent enrichment can be
carried out on these types of samples. Therefore the presented strategy for sialic acid
linkage specific esterification cannot currently be applied to intact tissue samples prior to
MALDI-imaging mass spectrometry, thus limiting the number of sialylated glycans
detected in imaging analyses.
Another factor to consider is that the glycomic studies carried out on tissues/fluids
were limited to acquisition of N-glycans only. Similar to the limitation stated in the
azido-sugar labeling and enrichment experiments, this relates primarily to the lack of an
enzyme which specifically releases O-linked glycans for structural elucidation of these
oligosaccharides.
Conceptual limitations also hinder the ability to cross-reference findings between
either of the presented approaches (in vitro and human proximal fluid/tissue studies).
The azido-sugar labeling, enrichment, and LC-MS/MS method provides proteomic and
glycosylation site information on sialoglycoproteins following 24 hours of TGFβ1
stimulation. On the other hand, data obtained from the human tissues/proximal fluids
methods provides information on the structure of sialylated N-glycans and their
distribution in NSCLC tissues. Therefore each of the presented methods provides a
distinct set of information which cannot be directly inter-related between sample types
without the need for additional experiments.
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5.2.3 Future Studies
The goal of the work presented in chapter 4 was to assess the implementation of
innovative MS glycomic analyses on underutilized starting materials which may have
merit for biomarker discovery efforts. Based on our success in identifying a variety of Nlinked glycans in each of these substrates, the most obvious next step will be to increase
the number of samples studied so that trends in expression of specific glycan structures
can be statistically evaluated. These efforts are already underway and relevant discoveries
will be correlated to outcome information also available from the lung cancer biospecimen resource network. In addition, these methods will be applied to a wider array
of lung proximal fluids as they become available. For example, exhaled breath
condensate and pleural fluid have both demonstrated promising results for proteomic
studies of lung cancer(261,262).
Another future endeavor will be to utilize an alternative means to quantify
proteins present in the BAL fluid, such iTRAQ or TMT tags. Our study relied on LCMS/MS and label-free quantification to catalogue the BAL proteome and explore
preliminary trends in the expression of proteins between diagnostic groups. This
approach was both rapid and suitable for this performing these experiments using limited
sample volume. However as procurement of these samples increases, future work should
be carried out using the most reliable quantitative methods for shotgun proteomic-type
approaches.
For imaging studies of N-glycans, a reasonable goal for future studies will be to
develop a method for on-tissue sialic acid linkage specific derivatization. This
achievement would likely increase the number of sialylated glycans detected on-tissue
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and thereby facilitate greater overlap of structures identified between matched samples.
The primary difficulty in achieving this end thus far has been the preservation of spatial
distribution of liberated glycans. As an alternative, tissue-imaging performed in negative
ionization mode also has the potential to accomplish this feat. In addition to these goals,
our workflow will also be modified to study glycan distribution following release with
glycosidases such as sialidase or fucosidase. This strategy would be worthwhile to gain a
better perspective of glycan diversity as it relates to tissue architecture. Furthermore, to
address the spatial resolution limitation of imaging mass spectrometry, methods such as
laser capture microdissection (LCM) could be implemented prior to MS analysis(263).
For example, using LCM to selectively isolate transformed cells, without inclusion of
adjacent heterogeneous cell populations, could serve to verify the specificity of cancerassociated glycan species. This approach has previously demonstrated utility in
proteomic and glycomic investigations and therefore would be an appropriate follow-up
to tissue imaging studies.
Finally, to address the conceptual limitation of not being able to directly compare
findings between the in vitro and human biofluids/tissues methods, we have begun
optimizing a strategy for intact glycopeptide analysis of biofluids and cell lysate (Figure
30). This method is based on a 2,2,2-trifluoroethanol acid and ammonium bicarbonate
solubilization of membrane proteins, HILIC enrichment of glycopeptides, and HCD-PDETD acquisition on the OrbiTrap Elite instrument. Data from this technique will serve to
verify glycan structures identified from MALDI-FT-ICR analyses as well as discern the
specific glycosylation sites and protein carriers from which they were derived. By using
an up-front immunoprecipitation or lectin affinity enrichment strategy prior to intact
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glycopeptide analysis, glycoproteins and glycan structures of interest can be crossreferenced between sample types.
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Method
1. Azido-sugar metabolic labeling,
Alkyne-agarose bead enrichment,
and LC-MS/MS

In vitro model of NSCLC

Information Obtained
1. Differentially sialylated
glycoproteins
2. N-linked glycosites where
ManNAcAz incorporated

Assess differentially sialylated glycoproteins
in proximal fluids/tissues

Assess sialylated glycan structures in cells

Future Studies

Intact Glycopeptide Analysis
Information Obtained
Glycoprotein quantification
Glycan structure
Glycosylation site

Method
1. Sialic acid linkage specific esterification
and MALDI-FT-ICR glycomics
2. N-glycan MALDI-Imaging MS

Human NSCLC Tissue/Proximal fluids

Information Obtained
1. Identify sialylated N-glycan
structures
2. Spatial distribution of Nglycans in lung tissue

Figure 30: Bridging Findings Between In vitro and Human Samples Methods
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